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Investigating the roles of p63 & p73 isoforms to therapeutically treat 
p53-altered cancers 
Avinashnarayan Venkatanarayan, M.S. 
Supervisory Professor: Elsa R. Flores, Ph.D. 
The TP53 tumor suppressor is mutated in approximately 50% of human 
cancers rendering cancer therapies ineffective. p53 reactivation suppresses tumor 
formation in mice. However, this strategy has proven difficult to implement 
therapeutically. An alternate approach to overcome p53 loss is to manipulate the 
p53-family members, p63 and p73, which interact and share structural similarities to 
p53. p63 and p73, unlike p53 are less frequently mutated and have two major 
isoforms with distinct functions which makes them unique targets for therapeutic 
intervention. The full-length acidic transactivation (TA) isoforms of p63 and p73 
function similar to p53. While the deltaN (ΔN) isoforms of p63 and p73, which lack 
the acidic transactivation domain, are overexpressed in cancers and function in a 
dominant negative manner against p53, TAp63 and TAp73. As result of the 
opposing isoform-specific function, the roles of p63 and p73 in tumorigenesis 
requires further characterization. In an attempt to identify novel therapeutic 
approaches to treat p53-altered cancers by utilizing the p53-family members, I aim 
to delineate the roles of ΔN isoforms of p63 and p73 in tumorigenesis.  
I have demonstrated that deletion of ΔNp63 or ΔNp73 in p53-deficient tumors 
mediates tumor regression through the upregulation of tumor suppressive isoforms, 
TAp63 and TAp73. Upon loss of ΔNp63 or ΔNp73, TAp63 and TAp73 activate IAPP 
	  	   viii	  
a metabolic regulator, which induces metabolic reprogramming resulting in tumor 
regression in p53-deficient mice. I have shown that IAPP, which encodes amylin, a 
37-amino acid peptide functions as a tumor suppressor in p53-deficient cancers. 
IAPP functions through the calcitonin and RAMP3 receptors to limit glucose uptake 
and reduce glycolysis in the cancer cells resulting in ROS accumulation and 
apoptosis. Additionally, I have also shown that use of Pramlintide, a synthetic analog 
of IAPP, mediates tumor regression in p53-deficient mice and apoptosis in multiple 
p53-mutant human cancer cell lines.  
Further, to therapeutically treat p53-deficient cancers in vivo, liposomal 
nanoparticle siRNA’s targeting ΔNp63 and ΔNp73 were administered into p53-
deficient mouse thymic lymphomas, which resulted in tumor regression. Taken 
together, my work has defined the isoform specific functions of p63 and p73 in 
tumorigenesis. Importantly, I have also demonstrated the use of pramlintide, a 
diabetic drug to treat p53-altered cancers. Thus, by understanding the interplay 
among the p53-family members, novel therapeutic methods could be designed to 
treat p53-altered human cancers.   
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Chapter 1: Introduction 
1.1. p53 as a tumor suppressor 
The TP53 gene encodes for p53, which is located on the chromosome locus 
17p13.1(1, 2). The TP53 gene is regarded as the “Guardian of the genome” due to 
its tumor suppressive functions, however TP53 is highly mutated in multiple 
cancers(3, 4). More than 50% of human cancers, harbor a complete inactivation of 
p53 function or gain of function of p53 due to mutations(5). This effect is well 
documented in Li-Fraumeni syndrome individuals who harbor p53 loss and are 
highly susceptible to tumor formation(6) and also the ability of the mouse models to 
develop spontaneous tumors upon loss of p53(7, 8).  
The p53 protein upon initial discovery as a complex with the SV40 T-antigen 
was hypothesized to function as a proto-oncogene(1). This notion was later proved 
to be incorrect as the initial experiments were performed using a mutated version of 
the TP53 gene. Later, wild-type p53 loss of function was observed in a subset of 
colon carcinomas suggesting that p53 could have tumor suppressive functions(1). In 
many cancers, loss of one copy of TP53 initiates the tumorigenesis process, which 
is immediately followed by the loss of heterozygosity further accelerating the tumor 
formation. However, in some cancers, TP53 loss could be the end result of a much 
more malignant tumor phenotype that could eventually lead to differentiation of the 
tumor cells further increasing their invasive and metastatic potential. Thus far, 
current research has been trying to determine the underlying mechanisms by which 
TP53 executes its tumor suppressive function.  
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Thirty years from its initial discovery, TP53 is also referred to as the “Master 
regulator of the genome” for its well-documented cellular functions. TP53 is a 
transcriptional factor that is involved in a multiple cellular functions and helps 
maintains cellular homeostasis. At physiological levels, the protein levels of p53 are 
low and under the regulation of E3 ubiquitin ligase called MDM2 and MDM4(9, 10), 
which bind to the amino terminus of p53. Upon different types of cellular stressors 
like DNA damage, hypoxia and oncogene activation, p53 levels increase in the cells 
imparting its protective genomic function. p53 forms a homotetramer and functions 
as a tumor suppressor by inducing cell death by activating PUMA(2, 11, 12), 
Noxa(2) and BAX(13, 14) or induces transient cell cycle arrest(15, 16) by activating 
p21(17, 18), p16(15, 19, 20) and PML. p53 can also induce cellular senescence, a 
more permanent form of cell cycle arrest. The normal function of p53 is to activate 
DNA damage repair pathway upon genomic instability. Apart from these classical 
functions of p53, more recently p53 has been demonstrated to play important roles 
in autophagy, cellular metabolism and stem cell maintenance.  
Our understanding of the function and roles of p53 in human cancers, were 
well-recapitulated using mouse models in which p53 is functionally inactivated(21). 
Trp53-null mice primarily develop thymic lymphomas at 90% incidence while the 
Trp53-heterzygous mice develop osteosarcomas and thymic lymphomas(22). 
However, in most cancers, TP53 is highly mutated that results in p53 gain of function 
further promoting aggressive tumor formation. The mutation related functions of p53, 
have generated a whole new area of research in characterizing the mutation related  
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Figure 1: p53-mutational frequency in human cancers. Spider plot representing 
the mutation frequency in TP53 across a panel of human cancers. Sequencing data 
from the Cancer Genome Atlas (TCGA) deposited from multiple human sequencing 
studies provide an overall mutational frequency for TP53 in multiple cancer types.  
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properties of mutant p53 in human cancers using mouse models specific to the 
common p53-mutations that have been identified(7, 8).  
1.2. p53 mutations in human cancer 
 TP53 gene is highly mutated in multiple human cancers. Recent sequencing 
efforts from the cancer genome atlas (TCGA) have identified a huge array of 
cancers in which TP53 is mutated (Figure 1). Somatic mutations generally occur in 
multiple genes in human cancer. In the case of TP53, due to its vital tumor 
suppressive functions it seems to be a commonly mutated target. Unlike most genes 
which have frame-shift or non-sense mutations, p53 in general has missense 
mutations that is characterized by single amino acid substitutions(23). These point 
mutant versions of p53 are stable and serve as dominant negative regulators of wild-
type p53. Typically, when mutant p53 expression is higher it affects the tetramer 
formation of wild-type p53 altering its function. Importantly, in tumors, when one 
copy of p53 is mutated it is followed immediately by the loss of heterozygosity (LOH) 
of the wild-type p53. This has led to the classification that p53-mutations result in 
“gain of function” activities accelerating tumor formation(7, 8). Although in some 
instances mutant p53 can mediate gain of function activities independent of wild-
type p53. Further, from the sequencing efforts on human cancers, p53 mutations are 
mostly restricted to the DNA binding domain and some of these frequent mutations 
in p53 are referred as “hotspot” mutations. To the test the effect of these mutations 
in tumorigenesis, similar to the Trp53-null mice that demonstrated the tumor 
suppressive function of p53, two knock-in mouse models that harbor hotspot 
mutations at R175 and R270 were generated(7, 8). These mice had diverse tumor 
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spectrum with increased metastasis highlighting the aggressiveness of p53-mutation 
driven tumors in these mice.  
 Mutant p53, unlike wild-type p53 does not directly bind to DNA to promote its 
proto-oncogenic functions. However, mutant p53 can interact with targets like NF-Y, 
Ets1, Pin1, MRE11, PML to promote oncogenic transformation(24, 25) or repress 
the activity of the other family members p63 and p73 that function as tumor 
suppressors(26, 27). Because of these widespread effects of mutant p53 function or 
p53 inactivation in human cancers current therapeutic approaches are targeted 
towards either reactivating wild-type p53 or to degrade mutant p53. Although, 
preliminary data in mouse models demonstrating active tumor suppression upon 
p53-reactivation has shown great promise, thus far therapeutically it is not been 
feasible. Also, drug inhibitor based approach to degrade mutant p53 is still under 
developmental stages which necessitates the need to find and develop alternate 
approaches to treat these human cancers(28-30).  
1.3. Therapeutic Strategies to activate the p53-pathway 
  p53 upon cellular stress, functions to induce cell cycle arrest or cell death in 
the “radiosensitive” tissues(15). This is one mechanism by which p53-potects the 
genome from different types of cellular stressors and DNA damage. In the context of 
the tumor, one mechanism by which chemotherapy functions is to induce damage 
which elicit a p53 response activating a downstream cellular cascade targeting the 
tumors cells. However, as previously discussed p53 is completely inactivated with a 
“loss of function” phenotype or mutated resulting in “gain of function” effects. This 
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necessitates the need to restore the function of the p53-pathway. Interestingly, in 
vitro restoration of p53 function induced cancer cell death and cell cycle arrest in 
human cancer cells(31). This was further validated in vivo using a conditional p53 in 
vivo mouse model of lymphomagenesis and osteosarcoma(32, 33). Interestingly, 
when p53 expression was restored the thymic lymphoma cells underwent cell death 
while the osteosarcoma cells underwent cell cycle arrest and cellular 
senescence(16, 32). This suggests that p53 executes its tumor suppressive function 
in a tissue dependent manner. Although these experiments provide a proof of 
principle mechanism to activate the p53-pathway, thus far restoring p53-function 
therapeutically as been challenging. 
1.3.1. Activating wild-type p53 function in human cancers 
 At physiological conditions, p53 is under the regulation of its E3 ubiquitin 
ligase MDM2(9, 34). Research work has demonstrated that in multiple human 
cancers, MDM2 and its counterpart, MDM4 are significantly overexpressed thereby 
repressing wild-type p53 function. Hence, one approach that is under development 
is to abrogate the p53-MDM2 interaction, which will restore wild-type p53 activity(35-
37). Multiple small molecule inhibitors(38) are under clinical development, but Nutlin-
3a has made significant progress in restoring wild-type p53 activity(39-41). Also, loss 
of p53 function in some tumors arises due to the mis-folding of the p53 protein. 
Currently, reconstituting levels of Zinc (Zn) in these cells have corrected the p53 
protein conformation in wild-type p53 thereby restoring its function(42). However, 
this approach cannot be used in mutant p53, as the residues that correspond to the 
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Zinc are mutated. Hence, alternate approaches need to be adopted to 
therapeutically treat p53-mutated cancers.  
1.3.2. Degrading mutant p53 function in human cancers 
 Mutant p53 exhibits a “gain of function” effect promoting tumor formation. 
Hence, current therapeutic strategies are targeted towards abolishing the activity of 
mutant p53 either directly or indirectly. Mutant p53 stabilization is achieved through 
its interaction with Hsp70 and Hsp90 through HDAC6(43, 44). Therapeutic use of 
HDAC inhibitors like SAHA have shown increased efficacy in degrading the mutant 
p53 in cancer cells, however, use of HDAC inhibitors has been demonstrated to 
degrade wild-type p53 restricting its use towards cancer treatment. Additional 
methods to downregulate the mutant p53 function is by targeting the effector 
pathways like the MAPK or PI-3K pathway that are activated by mutant p53 function. 
Thus far restoration of the p53-pathway still remains a challenge due the intricate 
complexities and this necessitates the need to identify and characterize alternate 
mechanisms to treat these p53-deficient human cancers.  
1.4. Utilizing the p53 family members p63 and p73 towards cancer treatment 
The p53 superfamily comprises of TP63 and TP73 along with TP53. For the 
last 30 years, the role of TP53 in tumor suppression has been well documented. 
Inactivation of TP53 in human tumors has defined the role of TP53 as a bonafide 
tumor suppressor. However, the functional roles of the family members TP63 and 
TP73 in tumorigenesis have been shadowed. TP63 and TP73 are located in the 
3q28 and 1p36 chromosome(45). Although TP63 and TP73 are evolutionarily older 
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to TP53, they are still considered as “younger siblings” of the TP53 gene. Although, 
p63 and p73 were initially identified as developmental regulators, the roles of these 
genes in tumorigenesis were indispensible as mice that harbor loss of p63 and p73 
were predisposed to tumor formation suggesting the role of these genes in tumor 
suppression(46).  
1.4.1. Structural homology among the p53 family members 
 The p53 family members, p63 and p73 share significant structural homology 
with p53 particularly in the DNA binding domain(45). As a result, several functions 
among the family members tend to overlap with each other. However, there is less 
similarity between p53 versus p63 and p73 in the oligomerization domain and the 
transactivation domain (TAD). This might be one of the reasons that p63 and p73 
does not form tetramers with p53 while activating other downstream targets. 
Interestingly, p63 and p73 are unique and encode multiple isoforms at both the N-
terminus and C-terminus (Figure 2). In general, TP63 and TP73 are broadly 
classified into two categories, the isoforms that encode an acidic transactivation 
domain (TA) which produce either TAp63 or TAp73 and the isoforms that lack the 
acidic domain called ΔN isoforms, which produce either ΔNp63 or ΔNp73 (Figure 
2)(45). The function of each of these isoforms is complex and tissue dependent. The 
full-length TAp63 and TAp73 isoforms in general are thought to function very similar 
to p53, while the shorter ΔN isoforms of p63 and p73, exhibit dominant negative 
effects against p53, TAp63 and TAp73(47-49). Similar, to the N-terminal isoforms, 
more than seven different kinds of C-terminal splice variants have been identified.  
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Figure 2: Sequence and structural homology of p53, p63 and p73. p63 and p73 
share significant structural homology with p53 particularly in the DNA binding 
domain. Both, p63 and p73, have unique N-terminal isoforms, the full-length acidic 
transactivation isoform, TAp63 or TAp73 and the shorter isoform that lacks the 
transactivation domain called ΔNp63 or ΔNp73 is transactivated from the 3’ cryptic 
promoter. Also, p63 and p73 encompass multiple C-terminal isoforms which requires 
further characterization. 
 
(Figure is taken with permission from Su, X., Chakravarti, D. and Flores, E.R. p63 
steps into the limelight: crucial roles in the suppression of tumorigenesis and 
metastasis. Nat. Rev Cancer. 2013; 13(2):136-43.) Licence Number: 351121299603. 
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The function of these C-terminal isoforms is under investigation and requires more 
characterization. 
1.4.2. Mutational status of p63 and p73 in human cancers 
 More than 50% of human cancers harbor p53 mutations that makes it difficult 
to target the p53-pathway. These mutations may be a result of the tumor 
suppressive function exhibited by p53. However, compared to p53, the other family 
members, p63 and p73 are less frequently mutated (Figure 2). Recent, sequencing 
data from multiple human cancers has demonstrated that mutation rates in p63 and 
p73 are less frequent compared to any of the other tumor suppressor genes 
including p53 (Figure 3). This makes both p63 and p73 novel targets for therapeutic 
intervention. Importantly, due to the structural similarlity, the functions of the family 
members could be used to target the p53-pathway. One speculation as to why p63 
and p73 are not mutated may be due to the important development roles played by 
the genes.  
1.5. Developmental roles of p63 and p73 
 p63 and p73 knockout mouse models targeting the DNA binding domains had 
severe developmental abnormalities suggesting the roles of these genes as 
developmental regulators. p63 knockout mice had a deformed epidermal skin layer 
with improperly formed limbs and facial structures(50, 51). Most of these mice were 
embryonic lethal and died due to desiccation and water loss. The phenotype of the 
p63 knockout mice closely resembled the cleft lip and palate syndrome in humans 
referred to as the ectrodactyly ectodermal dysplasia (EEC). Upon further 
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characterization of the developmental roles of the N terminal isoforms using 
conditional in vivo mouse models, it was evident that splice variants have distinct 
functions. The TAp63 isoforms are required to maintain the skin stem cells in 
quiescence(50) while the loss of ΔNp63 isoforms prevents skin cell differentiation 
and targets the cells to be more pluripotent(52, 53). On the contrary, the p73 has 
been demonstrated to play critical roles in immune response and neural 
development. p73 knockout mice are embryonically viable but are characterized by a 
runted phenotype and shortly die a few weeks after birth(54, 55). Upon 
characterization of the specific roles played by the TAp73 and ΔNp73 isoforms, it 
has become evident that loss of these isoforms results in defective closure of the 
neural tube and growth of the sub-ventricular zone  (SVZ) required for normal brain 
development(56-58). This highlights the important developmental functions of p63 
and p73.  
1.6. Tumor suppressive functions of p63 and p73 
 The roles of p63 and p73 in the development of skin and the neural 
development were well documented. However, the functional roles of these genes in 
other cellular processes were less studied. Given the structural similarity to p53, it 
was hypothesized that p63 and p73 could have similar function as they function as 
transcriptional factors as well. However, expression analysis from the human cancer 
tissues particularly from the colon, intestine and prostate demonstrated increased 
expression of p63 and p73(59-62). These findings suggested that both p63 and p73 
could have oncogenic properties. To further add to the complexity, mouse models 
targeting p63 and p73 had an accelerated tumorigenesis(46). The tumor spectrum of  
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Figure 3: Graph representing the mutational status across p53-family 
members in human cancers. Unlike TP53, which is highly mutated, TCGA 
sequencing analysis has revealed that TP63 and TP73 are less frequently mutated.  
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the p63 and p73 deficient mice had significant carcinomas and was completely 
divergent from the p53-deficient mice that generally develop lymphomas and 
sarcomas. This data highlights the indispensable role of p63 and p73 in tumor 
suppression(46). However, the reason for the increased expression of p63 and p73 
in the human tumor samples were not clear.  
 More recent experiments highlighted the independent roles of the N-terminal 
isoforms of p63 and p73. The antibodies used for detecting p63 and p73 did not 
differentiate the individual isoforms but rather p63 and p73 totally. It was 
demonstrated that TAp63 and TAp73, the full-length isoforms of p63 and p73 had 
functions similar to p53. In vitro experiments that express TAp63-gamma and 
TAp73-alpha in the human cancer cells induced cell death and cell cycle arrest 
independent of p53 function(63). Interestingly, in response to genotoxic stress, 
TAp63 and TAp73 were stabilized and had an increased effect in directing the 
cancer cells to undergo cell death. Further, to support the tumor suppressive notion 
of TAp63 and TAp73, mouse models targeting TAp63 and TAp73 were generated. 
Total loss of TAp63 in these mice had accelerated tumor spectrum with increased 
incidence of adenocarcinomas and metastasis(64, 65). It was also demonstrated 
that TAp63 functions to inhibit metastasis through Dicer regulated mechanism(66). 
Further, the roles of TAp63 in metabolism(67), stem cells(68) and polarity are 
currently being characterized. Similarly, the TAp73 knockout mice develop lung 
adenocarcinomas at a higher incidence, which correlates with a previous finding that 
p73-deficient mice have a 60% lung adenocarcinoma incidence(46). These findings 
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clearly demonstrate the key roles played by the TA isoforms of p63 and p73 in 
tumorigenesis and that they function as bonafide tumor suppressors.  
1.7. Roles of ΔN isoforms of p63 and p73 in tumorigenesis 
 In vitro cell culture and in vivo experiments have delineated the functions of 
the different isoforms of p63 and p73 in tumorigenesis and development(63, 69). 
Particularly, the roles of the TAp63 and TAp73 as tumor suppressors are well 
documented. However, the roles of the ΔN isoforms of p63 and p73 are less studied 
and controversial. Studies from human cancer tissues detected p63 and p73 
expression utilizing antibodies that do not differentiate the isoforms. Later, semi-
quantitative analysis demonstrated that these tumor samples had increased 
expression of ΔNp63 and ΔNp73 suggesting the oncogenic roles of these isoforms 
in tumorigenesis(49, 70). Further, in vitro experiments expressing ΔNp63 and ΔNp73 
inhibited apoptosis and cell cycle arrest in human cancer cells upon genotoxic 
stress(63, 71, 72). This may be due to the dominant negative effect of ΔN isoforms 
of p63 and p73 against p53, TAp63 and TAp73. Interestingly, in some instances, 
both ΔNp63 and ΔNp73 seem to respond upon DNA damage by activating genes 
involved in DNA repair like BRCA2, Rad51 and MRE11(69). This suggests that 
ΔNp63 and ΔNp73 do have protective genomic physiological functions as well. Thus 
in vitro experimental evidence has clearly demonstrated the complexity within the 
roles of ΔN isoforms of p63 and p73 in tumorigenesis. This necessitates the 
generation of conditional knockout mice that are required to decipher the role of 
these isoforms in tumorigenesis. 
	   16	  
 Previous total knockout mouse models for ΔNp63 and ΔNp73 have 
highlighted the roles of these genes in development. The ΔNp63 knockout mouse 
has defects in epithelial skin development and differentiation(53) while the ΔNp73 
knockout mice have defects in neural tube growth and closure(73). However, these 
models did not depict the roles of these genes in tumorigenesis. Hence, to test the 
role of these genes, our lab generated conditional knockout mouse models to 
determine whether ΔNp63(52, 74) and ΔNp73(74) function as oncogenes and tumor 
suppressors. The ΔNp63 mice were generated with a loss of one allele as ΔNp63 
homozygous deficient mice are embryonic lethal. Surprisingly, the ΔNp63 and 
ΔNp73 deficient mice did not develop any tumors. Hence, to further accelerate 
tumorigenesis and also determine the role of these isoforms in the context of p53-
loss, cohorts of mice harboring loss of ΔNp63 with p53 (ΔNp63+/-;p53-/-) and ΔNp73 
with p53 (ΔNp73-/-;p53-/-) were generated.  
1.8. Cancer cells and deregulated metabolism 
 Tumor cell metabolism has emerged as on the most important hallmarks of 
cancer in the recent years. There has been a tremendous impetus in understanding 
how a tumor evolves metabolically and adapts to the changes in the nutrients(75). 
Multiple research groups and studies have tried to delineate the complexities 
involved in the metabolic regulation. However, a complete characterization of these 
metabolic circuits is still being a challenge as tumor cells constantly evolve switching 
to multiple modes of nutrient sensing for survival. Research work is currently 
focused in understanding how to limit the nutrient consumption of these cancer cells 
or to deplete the nutrients to starve the cells, which could eventually reduce their  
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Figure 4: Warburg’s hypothesis on tumor cell metabolism. Normal differentiated 
tissues or cells, utilize glucose as an energy source through the glycolysis pathway 
and enter into Kreb’s cycle to produce more energy through oxidative 
phosphorylation. On the contrary, cancer cells, consume increased amounts of 
glucose and switch to produce lactate without entering oxidative phosphorylation. 
Cancer cells are dependent on this switch to aerobic glycolysis for proliferation.   
 
(Figure is taken with permission from Vander Heiden, M.G., Cantley, L.C. and 
Thompson, C.B. Understanding the Warburg effect: The metabolic requirements of 
cell proliferation. Science. 2009; 324(5930):1029-1033.) 
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proliferation rates and reduce tumor growth and spread. However, this approach as 
been challenging as the cancer cells do not depend on only one nutrient but 
constantly switch to other nutrients for their survival and importantly the complexity 
of the metabolic machinery makes it challenging to target a single pathway. 
However, a clear understanding of these pathways makes it a viable option to 
therapeutically target the cancer cells.  
1.8.1. Warburg Hypothesis on tumor cell metabolism 
In the early 1950, a german scientist Otto von Warburg, postulated that 
cancer cells proliferate at much higher rates with increased consumption of 
glucose(76). This results in an increased activity of the glycolysis pathway with the 
cancer cells secreting an acidic product lactate instead of targeting the cells into 
mitochondrial respiration. Based on this hypothesis, it was evident that cancer cells 
have increased glucose consumption and lactate secretion (Figure 4)(75). The acidic 
lactate medium provided a better environment for the cancer cells to proliferate. 
Although the amount of ATP from the glycolytic pathway is less in comparison to the 
Kreb’s cycle, the increased rate of proliferation in these cancer cells compensated 
for ATP loss with increased glucose consumption. Hence, to therapeutically target 
the glycolytic pathway to inhibit the cancer cells from proliferation and lactate 
production became a viable option. Current research work as also identified the key 
players that function as regulators of glucose uptake and those that could inhibit 
glycolytic pathway. Interestingly many of these regulators are activated by multiple 
transcription factors including p53(77).     
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However, based on Warburg’s hypothesis, it was believed that cancer cells 
do not depend on mitochondrial respiration(78). However, more recently, some 
studies have shown that mutations in the mitochondria could have adverse effects in 
the nutrient sensing functions of the cancer cells. Importantly, cancer cells attain the 
ability to switch to nutrients like glutamine to continue proliferation. This sudden 
influx in glutamine consumption accelerates the mitochondrial respiration further 
promoting tumor cell proliferatio(75). Some of the current research focus is also now 
targeted towards inhibiting the oxidative phosphorylation pathway in cancers.  
1.9. p53 and cancer cell metabolism 
 p53 functions as a transcriptional factor activating several downstream targets 
regulating classical cellular function like apoptosis, cell cycle arrest and cellular 
senescence. More recently, the roles of p53 in new cellular functions like stem cell 
maintenance, aging and metabolism have been explored. p53 has been 
demonstrated to regulate and activate genes involved in glycolysis and 
metabolism(77, 79). Primarily, p53 regulates GLUT2 and TIGAR (TP53-inducible 
glycolysis and apoptosis regulator)(79, 80). GLUT2 function to uptake glucose into 
the cell and p53 inhibits the activity of GLUT2. On the contrary, TIGAR, which is 
activated upon DNA damage by p53, encodes a bis-phosphatase enzyme that 
degrades fructose 2,6-bisphosphate and degrades glucose primarily inhibiting the 
glycolytic pathway(81). However, in some tissues like the intestine, TIGAR has been 
demonstrated to promote regeneration of the intestinal stem cells. As a result, 
expression of TIGAR in an intestinal tumor model promotes tumor formation(80). 
Another known regulator of p53 in metabolism is a gene involved in the 
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mitochondrial respiration referred to GLS2. GLS2 functions to release cytochrome C 
and regulate intracellular ROS in the cells. Upregulation of GLS2 releases 
cytochrome C resulting in induction of the apoptosis pathway(82). More recently, a 
p53 acetylation mutant mouse model demonstrated that p53 inhibits tumorigenesis 
by activating the metabolic regulators GLS2, TIGAR and GLUT2(81). This further 
suggests that utilizing these metabolic regulators could function as a novel approach 
to target the deregulated metabolism of these cancer cells.  
2.10. Islet amyloid polypeptide (IAPP) 
 IAPP is a transcriptional factor that encodes for amylin(83). Amylin is a 37-
amino acid polypeptide that is cosecreted along with insulin from the beta cells of the 
pancreas. However, expression of IAPP has been detected in other tissues, which 
include cornea, thymus and the ovary. At physiological levels, IAPP functions to 
reduce insulin mediated glucose uptake, implicating its role in maintaining glucose 
homeostasis(84). IAPP has also been demonstrated to induce apoptosis in some 
cellular contexts(85). Some studies suggest that IAPP mediates apoptosis through 
activation of p21 independent of p53 function(86), while some studies relate to 
metabolic stress induced toxicity by IAPP upon glucose clearance in the liver(87). 
IAPP since is a secreted protein has been shown to function through the activity of 
the calcitonin and RAMP3 receptors(88). Additionally, a synthetic analog of IAPP 
called pramlintide involved in glucose regulation is used commercially to treat type I 
and type II diabetic patients(89).  
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2.11. Reactive Oxygen Species (ROS) 
  ROS is a common by-product that is produced from different metabolic 
processes in the cell. Although, ROS, a class of free radicals primarily originates 
from the mitochondria, recent evidence suggests that intracellular ROS 
accumulation occurs upon metabolic stress and inhibition of cellular nutrients like 
glucose or glutamine or inhibition of the phosphate pentose pathway(78). At 
physiological state, the levels of ROS in the cells are under tight regulation. Low 
levels of ROS as in the case of cancer cells, generally promote tumor cell 
proliferation by activating oncogenes and inducing stress. However, in instances 
when cells accumulate increased amounts of ROS due to metabolic stress, it results 
in apoptosis or cellular senescence(90, 91). Recent evidence suggests that targeting 
a class of phosphatidyl kinases in p53-deficient tumors results in ROS-induced 
cellular senescence in breast tumors. This highlights the role of ROS as tumor 
suppressor(91). However, in some cancers, ROS accumulation activates oncogenes 
like HIF-1alpha driving tumorigenesis representing its oncogenic functions(92). 
Hence one approach to target cancer cells is to increase ROS levels, which will 
result in apoptosis or senescence in the tumor cells. Interestingly, the effect of ROS 
can be controlled or reversed using antioxidants. Antioxidants like hydrogen 
peroxide and N-acetly cysteine could function to reverse the effect of intra-cellular 
ROS suppressing the oncogenic functions of ROS(80, 93).  
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2.12. Therapeutically targeting p53-deficient and mutant cancers 
 Therapeutically reactivating wild-type 53 or degrading mutant p53 in human 
cancers has been challenging. But the role of this p53-pathway in activating 
downstream cellular cascade to induce apoptosis or cell cycle arrest is 
indispensable. By utilizing the p53-family members, p63 and p73, a new paradigm 
approach can be taken to reactivate the downstream components of the p53-
pathway. Importantly, by delineating the interplay among the family members a more 
clear strategy could be adopted to utilize p63 and p73 therapeutically(94).  
 TAp63 and TAp73 are bonafide tumor suppressors. However, because of the 
dominant negative effect of ΔN isoforms against p53, TAp63 and TAp73, the 
expression levels of the TA isoforms of p63 and p73 remain significantly low(49, 60). 
Ideally, by targeting ΔNp63 and ΔNp73, if the repressive effect is reduced, TAp63 
and TAp73 can compensate for p53 loss of function by activating downstream 
targets involved in multiple cellular processes. Hence, approaches to target ΔNp63 
and ΔNp73 in human cancers could be explored as an option to treat p53-deficient 
cancers. One approach to target ΔN isoforms of p63 and p73 could be the 
identification and use of small molecule inhibitors that could be used selectively to 
downregulate ΔNp63 and ΔNp73. Second approach, could be to identify microRNA’s 
(miRNA’s) that specifically bind to ΔNp63 or ΔNp73 and repress its function. 
miRNA’s are approximately 22-35nt oligomers that function to repress gene 
transcription. By activating these miRNA’s specific to ΔNp63/ΔNp73 or by 
introducing them exogenously we can target ΔNp63 and ΔNp73 to treat these 
tumors. Additionally, small interfering RNA’s (siRNA’s) could be used to target 
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ΔNp63 and ΔNp73 in human cancers. Previously, the use of siRNA’s to 
downregulate gene expression has been well demonstrated in human cancer cells. 
Recent studies have highlighted the use of in vivo delivery methods to deliver these 
siRNA’s. Some methods use cholesterol or other polymer based substances to coat 
the siRNA oligomers. But with these methods the issue was poor resorption into the 
tissues and also degradation by the phagosomes. One approach to deliver siRNA’s 
into the tissues that has a high penetrance is to coat the siRNA oligomers with nano-
liposomes. Nano-liposomes are neutral particles that do not carry any charge. These 
particles could be delivered directly into the region of the tumor or by systemic 
methods and are not phagocytosed. These options could be explored further to 
target ΔNp63 and ΔNp73 in human cancers.  
Alternatively, TAp63 and TAp73, very similar to p53 respond to genotoxic 
stress and DNA damage. Hence, to illicit a TAp63 and TAp73 response, both ΔN 
isoforms of p63 and p73 could be targeted along with treating the cells with a DNA 
damaging agent like cisplatin or doxorubicin. However, in the case of human 
cancers that harbor mutations in p53, this possibility would not feasible as mutant 
p53 forms hetero-tetramers with TAp63 or TAp73 and inhibits its transcriptional 
activity. Hence, to overcome the effects of mutant p53, we could simply target 
pathways that are independent of the p53 pathway.  
2.13. Long non-coding RNAs: Disease and Development 
 Long non-coding RNAs (lncRNAs) are a class of RNA molecules that are 
>200 nt in length and do not code for proteins(95). These lncRNAs function very 
	   24	  
similar to mRNAs and are involved in multiple cellular process and functions. 
lncRNAs comprise of the 80% of the non-coding part of the genome along with the 
other know miRNAs, pseudoRNAs, piwi and piRNAs(96, 97). lncRNAs were 
discovered in eighties but its functions were less characterized. However, unlike 
miRNAs or mRNAs, lncRNA are not evolutionary conserved. But with the advent of 
the sequencing efforts, the gene regulation and functions of the lncRNA in disease 
and development is being delineated. lncRNAs are classified into multiple types 
based on the position in the context of mRNA genes. The most common type of 
lncRNA is called long intergenic non-coding (linc) RNA whose function does not 
overlap with the neighboring genes(96). lncRNAs have been demonstrated to play 
diverse roles in gene regulation. They perform these functions by acting as 
scaffolding proteins, decoys, cofactors and guides(97). However, current 
understanding of these lncRNAs is limited to in vitro experiments and additional in 
vivo models should be developed to completely characterize its function. The 
functional characterization of these lncRNAs is gaining importance because of its 
implication in diseases like cancers. HOTAIR is one such lncRNA that is significantly 
overexpressed in prostate cancer(98). By determining the expression pattern of 
these lncRNAs they can serve as biomarkers for disease prognosis. Additionally, 
lncRNA can function as regulators or effectors of gene function. These roles of 
lncRNAs determine whether they function as tumor suppressors or oncogenes.  
2.14. lncRNAs and p53 regulation 
p53 functions in multiple ways to regulate genomic functions. p53 apart from 
its classical roles in apoptosis and cell cycle arrest also functions to mediate its 
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effectors functions by activating lncRNAs. The lncRNAs regulated by p53 are often 
grouped as “effectors”. This class of lncRNAs, which include linc-p21, PANDA and 
H19 play significant roles in preventing, cell proliferation and prevent 
tumorigenesis(99-102). Conversely, several lncRNAs function to regulate p53 
function which include MALAT1, MEG3 and ROR. Thus, it is evident that regulation 
of lncRNAs plays a significant role in regulating gene function. By understanding the 
function of these lncRNAs in regulating mRNA expression we can delineate novel 
pathways that could help design new therapies or serve as predictors of disease 
outcome.  
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Chapter 2. Materials & Methods 
Contents of this chapter is based on Venkatanarayan, A., Raulji, P., Norton, W., 
Chakravarti, D., Coarfa, C., Su, Xiaohua., Sandur, S.K., Ramirez, M.S., Lee, 
Jaehyuk., Kingsley, C.V., Sananikone, E.F., Rajapakshe, K., Naff, K., Parker-
Thornburg, J., Bankson, J.A., Tsai, K.Y., Gunaratne, P.H. and Flores, E.R. IAPP 
driven metabolic reprogramming induces regression of p53-deficient tumors in vivo. 
Nature. 2015; 517(7536),626-630. doi:10.1038/nature13910. 
 
Copyright permission not required since Nature journal policy states “Author retains 
the copyright to the published materials” 
2.1. Generation of ΔNp73 Conditional Knockout Mice 
The cre-loxP strategy was used to generate the ΔNp73 conditional knockout allele 
(ΔNp73fl). Genomic p73 DNA from intron 3 to intron 3’ was amplified from BAC 
clone DNA (BAC RP23-186N8, Children's Hospital Oakland Research Institute). 
LoxP sites flanking exon 3’ of p73 and neomycin (neo) gene flanked by frt sites 
inserted in intron 3’ were cloned into pL253(103). Mouse embryonic stem cells (G4) 
electroporated with the targeting vector were analyzed by Southern blot analysis for 
proper targeting of the ΔNp73 allele. Resulting chimeras were mated with C57BL/6 
albino females and genotyped as described below. Mice with germ line transmission 
of the targeted allele (conditional, flox neo allele, fn) were crossed to the FLPeR 
mice to delete the neo cassette.  Resulting progeny were intercrossed with Zp3-Cre 
(C57BL/6) transgenic mice(104). ΔNp73fl/+; Zp3-Cre females were mated with 
C57BL/6 males to generate ΔNp73+/- mice. The ΔNp73+/- mice were intercrossed 
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to generate ΔNp73-/- mice. Compound mutant mice were generated by intercrossing 
the ΔNp63+/- and ΔNp63fl/fl(52) and the ΔNp73-/- and ΔNp73fl/fl mice with the p53-
/- mice(22). All procedures were approved by the IACUC at U.T. M.D. Anderson 
Cancer Center. 
2.2. Genotyping 
Genomic DNA from tail biopsies was genotyped by Southern blot analysis by 
digesting genomic DNA with AflII and HindIII or by PCR using the following primers 
and annealing temperatures: 1) for wild-type: wt-F, 5'- ACAGTCCTCTGCTTTCAGC-
3' and wt-R (fl-R), 5'- CACACAGCA CTGGCCTTGC -3’, annealing temp: 58°C, 2) 
for ∆Np73flox: fl-F, 5' – CATAGCCATGGGCTCTCCT - 3' and fl-R (wt-R), 5'–
TGTCCTGCTGCTGGTTGTAT- 3', annealing temp: 63°C, 3) ΔNp73floxneo: flneo-F, 
5’-GGGAGGATTGGGAAGACAAT-3’ and flneo-R, 5’-
TGTCCTGCTGCTGGTTGTAT-3’ annealing temp:600C  and 4) for ∆Np73KO: ko-F, 
5’- CCTAGCCCAAGCATACTGGT-3’ and wt-R, 5’-TGTCCTGCTGCTGGTTGTAT-3’ 
annealing temp: 58°C. Primers used to genotype for the Cre gene are as follows: 
Cre-F, 5'–TGGGCGGCATGGTGCAAGTT-3' and Cre-R, 5'–
CGGTGCTAACCAGCGTTTTC-3', annealing temp: 60° C. The primers for 
ΔNp63WT, ΔNp63KO, ΔNp63flox and p53 were previously described(52, 105).  
2.3. Cell Lines 
Mouse embryonic fibroblasts (MEFs) for the indicated genotypes were generated as 
described previously(63). Human lung adenocarcinoma cells (H1299), colorectal 
adenocarcinoma cells (SW-480) and breast adenocarcinoma cells (MDA-MB-468) 
were purchased from ATCC and cutaneous SCC cell lines (SRB12, COLO16) were 
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a gift from Dr. K. Y. Tsai. The MEF’s, SW-480 and MDA-MB-468 cells were cultured 
in DMEM (Cellgro) and H1299 cell lines were cultured in RPMI 1640 (Cellgro). The 
SRB12 and COLO16(106) cell lines were grown in DMEM/Ham’s F12 50/50 
(Cellgro). All cell lines used in the study tested negative for mycoplasma.  
2.4. Immunhistochemistry  
Mice thymic lymphomas or thymii were dissected, fixed in 10% formalin, and 
embedded in paraffin.  Sections were dewaxed in xylene and re-hydrated using 
decreasing concentrations of ethanol. Antigens were unmasked in citrate buffer 
unmasking solution (Vector Laboratory) followed by incubation with blocking 
solution, and 18 hour incubation at 40C with the following antibodies: cleaved 
caspase 3 (1:200)(Cell Signaling), PCNA (1:500)(Cell Signaling), malondialdehyde 
(1:50)(Abcam). Visualization was performed using the ImmPact DAB peroxidase 
substrate kit (SK4105, Vector Laboratories) and counter-stained with Hematoxylin 
(H-3401, Vector Laboratories). The slides were mounted using VectaMount (H-5000, 
Vector Laboratories). Images were acquired using a Zeiss Axio microscope and 
analyzed with ProgRes Capture Pro 4.5 software. 
2.5. SA-β-gal staining 
SA-β-gal staining on mouse thymic lymphoma was performed as described 
previously(19). 
2.6. Quantitative real time PCR 
Total RNA was prepared from MEFs or mouse tissues using TRIzol reagent 
(Invitrogen)(50, 65, 107). cDNA was synthesized from 5mg of total RNA using the 
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SuperScript® III First-Strand Synthesis Kit (Invitrogen) according to the 
manufacturer’s protocol followed by qRT PCR using the SYBR Fast qPCR master 
mix (Kapa Biosystems). qRT-PCR was performed using a ABI 7500 Fast Real-time 
PCR machine. Primers for mouse TAp63, ΔNp63, PUMA, Noxa, bax, PML, p16 and 
p21(50, 65) and human TAp63, ΔNp63 and GAPDH were used as described 
previously (66, 68). Human primers for PUMA, Noxa, bax, PML, p16, p21 were used 
as described previously(19)  and GLS2 and TIGAR as described previously. Mouse 
primers for TAp73 are FOR:5’- GCACCTACTTTGACCTCCCC-3’, REV: 5’-
GCACTGCTGAGCAAATTGAAC-3’, ΔNp73 are FOR: 5’-
ATGCTTTACGTCGGTGACCC-3’, REV: 5’-GCACTGCTGAGCAAATTGGAAC-3’, 
IAPP are FOR: 5’- CTCCAAACTGCCATCTGAGGG-3’, REV: 5’- 
CGTTTGTCCATCTGAGGGTT-3’.   Human primers used for TAp73 are FOR: 5’- 
CAGACAGCACCTACTTCGACCTT-3’, REV: 5’-CCGCCCACCACCTCATTA-3’ and 
for ΔNp73 are FOR: 5’- TTCAGCCAGTTGACAGAACTAAG-3’, REV: 5’-
GGCCGTTTGTTGGCATTT-3’. 
2.7. Western blot analysis 
Fifty micrograms of protein were electrophoresed on a 10% or 15% SDS PAGE and 
transferred to PVDF membrane as described previously(50, 65, 107). Blots were 
probed with anti-p63 (1:500) (4A4, Santa Cruz), anti-TAp63 (1:1000) (BioLegend), 
anti-TAp73 (1:500)(IMG-246, Imgenex), anti-p73 (Mouse) (1:250)(IMG-259A, 
Imgenex), anti-p73 (1:1000) (human) (EP436Y, Abcam), anti-p53 (WT) 
(1:1000)(CM5, Vector Labs), anti-IAPP (1:1000)(ab103580, Abcam), anti-His 
(1:1000)(G18, Santa Cruz), anti-Hexokinase II (1:10000)(C64G5, Cell Signaling), 
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anti-calcitonin receptor (1:1000)(ab11042, Abcam), RAMP3(1:1000)(H125, Santa 
Cruz), and cleaved caspase 3 (1:1000)(Asp 175, Cell Signaling),  at 4oC for 18 hours 
followed by incubation for one hour at room temperature with the appropriate 
secondary antibodies conjugated to horseradish peroxidase (1:5000)(Jackson Lab). 
b-actin (Sigma 1:5000) was used as a loading control. Detection was performed 
using the ECL Plus Kit (Amersham) following the manufacturer’s protocol and x-ray 
autoradiography. 
2.8. Characterization of thymus using flow cytometry 
Thymii from 4 week old mice and thymic lymphomas from 10 week old mice were 
collected 48 hours after adenovirus infection. Single cells were obtained by 
homogenizing the thymii through a 0.75 mM filter. Cells were stained with CD3-PE 
(145-2C11), CD4-PerCP-Cy5.5 (RM4-5), CD8-APC (53-6.7), CD45-FITC (30-
F11)(BDPharmingen), AnnexinV-Pacific Blue (A35122, Life Technologies), and 7-
AAD (V35124, Invitrogen) and sorted using a BD Aria Cell Sorter or analyzed using 
the LSR Fortessa Cell Analyzer and FlowJo software. 
2.9. Chromatin Immunoprecipitation (ChIP) 
MEFs were grown to near confluence at passage 2 on DMEM media with 10% 
serum as previously described(63). Thymocytes from 6-week-old mice were 
collected 48 hours after adenovirus infection. Cellular proteins were cross-linked to 
DNA using 1% formaldehyde and chromatin was prepared as described 
previously(50, 65, 107). TAp63 and ∆Np63 ChIP analysis was performed using a 
pan-p63 antibody (4A4, Santa Cruz) as described previously and the TAp73 ChIP 
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was performed using a TAp73 antibody (ab14430, Abcam) and ∆Np73 ChIP was 
performed using a p73 antibody (IMG 259A, Imgenex). Putative TAp63 and TAp73 
binding sites were scanned 3000bp upstream of the 5’UTR and in intron 1 of the 
IAPP gene (NCBI Reference Sequence: NC_000072.5). qRT–PCR was performed 
by using primers specific for the indicated regions of the IAPP promoter:  Site 1 (-
406) -forward 5’-GTACATGAGGCTTGCTAAAGGC-3’ and (-329) -reverse 5’-
AGACCACAGAAAGCTCCCTC-3’, Site 2 (+761)-forward 
5’GCACAGAGTTGTTGCT-3’ and (+842) – reverse 5’-
CACACATGCAATGACAAACATTCT-3’, and non-specific site (+74911)- forward 5’- 
GGTGGCTCCTGTAGTATGTCT-3’ and (+75011) - reverse 5’- 
ACATCTCTAACAGCAAGAGACTCC-3’.  Similarly, putative ΔNp63 and ΔNp73 
binding sites were scanned 10000 bp upstream of the 5’UTR and in intron 1 of 
TAp63 and TAp73. qRT-PCR was performed by using the primers specific for the 
indicated regions on the TAp63 promoter: Site 1 (-41) –forward 5’-
CAGGAGCTCTCAAATCAAGTCAGA-3’ and (+37) –reverse 5’-
ATCACAGAAGCCAGGACTTGTCAC-3’ , and non-specific site (-3030) - forward 5’- 
GCTATAAATGTTTCCATGTGATGGATTGC-3’ and (-2973) - reverse 5’- 
TGCAGACTTAGCTATGGTCTCTTG-3’. Similarly, qRT-PCR was performed using 
the primers specific for the indicated regions on the TAp73 promoter: Site 1 (-1103) 
–forward 5’- CTAGCACACCAATCCAAGGAAAGA and (-1059) –reverse 5’- 
GCCTGCAGTCCGGGTTT-3’ and non-specific site (-2488) –forward 
5’ACTAGACCTCTGTACTTGTGAACATACATTT-3’ and (-2382) –reverse 5’-
GCACTCTCAFFATCCTGTAACAAAA-3’.  
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2.10. Dual luciferase reporter assay  
Luciferase assays were performed using p53-/-;p63-/- and p53-/-;p73-/- MEFs 
as described previously(69). To generate the luciferase reporter gene (pGL3-IAPP), 
the DNA fragment containing the TAp63/TAp73-binding site identified by ChIP was 
amplified from C57BL/6 genomic DNA by PCR with the following primers containing 
5’ XhoI and 3’ HindIII cloning restriction enzyme sites: IAPP 5’- 
ATACTCGAGGCACATCTAAGTTCATGAAGTGG-3’(forward) and 5’- 
ATAAAGCTTAGTTAACTCCTCAGTGGCCTTG-3’ (reverse). Similarly, a mutant 
version of the luciferase reporter gene (pGL3-IAPPMut) was generated using 
QuikChange Lightning (Agilent Technologies) following the manufacturer’s 
instructions. The following primers 5’ 
CATGAAGTGGGCAATTATAAAAGTACATCAGGGTTGCTAAAGGCTTTT-
3’(forward) and 5’-
AAAAGCCTTTAGCAACCCTGATGTACTTTTATAATTGCCCACTTCATG-
3’(reverse) were used to generate the mutant version. 
2.11. Reverse Transfection 
Cells were transfected with 50 nM siΔNp63 (SASI_Hs02 00328367)(Mission 
siRNA, Sigma), siΔNp73 (SASI_Hs02_00326884)(Mission siRNA, Sigma), siTAp63 
(SASI_Hs01_00246771) (Mission siRNA, Sigma), siTAp73 (SASI_Hs02_00339573) 
(Mission siRNA, Sigma), siRAMP3 (SASI_Hs01_00199036)(Mission siRNA, Sigma), 
siCalcitonin receptor (SASI_Hs01_00077738)(Mission siRNA, Sigma), siIAPP 
(SASI_Hs01_00183962) (Mission siRNA, Sigma) or  siNT(SIC_001)(Mission siRNA, 
Sigma) using Lipofectamine RNAiMAX (Invitrogen). The mixture of siRNA and 
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Lipofectamine were combined together and added to the well followed by the 
addition of 200,000 cells/well in a 6-well dish.  
2.12. Transfections - Generation of IAPP and Hexokinase II expressing cells 
3x105cells were plated in 10cm dishes. MEFs and human cancer cells were 
transfected with 8 mg Myc-DDK-IAPP (RC215074)(Origene) or 3.3mg HKII (Plasmid 
#25529)(Addgene) using X-tremeGENE HP (Roche) and incubated for 48-60hrs. 
Cells were selected with G418, MEFs (350mg/ml) and human cancer cells 
(500mg/ml) for a period of 9 days. 
2.13. Secreted IAPP Protein concentration 
Twelve hours after knockdown of ΔNp63/ΔNp73 in human cancer cells, fresh 
serum free media was added to the cells. Following a sixty-hour incubation, the 
media was collected and concentrated using Amicon Ultra-15 Centrifugal Filter Units 
(UFC901008, EMD Millipore).  
2.14. RNA Sequencing and Analysis 
Five µg of polyA+ RNA were used to construct RNA-Seq libraries using the 
standard Illumina protocol. Mouse mRNA sequencing yielded 30-40 million read 
pairs for each sample. The mouse mRNA-Seq reads were mapped using 
TopHat(108) onto the mouse genome and build UCSC mm9 (NCBI 37) and the 
RefSeq mouse genes. Gene expression and gene expression differences were 
computed using Cufflinks(108). For each species, a combined profile of all samples 
was computed; mRNA abundance was mean-centered and Z-score transformed for 
each mRNA individually. Principal component analysis was executed using the 
implementation within the R statistical analysis system. Hierarchical clustering of 
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samples was executed by first computing the symmetrical sample distance matrix 
using the Pearson correlation between mRNA profiles as a metric, supervised 
sample analysis was performed using the t-test statistics, and heatmaps were 
generated using the heatmap.2 package in R. For gene signatures and pathway 
analysis gene list from the RNA-Seq comparing ΔNfl/fl;p53-/- versus ΔNp63Δ/Δ;p53-
/- and ΔNp73Δ/Δ;p53-/- were obtained at a p-value <0.01. The genes upregulated in 
the ΔNp63Δ/Δ;p53-/- and ΔNp73Δ/Δ;p53-/- and down regulated in the ΔNfl/fl;p53-/- 
were selected. The relative fold change of the genes were calculated and sorted 
from highest to lowest. Genes with a greater than 1.5 fold-increase were selected 
and run through the Ingenuity Pathway Analysis (IPA) (Ingenuity Systems) to screen 
for pathways and processes. Genes from the selected pathways were cross-
referenced with the Gene Set Enrichment (GSEA)(Broad Institute) data analysis, 
DAVID Bioinformatics Resource 6.7 and GSEA implementation at the Molecular 
Signature Database (MSigD)(109).  
2.15. Magnetic Resonance Imaging 
MRI imaging was performed at 10 weeks of age when the tumours were 
established and the volumes range from 2.3 mm3 to 5 mm3. To reduce the variation 
between different groups of mice, a cohort of n=5 with similar tumour volumes was 
established and tumors regression was monitored by MRI. All mice were scanned 
once a week for a period of 35 weeks on a 7-Tesla, 30-cm bore BioSpec MRI 
system (Bruker Biospin Corp., Billerica, MA) . 
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2.16. Hyperpolarized Magnetic Resonance Spectroscopy 
Dynamic MR spectroscopy (MRS) of hyperpolarized (HP) [1-13C] pyruvate 
was performed in vivo in tumour bearing mice.  To achieve polarization, a 26-mg 
sample of pyruvic acid (Sigma-Aldrich, St. Louis, MO) with 15 mM of OX063 radical 
(GE Healthcare, Waukesha, WI) and 1.5-mM Prohance (Bracco Diagnostics Inc., 
Monroe Township, NJ) was polarized in a HyperSense DNP system (Oxford 
Instruments, Abington, Oxfordshire, UK) as previously described(110, 111).  The 
frozen sample was dissolved in a 4-mL buffer containing 40-mM TRIS, 80-mM 
NaOH, and 50-mM NaCl, resulting in a final isotonic and neutral solution containing 
80-mM [1-13C] pyruvate.  A dual-tuned 1H/13C linear RF volume coil with 72mm ID 
was used in conjunction with imaging gradients with 12cm ID.  For anatomic 
imaging, the 1H channel was used in transmit/receive mode.  In addition to localizing 
scans, flow-weighted oblique gradient echo images (TE = 1.4ms; TR = 55ms; 90° 
excitation; 3cm x 3cm FOV encoded over a 64 x 64 image matrix) were acquired to 
confirm that the slice prescription for 13C measurements would not be obfuscated 
by signals originating from within the heart. For carbon spectroscopy, the RF volume 
coil was used in transmit-only mode in conjunction with a custom-built 15-mm ID 13C 
surface coil for signal reception.   After dissolution, 200 µL of the HP [1-13C] pyruvate 
solution was administered to the animals via tail-vein catheter.  A slice-selective 
pulse-acquire sequence (TR = 1,500 ms; 15° flip angle; 5 KHz spectral bandwidth; 
2048 spectral points; 8-mm oblique slab; 120 repetitions) was used for dynamic 
spectroscopy beginning approximately 15s prior to injection.  Data were processed 
to generate spectral time-courses of the HP-pyruvate and its lactate product.  
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Spectra were phase adjusted and the area under the spectral peaks associated with 
[1-13C] pyruvate and [1-13C] lactate were integrated over time to reflect the overall 
signal observed from each metabolite over the course of the measurement.  Total 
lactate signal, which could only arise from interaction of HP pyruvate with relevant 
metabolic enzymes, was normalized to the total signal from pyruvate. 
2.17. Glycolysis Stress Assay  
Extra-cellular acidification rate (ECAR) was measured using the extracellular 
flux analyzer (SeaHorse Bioscience XF96) following the manufacturer’s instructions. 
Forty-eight hours after transfection, the cells were plated at a density of 1.5x104 cells 
per well in the XF 96-well cell culture plates. Twenty-four hours after seeding, the 
culture medium was replaced with 180 ml of running medium and incubated for 1 
hour at 370C in a non-CO2 incubator. Before calibration, 20 ml of 50 mM glucose, 11 
mM oligomycin and 650 mM 2-DG were aliquoted into each port in the sensor 
cartridge. ECAR was measured after the addition of glucose and oligomycin and 
before the addition of 2-DG. Extra-cellular acidification rate was normalized to 
mpH/min. 
2.18. Glucose Uptake Measurement 
Glucose uptake was calculated as a measure of glucose dependent proton 
secretion from the maximum and basal glucose consumption after addition of 20 ml 
of 50 mM glucose and measured using the extracellular flux analyzer (SeaHorse 
Biosciences XF96).  
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2.19. Glucose-6-phosphate Assay 
Glucose-6-phosphate was measured using the Glucose-6-phosphate assay 
kit (ab83426, Abcam) following the manufacturer’s instructions. Forty-eight hours 
after transfection, 2x106 cells were collected, homogenized and passed through a 10 
kD spin-column filter. The eluate was collected and glucose-6-phosphate enzyme 
and substrate reaction was performed for 30 min and absorbance was measured at 
450nm.  
2.20. Proliferation Assay 
The transfected human cancer cells were plated at a density of 5x103 cells in 
6 replicates in a 96-well dish. Twelve hours later, the cells were labeled with 10 mM 
EdU (5’-ethynyl-2’-deoxyuridine) for a period of 8 hours. The assay was performed 
using the Click-iT EdU microplate assay (Invitrogen).  Images were obtained using a 
Zeiss Axio fluorescent microscope and analyzed using the AxioVision Image 4.5 
software. 
2.21. Apoptosis Assay 
Cells were plated at a density of 1x104 cells in 6 replicates in a 96-well dish. 
Twelve hours later, the cells were washed with 1X Annexin binding buffer and a 
cocktail of 5ml Annexin V-Alexa Fluor 488 for 100mg/ml propidium iodide (PI) and 
2mg/ml Hoechst 33342 (Invitrogen) was added.  Images were captured using the 
Zeiss fluorescent microscope and Axiovision Image 4.5 software. Quantification of 
the percent apoptosis was obtained using a high-throughput immunofluorescence 
plate reader (Celigo). 
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2.22. ROS Assay 
Cells were plated at a density of 1x104 cells in 6 replicates in 96-well dish. 
Twelve hours later, the cells were incubated with a cocktail of 5 mM concentration of 
CellROX Deep Red Reagent (C10422, Invitrogen) and 2 mg/ml Hoechst 
33342(Invitrogen) for 45 minutes at 37oC. Images were captured using a Zeiss 
fluorescent microscope and Axiovision Image 4.5 software. Quantification of the 
percent ROS was obtained using a high-throughput immunofluorescence plate 
reader (Celigo)(112). 
2.23. In vitro Adeno-Cre Infection 
ΔNp63fl/fl;p53-/- and ΔNp73fl/flp53-/- MEFs were plated at a density of 
2.5x105 cells in 10 cm dishes before infection. Twelve hours later, MEFs were 
infected with Adeno-CMV-mCherry or Adeno-CMV-Cre-mCherry (Gene Transfer 
Vector Core Facility, University of Iowa).  The cells were infected at an MOI of 6000 
particles/cell. The efficiency of infection was quantified by assessing mCherry 
positive cells. 
2.24. In vivo Adeno-virus Infection and IVIS Lumina Imaging 
All mice were anesthetized using isoflurane and 2% oxygen and placed on a 
custom bed. An incision was performed to expose the sternum. Using a 28.5G U100 
Insulin syringe, Adeno-mCherry/Adeno-Cre-mCherry (Gene Transfer Vector Core 
Facility, University of Iowa), Adeno-IAPP-mCherry(Vector Labs) or Adeno-shIAPP-
U6-mCherry (TRCN0000416196, Mission shRNA)(Vector Labs) was surgically 
administered by intra-thymic injection (5x1012 viral particles/gram of body weight) 
through the 2nd and 3rd sternum. The incision was sealed using wound clips and 
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mice were allowed to recover.  To determine the efficiency of the in vivo viral 
delivery to the thymic lymphoma, IVIS Lumina Imaging (Perkin Elmer) was 
performed 48 hours later. Images were captured using a Mid-600 series bandwidth 
filter and analyzed using the Living Image® data analysis software. 
2.25. shRNA Knockdown 
shRNA plasmids for TAp63 (Clone ID: V3LMM_508694) and TAp73 (Clone 
ID: V3LMM_438557) were obtained from the MD Anderson shRNA core facility 
(Open Biosystems). 293T cells were plated at a density of 2.5 x 105 cells in 10 cm 
dishes. Three micrograms of shRNA and packaging vectors were transfected as 
described previously. Cells were selected using puromycin (3 mg/ml) for 7 days.  
2.26. In vitro and in vivo administration of 2-Deoxy-D-glucose 
1x104 cells were plated in 6 replicate wells in a 96-well dish. Twelve hours 
later, the human cancer cells were treated with 50 mM final concentration of 2-
Deoxy-D-glucose (2-DG) (D8375-5G, Sigma) for 1 hour. Similarly, 2-DG (500 mg/kg 
of tumour weight)(D8375-5G-Sigma) was administered directly into the lymphoma of 
mice as described earlier(110).  
2.27. N-acetyl-L-cysteine treatment 
1x104 cells were plated in 6 replicate wells in a 96-well dish. Twelve hours 
later, cells were treated with N-acetyl-L-cysteine (NAC) (2 mM)(A8199, Sigma) final 
concentration for a period of 1 hour. 
2.28. Amylin and caspase inhibitor treatment 
2x105 cells were plated in triplicate in a 6-well dish. Twelve hours later, cells 
were treated with Amylin peptide (5mM) (A5972, Sigma) or with a Caspase 1 
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inhibitor (20mM)(Z-YVAD-FMK-218746, Calbiochem) for a period of 48 hours.  
2.29. In vitro and in vivo administration of Pramlintide Acetate 
2x105 cells were plated in duplicate in a 6-well dish. Twelve hours later, cells 
were treated with 10 mg/ml Pramlintide acetate (AMYLIN Pharmaceuticals) or 
placebo for a period of 48 hours.  Pramlintide acetate (AMYLIN Pharmaceuticals) or 
placebo (sodium acetate/acetic acid) was surgically administered through non-
invasive intra-thymic injection using a multiple dose protocol of Pramlintide acetate 
(30 mg/gram of tumour weight).  One injection per week for three weeks was 
administered directly into the thymic lymphoma of the animal. Another cohort of mice 
was treated bi-weekly for 3 weeks by intra-venous (I.V.) tail-vein injection of 
Pramlintide acetate (45 mg/kg body weight) or placebo. The investigator was blinded 
to the treatment administered to each mouse. Tumour volumes were monitored 
weekly by MRI.  Health and blood glucose levels of the treated animals were 
monitored weekly. 
2.30. In vitro and In vivo administration of Calcitonin receptor antagonist 
2x105 cells were plated in duplicate in a 6-well dish. Twelve hours later, cells 
were treated with Calcitonin receptor antagonist (1 nM)(AC187, Tocris Bioscience) 
for a period of 48 hours with or without simultaneous Pramlintide treatment. 
Similarly, a chronic dose of Calcitonin receptor antagonist (1 nM/gram of tumour 
weight) was administered through non-invasive intra-thymic injections with one 
injection every week for a period of three weeks with or without simultaneous 
Pramlintide treatment. Tumour volume was monitored and measured weekly by 
MRI. 
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2.31. Survival Analysis  
Survival analysis was conducted for the IAPP, RAMP3 and CalCR gene in the 
following datasets: the Memorial Sloan Kettering Cancer Center and the TCGA 
Cancer cohort. We considered four major cancer types with high p53 mutation rates, 
which include lung squamous cell carcinoma(113), head & neck squamous cell 
cancer(114), basal breast cancer(115), and colon cancer(116). The co-expression of 
the three genes was analyzed in cases only with p53-mutation. In all cases, we 
considered gene expression changes above or below 2 standard deviations with 
respect to the normal controls.  The log-rank test and Cox P test was used to assess 
significance between the samples with or without expression changes of the IAPP, 
RAMP3 and CalCR gene using the cBioPortal for cancer genomics(117). 
2.32. Statistics 
Sample size for mouse cohorts in each experiment was chosen based on the 
penetrance of the thymic lymphoma phenotype of the p53-/- mouse model (80%).  
Twenty to thirty mice were used for survival analyses. Data were analysed using a 
one-way ANOVA test or a Student’s t-test (two-sided) was used for comparison 
between two groups of data. A p-value of 0.05 was considered significant. Data are 
represented as mean ± s.e.m. 
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Chapter 3. ΔNp63 and ΔNp73 function as oncogenes in a p53-deficient model 
of thymic lymphoma 
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driven metabolic reprogramming induces regression of p53-deficient tumors in vivo. 
Nature. 2015; 517(7536),626-630. doi:10.1038/nature13910. 
 
Copyright permission not required since Nature journal policy states “Author retains 
the copyright to the published materials” 
3.1. Introduction & Rationale 
 Most human cancers harbor inactivating or gain of function mutations in the 
p53 tumor suppressor gene(118).  In order to develop a better therapeutic 
alternative to treat these human cancers with p53 mutation, we explored the role of 
the p53-family members p63 and p73(119). However, the function of p63 and p73 is 
complex due to the presence of multiple splicing isoforms, namely the TA and ΔN 
isoforms(45). Previous research work has demonstrated that both TAp63 and TAp73 
function as bonafide tumor suppressors(65, 120). However, the role of the ΔN 
isoforms has been controversial due to its dominant negative functions(60). Both 
ΔNp63 and ΔNp73 function as dominant negative inhibitors of p53, TAp63 and 
TAp73. In vitro experiments suggest that ΔNp63 and ΔNp73 could function both as 
tumor suppressors and oncogenes(72, 121). Hence, to determine the role of the ΔN 
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isoforms of p63 and p73 in tumorigenesis, we generated conditional knockout 
mouse models for ΔNp63 (ΔNp63fl/fl)(74) and ΔNp73 (ΔNp73fl/fl)(74). These mice 
were further crossed to a Zp3 transgenic mouse to generate a ΔNp63+/-(52) and a 
ΔNp73-/- (74)compound mouse.  
 To further accelerate tumorigenesis and also understand the role of ΔNp63 
and ΔNp73 in the context of p53 deficiency, I crossed the ΔNp63+/- mice to the p53-
null mice and generated a ΔNp63+/-;p53-/- mice cohort and similarly, the ΔNp73-/- 
mice were crossed to the p53-null mice to generate a ΔNp73-/-;p53-/- mice. In this 
chapter, I further characterize the tumor spectrum obtained from these double 
mutant compound mice. I also investigate the response of these double mutant 
compound mice in response to genotoxic stress. Finally, I perform an acute deletion 
of the ΔN isoforms in the p53-deficient thymic lymphomas in vivo to determine the 
mechanistic function of the ΔN isoforms of p63 and p73 and also the interplay 
among the p63 and p73 isoforms in cancer. 
 
3.2. Results 
3.2.1. ΔNp63 and p53 or ΔNp73 and p53 double deficient compound mice have 
reduced thymic lymphomagenesis 
 A cohort of ΔNp63+/-;p53-/- (n=30) and ΔNp73-/-;p53-/- (n=30) mice were 
generated along with a cohort of p53-/- mice (n=30). I observed that the mice double 
deficient for ΔNp63 and p53 or ΔNp73 and p53 had a significant reduction in the 
thymic lymphomagenesis compared to the p53-/- mice (Figure 5a). The ΔNp63+/-  
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Figure 5: Decreased thymic lymphomagenesis and increased survival in mice 
double deficient for ∆Np63 and p53 or ∆Np73 and p53.  Quantification of thymic 
lymphoma incidence (n=30 mice) (a).  Table showing thymic lymphoma volumes.  
The difference in tumour volumes between p53-/- and ∆Np63+/-;p53-/- and p53-/- 
and ∆Np73-/-;p53-/-  was statistically significant with p values of <0.03 and <0.002 
respectively (b).  Kaplan Meier survival in mice (c).  Boxed numbers indicate median 
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survival.  Western blot analysis of thymic lymphomas of the indicated genotypes.  
Arrows indicate specific isoforms.  Asterisks indicate non-specific bands (d & e).  
Q-RT PCR for PUMA (f), Noxa (g), and bax (h) in thymic lymphomas of the 
indicated genotypes, n=4, p<0.005.  Immunohistochemistry (IHC) for cleaved 
caspase 3 in thymic lymphomas (i).  Quantification of apoptosis as assessed by 
cleaved caspase 3 staining (j), n=20 fields of 3 biological replicates, p<0.005.  Q-RT 
PCR for PML (k), p16 (l), and p21 (m) in indicated thymic lymphomas, n=4, p<0.005.  
IHC for PCNA in indicated thymic lymphomas (n).  Quantification of the percentage 
of proliferation as assessed by PCNA staining (o), n=20 fields of 3 biological 
replicates, p<0.005.  Statistical significance indicated by black asterisks. 
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;p53-/- mice had a tumor incidence of 29.7% and the ΔNp73-/-;p53-/- mice had a 
tumor incidence of 63.3% compared to the p53-/- mice which develop thymic 
lymphomas at a 90% incidence rate. Importantly, I also observed significant 
differences in the tumor volumes between the double deficient compound mice 
compared to the p53-null mice (Figure 5b). The thymic lymphomas from the 
ΔNp63+/-;p53-/- mice measured 2.8mm3 and the ΔNp73-/-;p53-/- mice measured 
1.3mm3 in volume compared to the p53-/- mice that measured 3.4mm3 in volume. 
Interestingly, I also observed that the double deficient compound mice (ΔNp63+/-
;p53-/- and ΔNp73-/-;p53-/-) mice had increased survival compared to the p53-null 
mice which normally die by 4 months of age (Figure 5c). Thus, the in vivo analysis 
from the double deficient mouse cohorts suggests that ΔNp63 and ΔNp73 could 
have oncogenic roles in p53-deficent thymic lymphomas. 
 To further characterize the phenotype of reduced thymic lymphoma incidence 
and decreased tumor volume in the double deficient compound mice, thymic 
lymphoma tissues from the double deficient compound mice (ΔNp63+/-;p53-/- and 
ΔNp73-/-;p53-/-) and p53-null mice were collected to perform western blot analysis, 
quantitative real-time PCR (qRT-PCR) and immunohistochemistry (IHC). Western 
blot analysis (Figure 5d-e) of the thymic lymphoma tissues from the ΔNp63+/-;p53-/- 
and ΔNp73-/-;p53-/- mice had increased expression of full-length isoforms of p63 
and p73, namely TAp63 and TAp73 compared to the p53-/- thymic lymphoma 
samples. This suggests that loss of ΔN isoforms of p63 and p73, results in the 
activation or upregulation of TAp63 and TAp73 in the thymic lymphoma tissues. 
Since, TAp63 and TAp73 are tumor suppressors(65, 120), I hypothesized that 
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TAp63 and TAp73 could function to mediate the reduced thymic lymphomagenesis 
in these double deficient mice. Indeed, qRT-PCR analysis of the double deficient 
thymic lymphoma tissues revealed a significant upregulation of the genes involved in 
apoptosis like PUMA, Noxa and BAX (Figure 5f-h).  This correlated with an increase 
in apoptosis in the double deficient lymphomas compared to the p53-null lymphomas 
as demonstrated by immunohistochemistry (Figure 5i-j). Also, cell-cycle arrest 
targets, namely, p16, p21 and PML were also upregulated in the double deficient 
thymic lymphomas compared to the p53-null lymphoma tissues (Figure 5k-m). This 
correlated with reduced proliferation in the double deficient lymphomas compared to 
the p53-null lymphoma tissues (Figure 5n-o). This suggests that upon loss of ΔNp63 
and ΔNp73 in p53-deficient lymphomas, TA isoforms of p63 and p73 are 
upregulated and compensate for p53-loss of function by activating downstream 
apoptosis and cell cycle targets mediating tumor regression. 
3.2.2. Increased apoptosis and cell-cycle arrest in the ΔNp63+/-;p53-/- and 
ΔNp73-/-;p53-/- thymocytes after genotoxic stress 
 TAp63 and TAp73 are tumor suppressors that are usually activated in 
response to genotoxic stress and DNA damage(63). Hence, to determine whether 
TAp63 and TAp73 induce apoptosis and cell cycle arrest in the double deficient 
thymus tissues, 4 week-old mice were treated with 10Gy gamma radiation, a dose 
that was previously demonstrated to induce a p53-dependent response. The double 
deficient thymocytes had an increased expression of TAp63 and TAp73 after DNA 
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Figure 6: Increased apoptosis and cell cycle arrest in ∆Np63+/-;p53-/-  and 
∆Np73-/-;p53-/- thymocytes after genotoxic stress.  Western blot analysis in 
thymocytes derived from mice 6 hours after treatment with 0 Gy or 10Gy gamma 
irradiation (a).  Q-RT PCR for TAp63 (b), TAp73 (c), PUMA (d), Noxa (e), and bax 
(f) from samples shown in (a), n=4, p<0.005. Q-RT-PCR normalized to samples 
treated with 0 Gy. Immunohistochemistry (IHC) for cleaved caspase 3 in samples 
from (a) (g).  Quantification of the percentage of apoptosis as assessed by cleaved 
caspase 3 staining (h), n=20 fields of 3 biological replicates, p<0.005.  Q-RT PCR 
for PML (i), p16 (j), and p21 (k) using total RNA from samples shown in (a), n=4, 
p<0.005.  IHC for PCNA in samples shown in (a) (l).  Quantification of the 
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percentage of proliferation as assessed by PCNA staining (m), n=20 fields of 3 
biological replicates, p<0.005. Statistical significance is indicated by black asterisks. 
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damage compared to the p53-null thymocytes (Figure 6a-c). This correlated with the 
increased relative expression of the apoptosis targets PUMA, Noxa and BAX (Figure 
d-f) and increased cell death as denoted by the IHC (Figure g-h) in the double 
deficient thymic lymphoma tissues compared to the p53-deficient lymphomas. Also, 
increased relative expression of the cell cycle targets namely p16, p21 and PML 
(Figure i-k) and reduced expression for cell proliferation (Figure l-m) was observed in 
the double deficient thymic lymphoma tissues compared to the p53-null samples. 
These data suggest that TAp63 and TAp73 are upregulated upon genotoxic stress 
and can compensate for p53 function by activating apoptosis and cell cycle targets.  
3.3.3. In vivo deletion of ΔNp63 or ΔNp73 in p53-deficient mice suppresses 
thymic lymphomagenesis 
 Initial analysis utilizing the ΔNp63+/-;p53-/- and ΔNp73-/-;p53-/- have clearly 
demonstrated that loss of ΔNp63 and ΔNp73 results in reduced thymic 
lymphomagenesis in the p53-deficeint mice(74). Additionally, TAp63 and TAp73 are 
upregulated in the double mutant thymic lymphoma and also upon genotoxic stress 
in the double deficient mouse thymocytes. Hence to further test whether TAp63 and 
TAp73 can compensate for p53-loss in suppressing lymphomagenesis, a cohort of 
ΔNp63fl/fl;p53-/- and ΔNp73fl/fl;p53-/- mice were generated.  These mice were aged 
up to 10 weeks and the presence of the thymic lymphoma was determined using a 
magnetic resonance imaging (MRI). Mice that have a tumor volume ranging from 
2.5mm3 to 5.8mm3 were selected for further analysis. A cohort of ΔNp63fl/fl;p53-/- 
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Figure 7: Acute deletion of ΔNp63 or ΔNp73 in p53-deficient thymic 
lymphomas mediates tumor regression. IVIS Lumina imaging of thymic 
lymphomas of mice of the indicated genotypes infected with Adenovirus (Ad)-
mCherry (a) or Ad-Cre-mCherry (b & c) at 10 weeks of age and 48 hours after 
adenoviral delivery.  Red fluorescence indicates viral delivery to the thymus shown 
by the yellow dashed ovals.  Red fluorescence near the mouth is due to auto-
fluorescence of calcium and mineral deposits in the teeth.  Magnetic Resonance 
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Imaging (MRI) of thymic lymphomas of indicated mice (d-i).  Tumour volume (mm3) 
within each panel. UN-D = undetectable.  Tumours indicated by the dashed yellow 
line.  Quantification of the indicated thymic lymphomas (j-l), n=9 mice. Kaplan Meier 
curve (m), n=9, p<0.005.  Boxed numbers represent median survival. 
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and ΔNp73fl/fl;p53-/- mice were administered either adenovirus CRE (Ad-CRE) or 
adenovirus-mCherry (Ad-mCherry) by intratumoral delivery. The intratumoral 
adenovirus delivery localization only to the region of the lymphoma was validated by 
IVIS lumina imaging (Figure 7a). The adenovirus CRE specifically deletes ΔNp63 or 
ΔNp73 in the p53-deficient thymic lymphomas, generating a ΔNp63Δ/Δ;p53-/- or a 
ΔNp73Δ/Δ;p53-/- cohort. Interestingly, upon administering Ad-CRE to the 
ΔNp63fl/fl;p53-/- and ΔNp73fl/fl;p53-/- thymic lymphomas, the mice had a significant 
reduction in the thymic lymphomas as accessed by the MR images compared to the 
ΔNfl/f;p53-/- mice administered with Ad-mCherry (Figure 7d-l). By 18 weeks, the 
thymic lymphoma in the ΔNp63Δ/Δ;p53-/- (Figure 7e, h & k) and ΔNp73Δ/Δ;p53-/- 
(Figure 7f, I & l) mice were undetectable while the ΔNfl/fl;p53-/- (Figure 7d, g & j) 
while mice administered with Ad-mCherry had a significant tumor burden. 
Importantly, the ΔNp63Δ/Δ;p53-/- and ΔNp73Δ/Δ;p53-/- mice had significant survival 
compared to the ΔNfl/fl;p53-/- mice which died by 18 weeks of age (Figure 7m). 
In order to further characterize, the reduction in the thymic lymphoma upon 
deletion of ΔNp63 or ΔNp73 in the p53-deficent mice, thymic lymphoma tissues from 
the ΔNp63Δ/Δ;p53-/- and ΔNp73Δ/Δ;p53-/- mice were collected 48 hours after 
administering Ad-CRE. Since, most of the biological functions like apoptosis or cell-
cycle arrest occur transiently, I was interested in understanding the molecular 
responses that could be activated after deleting ΔNp63 or ΔNp73 in the p53-
deficient thymic lymphomas. Interestingly, the ΔNp63Δ/Δ;p53-/- and ΔNp73Δ/Δ;p53-
/- thymic lymphoma tissues had increased expression of TAp63 and TAp73 after 
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Figure 8: Loss of ΔNp63 or ΔNp73 in p53-deficient thymic lymphomas results 
in upregulation of TAp63 and TAp73 with induction of apoptosis and cell cycle 
arrest. Quantitative real time (qRT-PCR)  (a-d). n=4, p<0.005 and western blot 
analysis using lysates from indicated thymic lymphomas 48 hours after infection with 
Adenovirus (Ad)-mCherry or Ad-Cre-mCherry (e). Quantitative real time (qRT-PCR) 
of thymic lymphomas 48 hours after infection with Ad-mCherry (∆Nfl/fl;p53-/-) or Ad-
Cre-mCherry (∆Np63∆/∆;p53-/- or ∆Np73∆/∆;p53-/-) (f-g). n=4, p<0.005.	  	   
Immunohistochemistry (IHC) for cleaved caspase 3 in thymic lymphomas 48 hours 
after infection with Ad-mCherry (∆Nfl/fl;p53-/-) or Ad-Cre-mCherry (∆Np63∆/∆;p53-/- 
or ∆Np73∆/∆;p53-/-) (h). Quantification of apoptosis as assessed by cleaved 
caspase 3 staining of the indicated thymic lymphomas (i), n=20 fields of 3 biological 
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replicates, p<0.005. Q-RT-PCR of thymic lymphomas 48 hours after treatment with 
Ad-mCherry (∆Nfl/fl;p53-/-) or Ad-Cre-mCherry (∆Np63∆/∆;p53-/- or ∆Np73∆/∆;p53-/-
), n=4, p<0.005 (j-k).  Senescence associated beta galactosidase (SA-β-gal) staining 
(blue) of thymic lymphomas 48 hours after treatment with Ad-mCherry (∆Nfl/fl;p53-/-) 
or Ad-Cre-mCherry (∆Np63∆/∆;p53-/- or ∆Np73∆/∆;p53-/-) (l) 
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deleting ΔNp63 and ΔNp73 compared to the ΔNfl/fl;p53-/- lymphoma tissues 
administered with Ad-mCherry (Figure 8a-e). This suggests that TAp63 and TAp73 
are activated upon loss of ΔNp63 and ΔNp73 in the p53-deficient thymic 
lymphomas. Interestingly, the increased expression of TAp63 and TAp73 in the 
ΔNp63Δ/Δ;p53-/- and ΔNp73Δ/Δ;p53-/- thymic lymphomas correlated with the 
increased expression of the apoptosis targets PUMA, Noxa and BAX (Figure 8f-g) 
and an increase in apoptosis (Figure 8h-i) compared to the ΔNfl/fl;p53-/- thymic 
lymphomas. Similarly, increased expression of cell cycle targets p16, p21 and PML  
(Figure 8j-k) and cellular senescence (Figure l) was observed in the ΔNp63Δ/Δ;p53-
/- and ΔNp73Δ/Δ;p53-/- thymic lymphomas. This data suggests that TAp63 and 
TAp73 can compensate for p53-loss of function by activating apoptosis and cell-
cycle arrest targets mediating tumor shrinkage.  
3.3.4. Loss of ΔNp63 and ΔNp73 in p53-deficient thymic lymphomas 
accelerates tumor regression 
 Ablation of ΔNp63 or ΔNp73 in p53-deficient thymic lymphomas mediates 
tumor regression(74). Importantly, the ΔNp63/ΔNp73 deleted p53-deficient mice 
have increased survival compared to the p53-deficient mice. Hence, to test whether 
deleting both ΔNp63 and ΔNp73 in the p53-deficient thymic lymphomas accelerates 
the tumor regression a cohort of ΔNp63fl/fl;ΔNp73fl/fl;p53-/- mice was generated. At 
10 weeks, MR imaging was performed to confirm the presence of a thymic 
lymphoma. ΔNp63 and ΔNp73 was acutely deleted using adeno-CRE in the p53-
deficient thymic lymphomas. Loss of ΔNp63 and ΔNp73 in the p53-deficient thymic 
lymphomas resulted in rapid reduction in the tumor volume (Figure 9a-t) and  
	   59	  
 
 
	   60	  
Figure 9:  Ablation of ΔNp63 and ΔNp73 in p53-deficient mice accelerates 
tumor regression. Magnetic Resonance Imaging (MRI) of mice of the indicated 
genotypes. (a-p) (n=4). Mice were administered with either Adeno-mCherry (a-d) or 
Adeno-CRE-mCherry (e-p). Tumour volume (mm3) within each panel. UN-D = 
undetectable.  Tumours indicated by the dashed yellow line.  Tumor volume 
quantification of thymic lymphomas (q-t), n=4 mice. Kaplan Meier curve (n), n=4, 
p<0.005.  Boxed numbers represent median survival. 
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Figure 10: Ablation of ΔNp63 and ΔNp73 in p53-deficient thymic lymphomas 
results in accumulation of ROS, apoptosis and cell-cycle arrest. IHC panels of 
the indicated genotypes representing staining for ROS, apoptosis and proliferation. 
Brown nuclei represent positive cells 
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Figure 11: Loss of ΔNp63/ΔNp73 in p53-deficient thymic lymphomas affects 
the CD4-CD8 double positive cells. Flow cytometry plots of the indicated 
thymocytes at 4-week of age (a-d). Bar graph showing quantification of CD4, CD8, 
and CD4/CD8 double positive (DP) cells. n=3 mice per genotype, p<0.005 (e). Flow 
Cytometry plots of thymic lymphoma cells 48 hours after adenovirus-mCherry or 
adenovirus-CRE treatment for the indicated genotypes (f-h). Bar graph showing 
quantification of CD4, CD8, and CD4/CD8 double positive (DP) cells in the indicated 
genotypes. n=3 mice per genotype, p<0.005 (i). Cartoon representation of isolation 
of CD45-postive thymic lymphoma cells from 10 week old mice of indicated 
genotypes (j).  Western blot analysis of CD45-postive thymic lymphoma cells after 
treatment with Ad-mCherry (ΔNfl/fl;p53-/-) or Ad-CRE-mCherry (ΔNp63Δ/Δ/;p53-/- 
and ΔNp73Δ/Δ;p53-/-) (k). Statistical significance is indicated by black asterisks. 
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increased survival (Figure 9n). The tumor regression phenotype also correlated with 
the increase in ROS, cell death and reduction in cell proliferation (Figure 10). This 
suggests that targeting ΔN isoforms of p63 and p73 could be used as a viable option 
to treat p53-deficient cancers. 
3.3.5. Loss of ΔNp63 or ΔNp73 in p53-deficient thymic lymphomas affects the 
CD4-CD8 double positive cells 
 The p53-deficient mice develop thymic lymphoma, which are of T-cell 
origin(22). In order to test whether depletion of either ΔN isoforms of p63 and p73 
affects the T cells development, a cohort of mice at 4 weeks was established. FACS 
analysis with the mouse thymocytes was performed using CD3, CD4 and CD8 
markers, which label the T-cell receptor complex, T-helper cells and T-lymphocytes 
respectively. The ΔNp63+/-;p53-/- and ΔNp73-/-;p53-/- mouse thymocytes had 
decreased number of CD4-CD8 double positive cells compared to the p53-deficient 
and the wild-type mouse thymocytes (Figure 11a-e). This suggests that reduction in 
the number of CD4-CD8 double positive cells correlates with the reduced tumor 
volume and incidence in the double mutant compound mice. Hence, to test whether 
this is the case, ΔNp63 and ΔNp73 were acutely deleted in the thymic lymphomas of 
ΔNp63fl/fl;p53-/- and ΔNp73fl/fl;p53-/- mice. Upon analyzing the p53-deficient thymic 
lymphoma cells, 48 hours after deletion of ΔNp63 or ΔNp73, I observed a significant 
reduction in the CD4-CD8 positive cells compared to the ΔNfl/fl;p53-/- thymic 
lymphoma cells (Figure 11f-i). This suggests that loss of ΔNp63 and ΔNp73 in the  
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Figure 12: ΔNp63 and ΔNp73 transcriptionally repress TAp63 and TAp73. 
Western blot analysis in ΔNp63fl/fl;p53-/- MEFs before (∆Np63fl/fl;p53-/-) and after 
(∆Np63∆/∆;p53-/-) Ad-cre administration (a). Q-RT-PCR for ΔNp63 (b) and TAp63 
(c) in indicated MEFs. Western blot analysis in ΔNp73fl/fl;p53-/-  and  
∆Np73∆/∆;p53-/- MEFs (d). Q-RT-PCR for ΔNp73 (e) and TAp73 (f) in indicated 
MEFs. n=4, p<0.005. Q-RT-PCR of chromatin Immunoprecipitation using indicated 
MEFs and an antibody for p63 (g) or p73 (h) n=3, p<0.005. 
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Table 1: Table showing ΔNp63 and ΔNp73 binding sites on the TAp63 and 
TAp73 promoter regions   
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p53-deficient thymic lymphomas affects T-cell development, thereby preventing T-
cell lymphoma formation.  
 Addtionally, to determine whether the stromal cells contribute to apoptosis in 
the p53-deficient thymic lymphoma cells after depletion ΔNp63 and ΔNp73, 
ΔNfl/fl;p53-/-, ΔNp63fl/fl;p53-/- and ΔNp73fl/f;p53-/- thymic lymphoma cells were 
FACS sorted for CD45 marker to select for T-lymphocytes. T-Lymphocytes from the 
indicated genotypes were infected with either Ad-CRE or Ad-mCherry (Figure 11j). 
Upon, deleting either ΔNp63 or ΔNp73 in the p53-/- T-lymphocytes, I observed 
increased expression of Caspase 3 compared to the ΔNfl/fl;p53-/- T-lymphocytes 
(Figure 11k). This suggests that upon loss of ΔN isoforms of p63 and p73, TAp63 
and TAp73 induce downstream apoptosis in the T-lymphocytes independently of the 
stromal cell populations in the thymic lymphomas of the p53-deficient mice. 
3.3.6. ΔN isoforms of p63 and p73 function as transcriptional repressors of 
TAp63 and TAp73 
ΔN isoforms function dominant negatively against p53, TAp63 and 
TAp73(45). Also, ΔNp63 and ΔNp73 function as transcriptional factors activating or 
repressing certain targets(69). Loss of ΔNp63 and ΔNp73 in the p53-deficient thymic 
lymphomas resulted in the upregulation of tumor suppressive isoforms, namely 
TAp63 and TAp73. Hence, to test whether this is the case, ΔNp63fl/fl;p53-/- and 
ΔNp73fl/fl;p53-/- mouse embryonic fibroblasts (MEFs) were generated. The MEFs 
were infected with adeno-CRE or Adeno-mCherry. Upon deleting ΔNp63 or  
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Figure 13: TAp63 and TAp73 are required for activation of apoptosis and cell 
cycle targets in p53-deficient cells.  Western blot analysis in ∆Np63-/-;p53-/- (a) or 
∆Np73-/-;p53-/- (b) MEFs treated with the indicated shRNAs; (shNT) indicates a 
non-targeting scramble shRNA.	  Q-RT PCR for PUMA (c), Noxa (d), bax (e), PML (f), 
p21 (g), and p16 (h) in the indicated MEFs expressing the indicated shRNAs, n=5, 
p<0.005. Statistical significance indicated by black asterisks. 
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ΔNp73 in the p53-deficient MEFs, I observed that TAp63 and TAp73 were 
significantly upregulated (Figure 12a-f). This suggests that ΔN isoforms could 
repress transcription of the tumor suppressive isoforms, TAp63 and TAp73. To test 
whether this is the case, chromatin immunoprecipitation  (ChIP) for ΔNp63 and 
ΔNp73 was performed on the promoter region of TAp63 and TAp73 (Table 1). I 
observed that ΔNp63 and ΔNp73 bind to the promoter region of TAp63 (Figure 12g) 
and TAp73 (Figure 12h), thereby transcriptionally repressing the activity of TA 
isoforms of p63 and p73. Thus targeting the ΔN isoforms in p53-deficient cells 
restores the transcriptional function of TAp63 and TAp73. TAp63 and TAp73 in-turn 
compensate for p53-loss by activating downstream apoptosis and cell cycle targets. 
3.3.7. TAp63 and TAp73 are required apoptosis and cell cycle arrest in p53-
deficient cells 
 Loss of ΔN isoforms of p63 and p73 results in upregulation of TAp63 and 
TAp73 in the p53-deficient cells and thymic lymphomas. TAp63 and TAp73 
upregulation correlates with the increased expression of downstream apoptosis and 
cell cycle arrest targets. This suggests that TAp63 and TAp73 compensate for p53-
loss. Hence, to test whether this is the case, TAp63 (Figure 13a) and TAp73 (Figure 
13b) were knocked down in the ΔNp63-/-;p53-/- and ΔNp73-/-;p53-/- MEFs. Upon 
down-regulation of TAp63 and TAp73, I observed a reduced expression of apoptosis 
targets (Figure c-e), PUMA, Noxa and BAX and the cell cycle arrest targets (Figure 
f-h), p21, p16 and PML. This suggests that apoptosis and cell cycle arrest targets 
are dependent on TAp63 and TAp73 function in the p53-deficient cells and thymic 
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lymphomas. This further highlights the tumor suppressive role of the TA isoforms of 
p63 and p73 in treating cancers.  
Discussion 
 TP53 gene is highly mutated in human cancers and therapeutic intervention 
to reactivate or target the p53-pathway is pivotal due to its tumor suppressive 
functions(5, 122). Here, we utilized the p53-family members, p63 and p73 as an 
alternative strategy to treat p53-deficient cancers. p63 and p73 are structurally 
similar to p53 and are less frequently mutated which makes them unique targets for 
therapeutic intervention(45). Interestingly, p63 and p73 have multiple splice variants, 
broadly classified as TA (trans-activating) isoforms and ΔN (dominant negative) 
isoforms of p63 and p73.  I have demonstrated that deleting ΔNp63 or ΔNp73 in p53 
deficient thymic lymphomas results in rapid tumor regression and increased survival. 
The loss of ΔN isoforms in these p53-deficient tumor samples correlates with 
increased expression of TAp63 and TAp73 and downstream apoptosis and cell cycle 
arrest pathways. This suggests that ΔNp63 and ΔNp73 function dominant negatively 
against TAp63 and TAp73. Indeed, ΔNp63 and ΔNp73 binds to the promoters of the 
TAp63 and TAp73 preventing their transcriptional function. Upon loss of ΔN isoforms 
of p63 and p73, TAp63 and TAp73 are activated further inducing downstream 
apoptosis and cell cycle targets. Interestingly, I was also able to demonstrate that 
the induction of apoptosis and cell cycle arrest in the p53-deficient cells and thymic 
lymphomas were dependent on TAp63 and TAp73. This highlights the 
compensatory tumor suppressive role of TAp63 and TAp73 in targeting p53-deficient 
cancers. Importantly, I have demonstrated that ΔNp63 and ΔNp73 function as 
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oncogenes in the p53-deficient thymic lymphomas and therapeutic targeting of these 
oncogenic isoforms serves as a novel approach to treat p53-deficient cancers.  
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4. Chapter 4: IAPP driven metabolic reprogramming induces regression of 
p53-deficient tumors in vivo through the calcitonin and RAMP3 receptors 
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Chapter 4: IAPP driven metabolic reprogramming induces regression of p53-
deficient tumors in vivo through the calcitonin and RAMP3 receptors 
Contents of this chapter is based on Venkatanarayan, A., Raulji, P., Norton, W., 
Chakravarti, D., Coarfa, C., Su, Xiaohua., Sandur, S.K., Ramirez, M.S., Lee, 
Jaehyuk., Kingsley, C.V., Sananikone, E.F., Rajapakshe, K., Naff, K., Parker-
Thornburg, J., Bankson, J.A., Tsai, K.Y., Gunaratne, P.H. and Flores, E.R. IAPP 
driven metabolic reprogramming induces regression of p53-deficient tumors in vivo. 
Nature. 2015; 517(7536),626-630. doi:10.1038/nature13910. 
 
Copyright permission not required since Nature journal policy states “Author retains 
the copyright to the published materials” 
4.1. Introduction and Rationale 
 ΔNp63 and ΔNp73 function dominant negatively against p53, TAp63 and 
TAp73(47, 60). I have demonstrated that targeting the ΔN isoforms of p63 and p73 
in p53-deficient tumors mediates tumor regression in a TAp63 and TAp73 
dependent manner(74). This suggests that TAp63 and TAp73 function as bonafide 
tumor suppressors activating apoptotic and cell cycle targets to mediate tumor 
suppression. Thus TAp63 and TAp73 compensate for p53-loss of function in p53-
deficient tumors. This makes p63 and p73 as important targets for therapeutic 
intervention to treat p53-deficient cancers. Hence it is necessary to understand and 
delineate the global mechanisms by which TAp63 and TAp73 mediate its tumor 
suppressive functions apart from activating apoptosis and cell cycle arrest pathway.  
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 More recently, p53 has been demonstrated to mediate its tumor suppressive 
functions by activating certain metabolic and immune regulators, suppressing 
pluripotent factors and also impacting lipid biosynthesis. Given that tumor cells 
consume increased amounts of glucose and switch to a more aerobic form of 
respiration, regulation of the glycolytic pathway serves as an important pathway to 
be targeted. The p53 tumor suppressor activates two well-known metabolic 
regulators GLS2, TIGAR to suppress tumorigenesis. Given the similarity to p53, I 
was interested in understanding global transcriptional profile or targets activated by 
TAp63 and TAp73 independent of p53 in suppressing tumorigenesis.  
 
4.2. Results 
4.2.1. Loss of ΔNp63 and ΔNp73 establishes a novel metabolic gene signature 
in p53-deficient thymic lymphomas 
 Loss of ΔNp63 and ΔNp73 in p53-deficient thymic lymphomas mediates 
tumor regression by induction of apoptosis and cell cycle arrest in a TAp63 and 
TAp73 dependent manner. To test whether TAp63 and TAp73 could activate other 
upstream regulators or pathways to mediate tumor suppression, we performed RNA-
sequencing using the thymic lymphoma samples from the ΔNp63Δ/Δ;p53-/-, 
ΔNp73Δ/Δ;p53-/- and ΔNfl/fl;p53-/- 48 hours after adenovirus infection. We observed 
that ΔNp63Δ/Δ;p53-/- and ΔNp73Δ/Δ;p53-/- lymphoma samples clustered together  
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Figure 14: Loss of ΔNp63 and ΔNp73 reveal a novel metabolic gene signature. 
Ingenuity Pathway Analysis (IPA) of RNA-sequencing from thymic lymphomas 48 
hours after infection with adenoviruses (a).  Red oval indicates significantly 
upregulated metabolic genes.  Q-RT-PCR for IAPP (b), GLS2 (c) and TIGAR (d) in 
thymic lymphomas or MEFs of the indicated genotypes using a non-targeting shRNA 
(shNT) or shRNAs for TAp63 (shTAp63) or TAp73 (shTAp73) (e-f), n=4, p<0.005.  
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and separately from the ΔNfl/fl;p53-/- thymic lymphoma samples (Appendix 1). 
Ingenuity pathway analysis (IPA) (Figure 14a) revealed a novel metabolic gene 
signature between the ΔNfl/fl;p53-/- versus ΔNp63Δ/Δ;p53-/- and ΔNp73Δ/Δ;p53-/- 
thymic lymphoma samples. To further determine the TAp63 and TAp73 targets, 
genes that have a 2-fold mRNA expression in both the ΔNp63Δ/Δ;p53-/- and 
ΔNp73Δ/Δ;p53-/- thymic lymphomas compared to the ΔNfl/fl;p53-/- tumors were 
analyzed. Further, genes that shared a p53-consensus binding site were shortlisted. 
qRT-PCR was performed to determine the fold-change expression levels of these 
genes in the ΔNp63Δ/Δ;p53-/- and ΔNp73Δ/Δ;p53-/- tumors samples. Based on the 
relative fold-change expression, three genes were shortlisted, two of which namely, 
GLS2 (Figure 14c) and TIGAR (Figure 14d), which were previously characterized 
p53-regulated metabolic targets and another novel less characterized gene called 
IAPP(85). GLS2 and TIGAR play critical roles in mitochondrial respiration(82) and 
glycolysis(123). Islet amyloid polypeptide (IAPP) is a 37 amino acid polypeptide that 
encodes for amylin(84). IAPP had a >2-fold expression in both ΔNp63Δ/Δ;p53-/- and 
ΔNp73Δ/Δ;p53-/- samples (Figure 14b). Further, upon downregulating TAp63 and 
TAp73 in the double mutant MEFs, expression levels of IAPP and GLS2 were 
significantly downregulated (Figure 14e & f). This suggests that IAPP could be 
activated by TA isoforms of p63 and p73.  Since IAPP was expressed at higher 
levels in the double mutant thymic lymphomas I suspect that IAPP could be 
functionally implicated in the tumor regression associated with loss of ΔN isoforms of 
p63 and p73 in p53-deficient cancers.    
 
	   76	  
 
 
 
 
 
Table 2: Table showing TAp63 and TAp73 consensus binding sites on the 
IAPP promoter 
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Figure 15: IAPP functions as a downstream target of TAp63 and TAp73.  
Q-RT-PCR of Chromatin Immunoprecipitation using MEFs (a & b) and thymocytes 
(c & d) of the indicated genotypes, n=3, p<0.005. Dual luciferase reporter assay for 
pGL3-IAPP (e & f) and a mutant version of the IAPP reporter gene (pGL3-IAPP 
MUT) (g & h).  Genotypes of MEFs and vectors used are shown.  V represents 
pcDNA3 vector. Western blot analysis of the indicated MEFs expressing IAPP or 
siRNAs for a non targeting sequence (siNT) or IAPP (siIAPP) (l & m).  Statistical 
significance indicated by black asterisks. 
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4.2.2. IAPP functions as a downstream target of TAp63 and TAp73 
 IAPP expression was significantly upregulated in the ΔNp63Δ/Δ;p53-/- and 
ΔNp73Δ/Δ;p53-/- thymic lymphoma tissues compared to the ΔNfl/fl;p53-/- tumors. 
Since, ΔNp63Δ/Δ;p53-/- and ΔNp73Δ/Δ;p53-/- tumors have increased expression of  
TAp63 and TAp73, I hypothesized that TAp63 and TAp73 could transcriptionally 
activate IAPP. To test whether this was the case, chromatin immunoprecipitation 
assay was performed (ChIP) on the promoter and intron 2 site of the IAPP gene 
using MEFs (Figure 15a & b) and thymocytes (Figure 15 c & d) (Table 2). I observed 
that binding of TAp63 and TAp73 onto the IAPP sites were observed in the ΔNp63-/-
;p53-/- and ΔNp73-/-;p53-/- MEFs. Similarly, increased binding of TAp63 and TAp73 
on the promoter of IAPP was observed upon deleting ΔNp63/ ΔNp73 in the p53-
deficient thymocytes. This data suggests that TAp63 and TAp73 bind to the 
promoter region of IAPP and could transcriptionally activate IAPP.  
 To test whether TAp63 and TAp73 transcriptionally activate IAPP, luciferase 
reporter assay was performed using p63-/-;p53-/- and p73-/-;p53-/- double mutant 
MEFs. Upon, transfecting the MEFs with indicated plasmids, I observed that TAp63 
and TAp73 to be a strong inducer of IAPP expression (Figure 15 e & f). However, 
when the TAp63/TAp73 consensus-binding site on the IAPP promoter region was 
mutated (Figure 15 g-h), no luciferase activity was observed. This suggests that 
TAp63 and TAp73 transcriptionally activate IAPP.  
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Figure 16: IAPP functions as a regulator of glycolysis in mouse embryonic 
fibroblasts. Western blot analysis for IAPP in the indicated MEFs and treatment 
conditions, (n=3) (a& b). Seahorse glyocolysis stress assay using the indicated 
MEFs(c) (n=3).    
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4.2.3. IAPP functions as a critical regulator of glycolysis in mouse embryonic 
fibroblasts  
Majority of the genes in the RNA-sequencing analysis have an enriched 
metabolic gene signature. Particularly, TIGAR and GLS2 function as regulators of 
glycolysis(123) and mitochondrial respiration(82). Similarly, IAPP has been 
previously characterized to play roles in glucose metabolism, apoptosis and 
autophagy(83). IAPP has been demonstrated to reduce glucose uptake and inhibit 
glycolysis(84, 124). IAPP inhibits glycolysis by reducing hexokinase activity indirectly 
by increasing glucose-6-phosphate levels. Hence to test the potential role of IAPP in 
glycolysis, I performed a glycolysis stress assay using MEFs of the indicated 
genotypes. The ΔNp63-/-;p53-/- and ΔNp73-/-;p53-/- MEFs have increased 
expression of IAPP (Figure 16 a & b) and have reduced glycolytic capacity similar to 
the wild-type MEFs in comparison to the p53-/- MEFs (Figure 16c). Upon, 
expressing IAPP in the p53-/- MEFs resulted in a shift in the glycolytic capacity 
closer to the wild-type MEFs (Figure 16c). This suggests that IAPP functions to 
reduce glycolysis in these p53-deficient cells. To test whether IAPP functions a 
critical regulator of glycolysis, the IAPP expression was down regulated in the 
ΔNp63-/-;p53-/- and ΔNp73-/-;p53-/- MEFs (Figure 16 a & b). I observed a significant 
increase in the glycolytic capacity much closer to p53-/- MEFs (Figure 16c). This 
highlights the role of IAPP as a critical regulator of glycolysis. 
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Figure 17: IAPP functions as a tumor suppressor in vivo. Western blot analysis 
showing IAPP expression in the indicated thymic lymphomas, n=5 mice (a). Thymic 
lymphomas were infected with Adenovirus (Ad)-mCherry (b & i), Adenovirus (Ad)-
IAPP-mCherry (+IAPP)(c & j), Ad-shIAPP-mCherry (d, e, k & l), or treated with 
pramlintide intratumoural (I.T.) (f & m) or intraveneous (I.V.) (g & n), or 2-DG (h & 
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o).  Yellow dashed lines indicate tumour. Volume of tumour shown. UN-D = 
undetectable. Quantification of the indicated thymic lymphomas (p-v).  n=7 mice per 
group. Significance indicated by the asterisks, p<0.005. Kaplan Meier survival 
indicating thymic lymphoma free survival (w). n=8 mice per group, p<0.005 
Quantification of in vivo pyruvate to lactate conversion using dynamic magnetic 
resonance spectroscopy as a measurement of glycolysis, n=3 mice, p<0.005 (x)  
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4.2.4. IAPP functions as a tumor suppressor in vivo 
 IAPP has been demonstrated to inhibit glycolysis by blocking hexokinase 
activity(84). Also, I have observed that expressing IAPP in p53-deficient MEFs 
reduces glycolytic capacity in these cells highlighting the role of IAPP as a regulator 
of glycolysis. Since, cancer cells and tumors support the notion of Warburg’s 
hypothesis with increased glycolytic rates(75, 76), I wanted to test whether IAPP can 
inhibit glycolysis in the p53-deficient tumors in vivo. Hence, IAPP was expressed in 
the p53-deficient thymic lymphomas (Figure 17a). Interestingly, upon expressing 
IAPP, the p53-deficient thymic lymphomas had a massive tumor regression and 
increased survival compared to the p53-deficient thymic lymphomas that do not 
express IAPP (Figure 17 b-c, i-j, p-q & w). To test whether IAPP could function as 
tumor suppressor by itself, IAPP expression was down regulated in the 
ΔNp63Δ/Δ;p53-/- and ΔNp73Δ/Δ;p53-/- thymic lymphomas in which IAPP expression 
is high (Figure 17a). Upon down regulating IAPP expression in these thymic 
lymphomas, the tumors continued to progress similar to the p53-deficient thymic 
lymphomas (Figure 17 d-e, k-l, r-s & w). Importantly, IAPP expressing p53-deficient 
mice had increased survival compared to the p53-deficient or ΔNp63/p53 and 
ΔNp73/p53 double deficient mice in which IAPP was down regulated. This suggests 
that IAPP functions as bonafide tumor suppressor in p53-deficient cancers.  
 To further determine whether IAPP mediates the tumor regression in the p53-
deficient thymic lymphomas by glycolytic inhibition. We performed an in vivo 
dynamic magnetic hyper-sense resonance spectroscopy to measure the total 
amount of pyruvate getting converted into lactate, which serves as a proxy for  
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Figure 18: IAPP expression induces ROS accumulation and apoptosis in the 
p53-deficient thymic lymphomas. Immunohistochemistry for reactive oxygen 
species (ROS) or cleaved caspase 3 (a).  Positive nuclei are brown. 
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glycolysis(110) within the tumor (Figure 17x). We observed that in the ΔNp63/p53 
and ΔNp73/p53 double deficient tumors and p53-deficient tumors expressing IAPP, 
lactate levels were significantly down regulated indicative of reduced glycolysis 
compared to the p53-deficient tumors. Conversely, when IAPP was down regulated 
in the ΔNp63/p53 and ΔNp73/p53 double deficient tumors lactate levels were 
significantly higher and similar to the p53-deficient tumors suggesting increased 
glycolytic activity (Figure 17x). This suggests that IAPP functions a critical regulator 
of glycolysis in vivo. Importantly, IAPP mediated metabolic inhibition results in tumor 
regression in p53-deficient mice. 
4.2.5. IAPP mediates tumor regression in p53-deficient mice through induction 
of ROS and cell death in vivo 
 IAPP functions as a bonafide tumor suppressor in p53-deficient mice by 
glycolytic inhibition. I wanted to delineate the mechanism by which glycolytic 
inhibition in the tumors results in tumor regression. Previous studies have reported 
that tumor cells are particularly sensitive to metabolic stress(125). Metabolic stress 
encountered by the tumor cells correlate with intracellular reactive oxygen species 
(ROS) levels(125). In general, ROS levels are maintained at low levels and promote 
tumor cell proliferation. However, under increased metabolic stress in the tumor 
cells, ROS levels tremendously increase resulting in cell death or cellular 
senescence(125). Recently, p53 has been demonstrated to induce metabolic stress 
inhibiting glycolytic pathway resulting in ROS mediated cellular senescence(126).  
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Figure 19: ΔNp63/ΔNp73 ablation induces apoptosis and cell-cycle arrest in 
p53-deficient human cancer cells.  Representative western blot analysis (a), n=4.  
Immunofluorescence (IF) for apoptosis and EdU incorporation (b). Quantification of 
apoptosis (c) and proliferation (d), n=20 fields of 3 biological replicates, p<0.005. 
Q-RT-PCR for the target genes indicated on the x-axis in the indicated H1299 cells 
expressing the indicated siRNAs (e), n=4.  Asterisks indicate statistical significance 
(p<0.005) relative to siNT. 
 
 
 
	   87	  
Interestingly, IAPP functions to inhibit glucose uptake and block glycolysis. This 
results in increased nutrient related stress for the tumor cells probably leading to 
intracellular accumulation of ROS and apoptosis (Figure 18a). Indeed, in the 
ΔNp63/p53 and ΔNp73/p53 double deficient tumors and p53-deficient tumors 
expressing IAPP, had increased accumulation of ROS that correlated with increased 
apoptosis compared to the p53-deficient tumors. On the contrary, ΔNp63/p53 and 
ΔNp73/p53 double deficient tumors in which IAPP was down regulated had no 
accumulation of ROS or cell death (Figure 18a). This suggests that IAPP mediates 
tumor regression in p53-deficient mice through the induction of ROS and cell death. 
4.2.6. TAp63 and TAp73 compensate for p53-loss by metabolic reprogramming 
in p53-deficient human cancer cells 
 By targeting the oncogenic isoforms of p63 and p73, I have demonstrated a 
novel approach to treat p53-deficient tumors in mice. The tumor regression observed 
in the p53-deficient thymic lymphomas is through the activation of tumor suppressive 
isoforms, TAp63 and TAp73. Interestingly, TAp63 and TAp73 transactivate IAPP, a 
metabolic regulator that functions to mediate tumor regression in p53-deficient mice. 
However, ~50% of the human cancers exhibit either deletions or mutations in the 
p53 gene. Since, therapeutic approaches to treat p53-altered human cancers are 
ineffective, I wanted to test whether tumor regression mediated by loss of ΔNp63 
and ΔNp73 could be extended to p53-deficient cancers. To test this hypothesis, I 
extended my analysis to a panel of p53-deficient and mutant cancers. p53-deficient 
human lung adenocarcinoma cells were co-transfected with siRNA’s targeting either 
ΔNp63 or ΔNp73 in combination with siRNA’s for TAp63 and TAp73. I observed that  
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Figure 20: IAPP mediated glycolytic inhibition results in ROS-induced cell 
death in p53-deficient cancer cells. Western blot analysis of H1299 cells treated 
with the indicated siRNAs (a). Extracellular acidification rate as a measure of 
glycolysis (b), n=3, p<0.005. Legend in c is color-coded and corresponds to panels 
b, d-g.  Immunofluorescence (IF) (d) and quantification (e) for ROS (red) or 
apoptosis (green or green/red) (f & g) 
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upon down-regulation of ΔNp63 or ΔNp73, TAp63 and TAp73 upregulation 
correlated with the increase in IAPP expression in these p53-deficient human cancer 
cells (Figure 19a). The increase in expression of TA isoforms of p63 and p73 also 
resulted in the upregulation of apoptosis and cell-cycle arrest targets which in-turn 
results in the induction of apoptosis and cell cycle arrest (Figure 19b-e). 
4.2.7. IAPP directs p53-deficient human cancer cells to a ROS-induced cell 
death through metabolic reprogramming 
 IAPP expression was upregulated in p53-deficient human cancer cells after 
down-regulation of ΔNp63 and ΔNp73 (Figure 20a). This suggests that IAPP could 
have functional implications in targeting p53-deficient cancer cells to undergo 
apoptosis. Hence, to test whether IAPP functions as a metabolic regulator in p53-
deficient human cancer cells. p53-deficient lung adenocarcinoma cells were 
transfected with siRNA’s for ΔNp63, ΔNp73 individually or in combination with 
siRNA’s for IAPP. Also, IAPP was expressed directly in the p53-deficient cancer 
cells as well. I observed that after down regulation of ΔNp63/ΔNp73 or expressing 
IAPP there was significant reduction in the glucose uptake and glycolytic capacity in 
the p53-deficient human cancer cells compared to the non-targeting treated cells. 
(Figure 20b). Conversely, upon down regulating ΔNp63/ΔNp73 in combination with 
IAPP the glycolytic capacity was very similar to the p53-deficient human cancer cells 
treated with non-targeting siRNA’s (Figure 20b). This suggests that IAPP functions 
as a critical regulator of glycolysis in p53-deficient human cancer cells.  
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Figure 21: IAPP suppresses glycolysis by inhibiting hexokinase. Western blot 
analysis of H1299 cells expressing the indicated siRNAs and expression of HKII (a). 
Bar graph indicating glucose dependent proton secretion as a measure of glucose 
uptake (b) and intracellular levels of glucose-6-phosphate in H1299 cells with the 
indicated siRNAs and treatments (c).	  	   Color coded legend for panels b & c (d). 
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To test whether IAPP mediated glycolytic inhibition resulted in ROS accumulation 
and cell death, the p53-deficient human cancer cells were treated with the different 
indicated siRNA’s. Upon knockdown of ΔNp63/ΔNp73 or expression of IAPP, a 
significant accumulation of intra-cellular ROS (Figure 20d & e) that correlated with 
the cellular apoptosis (Figure 20f & g) was observed. This effect was completely 
rescued upon treating the cells with siRNA’s for ΔNp63/IAPP and ΔNp73/IAPP or by 
using an anti-oxidant like N-acetyl cysteine (NAC), functions as a scavenger 
reducing cellular ROS. This suggests that targeting ΔNp63/ΔNp73 or expressing 
IAPP can be used as a viable option to treat p53-deficient cancers. 
4.2.8. IAPP functions as a metabolic regulator by inhibiting hexokinase 
 IAPP functions as a bonafide tumor suppressor in p53-deficient human 
cancer cells. However, the mechanism by which IAPP exhibits its tumor suppressive 
functions remains unclear. Previous biochemical analysis has revealed that at 
physiological levels, IAPP functions to inhibit glucose uptake and also increase 
glucose-6-phosphate (G-6-P) levels(84). Subsequent increase in G-6-P levels 
results in a feedback inhibition of hexokinase, the rate-limiting enzyme in the 
glycolytic pathway. Hence to test whether IAPP mechanistically functions in the 
similar manner in p53-deficient human cancer cells, I measured glucose uptake and 
gluose-6-phosphate accumulation in the p53-deficient cancer cells. I observed that 
upon down regulating ΔNp63/ΔNp73 or expressing IAPP there was a significant 
reduction in the glucose uptake (Figure 21b) and accumulation of the glucose-6-
phosphate levels (Figure 21c) in the p53-deficient cancer cells. However, this effect  
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Figure 22: Systemic delivery of pramlintide mediates tumor regression in p53-
deficient mice. Cartoon indicating schedule of MRI imaging and injection (Inj.) of 
pramlintide in mice with p53 deficient thymic lymphomas (a).  MRI imaging at 10, 11, 
12 and 13 weeks after treatment with placebo (b-e) or pramlintide (g-n). 
Quantification of tumour volumes in placebo (n=3) (f) and pramlintide treated mice 
(n=7) (o), p<0.005.  Statistical significance indicated by black asterisk. 
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Figure 23: 2-deoxy-D-glucose functions as potent glycolytic inhibitor. 
Immunofluorescence analysis for ROS (red) or apoptosis (green or green/red) in 
H1299 cells expressing the indicated siRNAs and treated with 2DG and/or NAC (a).  
 
 
 
 
	   94	  
was rescued after treating the cells with siRNA’s for either ΔNp63/IAPP or 
ΔNp73/IAPP.  
Additionally, to further validate whether IAPP suppresses glycolysis through 
inhibition of hexokinase, Hexokinase II (HKII) was expressed after knockdown of 
either ΔNp63 or ΔNp73 in the p53-deficient human cancer cells (Figure 21a). A 
significant increase in the glucose uptake (Figure 20b & 21b) and the glycolytic 
capacity (Figure 20b)  and reduction in the G-6-P levels (Figure 21c) in the p53-
deficient cancer cells similar to the cells treated with NT siRNA’s was observed. This 
further correlated with very less or no intra-cellular ROS accumulation (Figure 20d & 
e) and no induction of apoptosis (Figure 20f & g). This suggests that IAPP functions 
to suppress glycolysis by inhibiting hexokinase activity in the p53-deficient cancer 
cells.  
4.2.9. Pramlintide, a synthetic analog of IAPP: as a glycolytic inhibitor to treat 
p53-deficient cancer cells 
 IAPP encodes for amylin, a 37-amino acid peptide secreted from the beta 
cells in the pancreas. I have demonstrated that IAPP functions as a bonafide tumor 
suppressor in a p53-deficient model of thymic lymphoma and also in p53-deficient 
cancer cells. IAPP exhibits its tumor suppression through metabolic reprogramming 
and inhibiting glycolysis. Interestingly, a synthetic analog of amylin called 
pramlintide(89) is used in the treatment of diabetes type I and II. Hence, I was 
interested to test whether pramlintide could be used as an anti-cancer drug to treat 
p53-deficient tumors and human cancer cells.  
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 Hence, to test the use of pramlintide as an anti-cancer drug, p53-deficient 
mice that had a significant thymic lymphoma at 10 weeks were administered a single 
dose of pramlintide intratumorally. By 13 weeks, I observed that the pramlintide 
treated mice had a significant reduction in the tumor volume compared to the p53-
deficient mice treated with placebo (Figure f-g, m-n, t-u). This tumor regression 
correlated with the reduction in the lactate production as measured by the in vivo 
conversion of C13-pyruvate to lactate suggesting that pramlintide also functions to 
inhibit glycolysis (Figure 17x). Additionally, pramlintide treatment resulted in the 
accumulation of intracellular ROS and induction of apoptosis in the p53-defcient 
tumors highlighting the mechanism of tumor regression (Figure 18a). To test 
whether pramlintide functions similar to other known glycolytic inhibitors, I treated 
the p53-deficient mice with 2-deoxy D-glucose (2-DG), a known glycolytic inhibitor 
(Figure 17h, o & v). I observed similar phenotype of reduction in the lactate 
production, accumulation of ROS and apoptosis in the p53-deficient tumors upon 
treating the mice with 2-DG suggesting that pramlintide functions as a glycolytic 
inhibitor mediating tumor regression. Finally, to test whether systemic in vivo delivery 
of pramlintide mediates tumor regression in the p53-deficient mice, a bi-weekly dose 
of pramlintide was administered for a period of 3 weeks intravenously to the p53-
deficient mice with significant thymic lymphoma (Figure 22a). I observed that, 
systemic in vivo delivery of pramlintide resulted in rapid tumor regression in the p53-
deficient mice compared to the placebo treated mice (Figure b-n). This highlights the 
use of pramlintide as an anti-cancer drug to treat p53-deficient tumors.  
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 To further test the effect of pramlintide in treating p53-deficient human cancer 
cells, human lung cancer cells were treated with pramlintide. Upon administration of 
pramlintide, I observed a significant reduction in the glucose uptake and glycolytic 
capacity (Figure 20b & 21b)) and an increase in the G-6-P levels (Figure 21c)  of the 
p53-deficient human cancer cells. This further correlated with the accumulation of 
intracellular ROS and cell death in the p53-deficient cancer cells, which was further 
rescued upon treatment with the N-acetyl cysteine (Figure 20c-f). This suggests that 
pramlintide, a synthetic analog of amylin, functions to suppress glycolysis by 
inhibiting hexokinase II (HKII). Importantly, I have also demonstrated the use of a 
diabetic drug as a potential anti-cancer drug to treat p53-deficient cancers.  
Discussion:  
 Deletion of ΔNp63/ΔNp73 in the p53-deficient mouse tumors, mediates tumor 
regression in a TAp63 and TAp73 dependent manner. Interestingly, TA isoforms of 
p63 and p73, which function as transcriptional regulators mediate tumor suppression 
through activating multiple pathways like apoptosis and cell-cycle arrest. In the p53-
deficient thymic lymphomas, I observe that TAp63 and TAp73 induce metabolic 
reprogramming by recruiting a metabolic regulator IAPP, upon deleting ΔNp63 and 
ΔNp73. IAPP, which encodes for amylin is a 37-amino acid peptide that functions to 
maintain glucose homeostasis(84). In the p53-deficient tumors and p53-deficient 
cancer cells, IAPP functions as tumor suppressor inhibiting glucose uptake and 
suppressing glycolysis. IAPP, mediates its tumor suppressive function by inhibiting 
hexokinase (HKII) rate-limiting enzyme in the glycolysis pathway. IAPP mediated 
glycolytic inhibition results in the accumulation of intracellular ROS resulting in 
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apoptosis in the cancer cells. Additionally, pramlintide, a synthetic analog of IAPP, 
used in the treatment of diabetes(89), mediates tumor regression and tumor cell 
death in p53-altered cancers. Pramlintide mediates tumor cell death in p53-altered 
cancers by glycolytic inhibition resulting in ROS accumulation and apoptosis whose 
functions are very similar to known glycolytic inhibitor, 2-DG (Figure 23).  However, 
unlike 2-DG which is highly toxic, pramlintide is less toxic and is also commercially 
available. Thus, this chapter highlights the identification of a novel metabolic 
regulator, IAPP and potential use of pramlintide to treat p53-deficient cancers 
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Chapter 5: IAPP functions through the Calcitonin and RAMP3 receptors to 
suppress tumorigenesis  
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Chapter 5: IAPP functions through the calcitonin and RAMP3 receptors to 
suppress tumorigenesis 
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driven metabolic reprogramming induces regression of p53-deficient tumors in vivo. 
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5.1. Introduction and Rationale 
 IAPP that encodes amylin functions as a secreted protein mediating glucose 
clearance at physiological conditions(84). IAPP functions as a tumor suppressor 
inhibiting glycolysis in p53-deficient cancers. Since, IAPP is a secreted protein it is 
still unclear the mode of action of IAPP to execute its tumor suppressive functions. 
Previous studies have demonstrated that IAPP requires and binds to the calcitonin 
and RAMP family of receptors(127). Since, IAPP could execute its functions both 
intrinsically and extrinsically, it is important to understand and determine the role of 
the receptors in IAPP-mediated tumor suppression in p53-deficient cancers. 
Additionally, the activity of the receptors could serve as a biomarker in identifying a 
subgroup of patients responding to pramlintide-based therapies.  
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5.2. Results 
5.2.1. Calcitonin and RAMP3 receptors are required for secreted IAPP function 
in p53-deficient cancer cells 
Since, IAPP is a secreted protein and has been previously demonstrated to 
show sensitivity to the Calcitonin and RAMP3 receptors(127), I wanted to determine 
whether IAPP requires the activity of the receptors to execute its tumor suppressive 
functions. To test whether this is the case, media enriched for IAPP was 
concentrated after treating the p53-deficient cancer cells with siRNA’s for ΔNp63 
(siΔNp63M) and ΔNp73 (siΔNp73M). This concentrated media (siΔNp63M or 
siΔNp73M) was added to the p53-deficient cancer cells in which expression of the 
Calcitonin and RAMP3 receptors were downregulated after siRNA treatment or to 
the cells treated with NT siRNA (Figure 24a-c). I observed a significant reduction in 
glycolysis (Figure 24d) and increase in intra-cellular ROS (Figure 24f) and cell death 
(Figure 24g) upon addition of IAPP (siΔNp63M/ siΔNp73M) enriched media to the 
p53-deficient cancer cells treated with NT siRNA’s. However, this effect was not 
observed in the p53-deficient cancer cells in which calcitonin receptor and RAMP3 
receptor was downregulated (Figure 24 d,f-g). This suggests that IAPP requires the 
activity of the calcitonin and RAMP3 receptors to execute its tumor suppressive 
functions.  
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Figure 24: IAPP functions through the activity of the calcitonin and RAMP3 
receptors. Cartoon depicting treatment of cells expressing the indicated siRNAs and 
treated with media from the cells secreting IAPP on the left (a). Western blot 
analysis of H1299 cells expressing the indicated siRNAs (b) or concentrated media 
derived from H1299 cells expressing siNT, si∆Np63, or si∆Np73 (c). Extracellular 
acidification rate (ECAR) in H1299 cells (d). Extracellular acidification rate (ECAR) 
using H1299 cells expressing the indicated siRNAs and treated with the indicated 
media containing secreted IAPP and treated with the indicated Amylin Inhibitor (A.I.) 
(e)Immunofluorescence (IF) for ROS (f) and apoptosis (g)  
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Figure 25: Calcitonin and RAMP3 receptor are required for IAPP/Pramlintide 
function in vivo. MRI and quantification of thymic lymphomas treated with placebo 
(a, d, & g), pramlintide (b, e, & h), or pramlintide plus calcitonin inhibitor (CalR I) (c, 
f, & i), n=5 mice 
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To test whether glycolytic inhibition in the p53-deficient cancer cells is 
mediated through the IAPP enriched in the media, the NT siRNA treated cancer cells 
were further treated with amylin inhibitor (A.I.). The amylin inhibitor functions as an 
agonist and prevents secreted IAPP binding to the receptors. Upon addition of 
media enriched with IAPP (siΔNp63M or siΔNp73M) to p53-deficient cells treated with 
A.I. I did not observe any differences in the glycolytic capacity (Figure 24e) or 
accumulation of ROS (Figure 24f) and apoptosis (Figure 24g). This suggests that 
secreted IAPP is required to induce glycolytic inhibition, ROS accumulation and 
apoptosis p53-deficient cancer cells. Further, to test whether, cell death observed in 
the p53-deficient cancer cells upon IAPP induction is through the intrinsic cell death 
pathway, siNT treated p53-deficient cells were treated with caspase inhibitor. The 
treatment with caspase inhibitor completely rescued the effect of IAPP on induction 
of cell death (Figure 24g). This suggests that IAPP activates cell death machinery to 
mediate its tumor suppressive function in the p53-deficient human cancer cells.  
5.2.2. Pramlintide therapy requires the activity of the calcitonin and RAMP3 
receptors 
 IAPP requires the activity of the calcitonin and RAMP3 receptors to perform 
its tumor suppressive function in the p53-deficient human cancer cells. To further 
determine the importance of the receptors in vivo, p53-deficient mice with thymic 
lymphoma at 10 weeks of age were treated with pramlintide by itself or in 
combination with calcitonin receptor inhibitor (Figure 25). The calcitonin receptor 
inhibitor prevents binding of IAPP/pramlintide to the calcitonin receptor. Upon 
pramlintide treatment, the p53-deficient tumors regressed as previously 
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demonstrated (Figure 25 b, e & h). However, upon inhibition of the calcitonin 
receptor, pramlintide treatment was ineffective and the tumors progressed to grow 
similar to the placebo treated p53-deficient mice (Figure 25 c,f & i). This suggests 
that calcitonin and RAMP3 receptors are required the tumor suppressive function 
exhibited by IAPP/Pramlintide in treating p53-deficient cancers.  
Discussion 
 IAPP is cosecreted along with insulin from the beta cells of the pancreas. 
Although, IAPP was previously demonstrated to utilize the calcitonin and RAMP-
family of receptors, the mode of action of IAPP was still unclear. I have 
demonstrated that IAPP/pramlintide mediates its tumor suppressive function through 
the calcitonin and RAMP3 receptors. Abolishing the activity of either calcitonin or the 
RAMP3 receptor renders IAPP/pramlintide function ineffective. This highlights an 
important association of IAPP function with its receptors. Since, pramlintide could be 
used as a potential drug to treat p53-deficient cancers, determining the status of the 
receptors will enable selecting patient cohorts responding to the pramlintide 
treatment and also ensure improved drug efficacy.  
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Chapter 6: Therapeutic approaches to treat p53-mutated human cancers 
6.1. Introduction and Rationale: 
 TP53 functions as well-documented tumor suppressor. However, most human 
cancers, harbor p53-mutations altering its function(118). Majority of the human 
cancers carry a common set of mutations commonly referred to as “Hot Spot” 
mutations. Mutations in the p53-gene have gain of function activities and in many 
cases promote tumor progression. The oncogenic properties of mutant p53 are 
carried out by competitive binding to other tumor suppressors or by activating 
oncogenes. Current therapeutic strategies are aimed towards downregulating the 
activity of mutant p53 in human cancers and reactivating wild-type p53(128). 
However, this therapeutic strategy has been challenging due to the multiple 
interactions of p53 with other pathways. Hence, this necessitates the need to identify 
other novel mechanisms to treat mutant p53 tumors. In this chapter, I aim to 
delineate the interaction between mutant p53 and the p53-family members p63 and 
p73. Additionally, use of pramlintide to therapeutically treat p53-mutated cancers will 
be tested.  
6.2. Results 
6.2.1. Interaction between mutant p53 and p53-family members, p63 and p73 
 Previously, I have demonstrated that targeting the oncogenic ΔN isoforms of 
p63 and p73, results in tumor regression in p53-deficient cancers. This tumor  
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Figure 26: Deletion of ΔNp63/ΔNp73 in combination with genotoxic stress 
induces apoptosis and cell-cycle arrest in p53-mutant human breast cancer 
cells. Representative western blots with the indicated genotypes (a & b) (n=3). 
Immunofluorescence (IF) and quantifications for apoptosis (c & e) and proliferation 
(d & f) for the indicated siRNA’s with or without doxorubicin treatment. (n=3) Q-RT 
PCR analysis for the apoptosis and cell-cycle arrest targets for the indicated siRNA’s 
with of without doxorubicin treatment (n=3, p<0.0005). Asterisks represent 
significance.  
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Figure 27: Deletion of ΔNp63/ΔNp73 in combination with genotoxic stress 
induces apoptosis and cell-cycle arrest in p53-mutant human colorectal 
cancer cells. Representative western blots with the indicated genotypes (a & b) 
(n=3). Immunofluorescence (IF) and quantifications for apoptosis (c & e) and 
proliferation (d & f) for the indicated siRNA’s with or without doxorubicin treatment. 
(n=3) Q-RT PCR analysis for the apoptosis and cell-cycle arrest targets for the 
indicated siRNA’s with of without doxorubicin treatment (n=3, p<0.0005). Asterisks 
represent significance. 
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regression is mediated through the activation of tumor suppressive isoforms of p63 
and p73, namely TAp63 and TAp73. Hence, to determine whether targeting ΔNp63 
and ΔNp73 could mediate tumor regression in mutant p53 human cancer cells, 
ΔNp63 and ΔNp73 was downregulated to two mutant human cancer cells namely, 
MDA MD468 breast adenocarcinoma cells (Figure 26) and SW 480 colorectal 
adenocarcinoma (Figure 27) that harbor p53 mutations. Upon silencing ΔNp63 and 
ΔNp73 in the mutant p53 human cancer cells, I observed a significant increase in 
the expression of TAp63 and TAp73 (Figure 26a & 27a), validating our previous 
finding that loss of ΔN isoforms of p63 and p73 restores the expression of TAp63 
and TAp73 in human cancer cells. To further test whether increased expression of 
TAp63 and TAp73 correlates with the cell death and cell cycle arrest, qRT-PCR for 
apoptosis and cell cycle targets and an apoptosis assay and EdU incorporation 
assay was performed in the mutant p53-cancer cells after downregulating either 
ΔNp63/ΔNp73. Interestingly, no increase in expression levels of the targets (figure 
26e & 27e), cell death (Figure 26c,g & 27c,g) or decrease in cell cycle arrest (Figure 
26d,h & 27d,h) was observed in the ΔNp63/ΔNp73 downregulated p53-mutant 
cancer cells compared to the cells treated with the NT siRNA’s. This suggests that 
although loss of ΔN isoforms of p63 and p73, restores the expression of TAp63 and 
TAp73 in mutant human cancer cells, the TA isoforms of p63 and p73 could not 
execute its tumor suppressive function in the mutant p53-cancer cells. One of the 
reasons for TAp63 and TAp73 to not execute its tumor suppressive function in 
mutant p53-human cancer cells could be due the gain-of function effect of mutant  
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Figure 28: Deletion of ΔNp63/ΔNp73 in combination with mutant p53 induces 
apoptosis and cell cycle arrest in p53-deficient human breast cancer cells. 
Representative western blot analysis with the indicated siRNA’s (a) (n=3). 
Immunofluorescence (IF) and quantification for apoptosis (b & c) and for cell-cycle 
arrest (b & d) for the indicated siRNA treatment conditions.   
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Figure 29: Deletion of ΔNp63/ΔNp73 in combination with mutant p53 induces 
apoptosis and cell cycle arrest in p53-deficient human colorectal cancer cells. 
Representative western blot analysis with the indicated siRNA’s (a) (n=3). 
Immunofluorescence (IF) and quantification for apoptosis (b & c) and for cell-cycle 
arrest (b & d) for the indicated siRNA treatment conditions. 
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p53 which could form tetramers with TA isoforms of p63 and p73, preventing its 
transcriptional function(129). 
6.2.2. Targeting the ΔN isoforms of p63 and p73 combined with genotoxic 
stress induces cell death and cell-cycle arrest in mutant p53 human cancer 
cells 
 Gain of function effects of mutant-p53 prevents TAp63 and TAp73 from 
executing their tumor suppressive function after ablation of ΔNp63 or ΔNp73 in the 
p53- mutant human cancer cells. However, a significant increase in the expression 
TAp63 and TAp73 after ablation of ΔNp63/ΔNp73 in the mutant p53-cancer cells 
was observed. Since, TAp63 and TAp73 also respond to genotoxic stress, I wanted 
to determine whether loss of ΔN isoforms of p63 and p73 in combination with 
genotoxic stress would mediate cell death or cell-cycle arrest in the mutant p53 
cancer cells. Interestingly, loss of ΔNp63/ΔNp73 in combination with genotoxic 
stress resulted in a significant increase in the expression of TAp63/TAp73 (Figure 
26b & 27b), which further correlated with the increase in expression of apoptosis and 
cell cycle targets (Figure 26f & 27f), induction of cell death (Figure 26 c,g & 27 c,g) 
and cell cycle arrest (Figure 26d,h & 27d,h) in the mutant p53-human cancer cells. 
This suggests that significantly increasing the expression of TAp63 and TAp73 in the 
mutant p53 cancer cells could function to overcome the gain-of function effect of 
mutant p53 resulting in cancer cell death and cell-cycle arrest.  
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6.2.3. Mutant p53 inhibits TAp63 and TAp73 mediated tumor suppression in 
human cancer cells 
Targeting ΔNp63 and ΔNp73 in mutant p53 human cancer cells restores 
expression of TAp63 and TAp73. However, due to the gain of function effects of 
mutant p53, TAp63 and TAp73 tumor suppressive function is inhibited. Hence, to 
test whether this is the case, siRNA’s targeting p53 was used by itself or in 
combination with siRNA’s for ΔNp63 and ΔNp73 in the mutant p53 human cancer 
cells (Figure 28a & 29a). An increase in apoptosis (Figure 28b-c & 29b-c) and 
decrease in proliferation (Figure 28b,d & 29b,d) in the mutant p53 human cancer 
cells was observed upon downregulating both ΔNp63/p53 and ΔNp73/p53 in 
comparison to downregulating only p53. Induction of apoptosis and cell cycle arrest 
correlated with the increased expression of TAp63 and TAp73 in the p53-mutant 
human cancer cells. This suggests that mutant p53 inhibits TAp63 and TAp73 from 
mediating its tumor suppressive functions. Hence, targeting ΔN isoforms of p63 and 
p73 in combination with mutant p53, serves as novel approach to treat these cancer 
types.  
6.2.4. Pramlintide based therapy to treat p53-mutant cancers 
 Previously, I have demonstrated that Pramlintide, synthetic analog of 
amylin/IAPP mediates cancer cell death in p53-deficient cancer cells. Pramlintide 
mediates its tumor suppressive function by suppressing glycolysis through the 
inhibition of hexokinase activity. Importantly, the function of Pramlintide is mediated  
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Figure 30: Pramlintide treatment suppresses glycolysis and results in ROS-
induced apoptosis in p53-mutant human cancer cells. Extracellular acidification 
rate (ECAR) as a measure of glycolysis in SW480 (a), MDA- MB-468 (b), SRB12 (c) 
and COLO16 (d) human cancer cell lines after treatment with placebo, pramlintide, 
or pramlintide and a calcitonin receptor inhibitor (CalR I.), n=3, p< 0.005. Glucose, 
oligomycin, and 2-Deoxy-D-Glucose (2-DG) were supplied to the media at the 
indicated time points shown on the x-axis. Immunofluorescence for ROS (red) (h) 
and apoptosis (green) (i) on the indicated cells, n=3. 
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downstream of the transcriptional activity of p53 and its family members. This 
highlights a novel approach to treat p53-mutated cancers as the pramlintide 
mediates its function independently of p53-status. Hence, to test whether pramlintide 
could be used to treat p53-mutant cancers, a panel of mutant p53 human cancer cell 
lines that include, SW480 (colorectal adenocarcinoma) (Figure 30a), MDA- MB-468 
(breast adenocarcinoma) (Figure 30b), COLO16 and SRB12 (squamous cell 
carcinoma) (Figure 30c&d) were selected. Upon treating the mutant p53 human 
cancer cells with pramlintide, significant reduction in the glycolytic capacity that 
correlated with an increase in intracellular ROS (Figure 30e) and cell death (Figure 
30f) compared to the cell lines treated with the placebo was observed. To test 
whether apoptosis observed in the mutant p53 cancer cells is due effect of 
pramlintide, the cancer cells were treated with pramlintide by itself or in combination 
with calcitonin receptor inhibitor. The p53-mutant human cancer cells treated with 
calcitonin receptor inhibitor did not respond to pramlintide treatment suggesting that 
pramlintide mediated inhibition of glycolysis mediates tumor cell death in the p53-
mutant human cancer cells. Importantly, the use of Pramlintide serves as a novel 
approach to treat hard to treat p53-mutant human cancer cells.  
6.2.5. Pramlintide based therapy to treat squamous cell cancers (SCC) 
 Squamous cell cancers (SCC) are a type of skin cancer. SCC is caused 
primarily due to the multiplication of the epithelial cells of the skin, head and neck, 
linings of the digestive tract, lungs and genitals(106, 130). One of the factors that 
promote SCC formation is the exposure to UV skin light over an extended period of 
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Table 3: Table representing a panel of patient derived human squamous cell 
carcinomas cells with alterations in p53.  
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Table 4: Table representing a classification of human SCC cells based on the 
basal glycolytic profile  
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Figure 31: Pramlintide treatment suppresses glycolysis in human SCC cells. 
Extracellular acidification rate as a measure of glycolysis in a panel of human SCC 
cells SRB1 (a), SRB12 (b), COLO16 (c), RDE B2 (d), RDE B3 (e), RDE B4 (f), SCC 
T1 (g), SCC T2 (h), SCC T3 (i), SCC T8 (j) and SCC 1C1 (k) subjected to indicated 
doses of pramlintide treatment.   
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Figure 32: Pramlintide treatment induces apoptosis in human SCC cells. 
Quantification of apoptosis (Annexin V and PI) in a panel of human SCC cells SRB1 
(a), SRB12 (b), COLO16 (c), RDE B2 (d), RDE B3 (e), RDE B4 (f), SCC T1 (g), 
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SCC T2 (h), SCC T3 (i), SCC T8 (j) and SCC 1C1 (k) subjected to indicated doses 
of pramlintide treatment.   
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time promotes loss of elasticity and pigmentation of the cells. Approximately, 
700,000 cases of SCC have been diagnosed every year(130). There are multiple 
gene alterations that drive tumor formation and one of the alterations occur in the 
TP53 gene due to point mutations and truncating mutations(113, 114). Currently, 
therapeutic approaches to treat SCC are limited. Since, pramlintide treatment has 
shown tremendous potential in treating p53-mutant human cancer cells, I was 
interested in determining the therapeutic efficacy of treating SCC human cancer 
cells with pramlintide. Hence a panel SCC human cancer cells with mutations in p53 
gene were selected (Table 3). Since, pramlintide functions by inhibiting glycolysis, 
the basal glycolytic capacity of these SCC panel of cells was determined to classify 
the cells based on their glycolytic profile (Table 4). The SCC human cancer cells 
were classified into three types, highly glycolytic, medium glycolytic and less 
glycolytic based on their glycolytic prolife (Table 4). I suspect that SCC cells with 
higher glycolytic rate would respond with better efficacy to pramlintide treatment.  
6.2.6. Pramlintide treatment inhibits glycolysis and induces cell death in the 
human SCC cells 
 To test whether pramlintide mediates glycolytic inhibition in the human SCC 
cells, the glycolytic capacity of the cells was measured with increasing 
concentrations of pramlintide. I observed differences in the response to pramlintide 
depending on the basal glycolytic profile of the SCC cells (Figure 31). However, in 
most of the SCC cells, I observed an increased suppression of glycolysis at a higher 
concentration of pramlintide. Additionally, the glycolytic inhibition correlated with a 
increase in cell death in the SCC cells as measured by the Annexin V and propidium 
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iodide staining (Figure 32). This highlights the importance to using pramlintide-based 
therapy to treat human SCC cancers. Currently, I am testing the use of pramlintide in 
the patient derived models (PDX) using the human SCC cells. Also, I am interested 
in determining whether pramlintide affects mitochondrial respiration in the SCC cells.  
Discussion 
 Approximately, 50% of human cancer harbor mutations in the p53 gene(122). 
Mutant p53 functions as a proto-oncogene promoting tumorigenesis. Further, 
because of its gain of functions effects, targeting mutant p53 in human cancers has 
been challenging. In this chapter, I have demonstrated that mutant p53 inhibits 
TAp63/TAp73 mediated tumor suppression in p53-mutated human cancers.  
Targeting the oncogenic isoforms of p63 and p73 in combination with genotoxic 
stress could result in significant accumulation of TAp63 and TAp73, thereby 
overcoming mutant p53 effect. However, administration of genotoxic stress results in 
non-specific activation multiple other pathways.  
 As a novel approach to treat p53-mutant cancers, I have proposed the use of 
pramlintide, a synthetic analog of IAPP. Pramlintide functions by inhibiting glycolysis 
and functions independently of the status of the p53-family members. Preliminary 
data from my thesis has shown great promise in mediating tumor cell death in a 
panel of mutant p53 human cancer cells. Currently, I have expanded my analysis to 
human squamous cell cancers and their treatment with pramlintide. Initial in vitro 
results have demonstrated that pramlintide functions effectively in highly glycolytic 
tumor cells by blocking glycolysis and inducing apoptosis.  
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Chapter 7: Therapeutically targeting the oncogenic isoforms of p63 and p73 to 
treat p53-deficient human cancers  
7.1. Introduction and Rationale 
 ΔNp63 and ΔNp73 have been demonstrated to function as oncogenes in p53-
deficient human cancers. Importantly, ablation of these oncogenic isoforms of p63 
and p73 has identified a new therapeutic approach to treat p53-deficient cancers. 
Previously, I have demonstrated that ablation of ΔNp63 and ΔNp73 mediates tumor 
regression through the activation of TAp63 and TAp73, the tumor suppressive 
isoforms of p63 and p73. Hence, by therapeutically targeting ΔNp63/ΔNp73 in p53-
defcient cancers will activate the tumor suppressive properties of TAp63 and TAp73. 
Additionally, we have also performed a miRNA-sequencing on the p53-deficient 
thymic lymphoma tissues in which either ΔNp63/ΔNp73 was ablated.  
To therapeutically target ΔN isoforms of p63 and p73 in p53-deficient 
cancers, in vivo, I have adopted a DOPC liposomal nanoparticle(131, 132) delivery 
approach of utilizing siRNA’s targeting ΔNp63. These liposomal coated nanoparticle 
siRNA’s could be delivered to the site of the tumor and are not phaogcytosed. This 
enables us to develop a novel approach to treat p53-deficient tumors by targeting 
the oncogenic isoforms of p63 and p73.  
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7.2. Results 
7.2.1. Liposomal siRNA delivery of ΔNp63 mediates tumor regression in p53-
deficient mice 
 Ablation of ΔNp63 mediates tumor regression through the activation of 
TAp63. To therapeutically target ΔNp63 in p53-deficient tumors, I performed a 
liposomal delivery of siRNA targeting ΔNp63 into the p53-deficient thymic lymphoma 
at 10 weeks. Administration of liposomal coated siRNA’s was specifically localized 
only to the region of the thymic lymphoma as visualized by the IVIS lumina imaging 
(Figure 33a-i).  ΔNp63 expression was downregulated 48 hours after administration 
of the DOPC liposomal siRNA in the p53-deficient thymic lymphoma. This correlated 
with the increase in the expression of TAp63 and also downregulation of DGCR8, 
another downstream target of ΔNp63 (Figure 33j). Additionally, the downregulation 
of ΔNp63 expression in the p53-deficeint thymic lymphoma tissues correlated with 
the increase in apoptosis and cell-cycle arrest 48 hours after treatment with siRNA’s. 
(Figure 33k) This suggests that therapeutically targeting ΔNp63 in p53-defcient 
tumors in vivo, induces cell death and cell cycle arrest.  
Since, targeting ΔNp63 in p53-deficient cancers in vivo was therapeutically 
feasible, I wanted to test whether siRNA mediated knockdown of ΔNp63 would 
mediate tumor regression in p53-deficient mice. To determine the stability of the 
siRNA’s in  vivo, a single does of siΔNp63 was administered into the p53-deficient 
thymic lymphoma. The thymic lymphomas tissues treated with siΔNp63 were  
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Figure 33: Liposomal siΔNp63 administration in p53-deficient thymic 
lymphomas induces apoptosis and cell cycle arrest. IVIS Lumina imaging of 
p53-deficient thymic lymphomas administered with DOPC liposomal nanoparticle 
coated siRNA’s. Presence of the red color marks the region of the siRNA 
administration which is localized to the thymic lymphoma (a-i). Representative 
western blot analysis of p53-deficient thymic lymphoma tissues 48 hours after 
treatment with indicated siRNA’s (j) (n=3). Immunohistochemistry (IHC) panel of for 
apoptosis and proliferation in p53-deficient thymic lymphoma tissues 48 hours after 
treatment with indicated siRNA’s. Brown nuclei labels the positive cells.    
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Figure 34: Therapeutically targeting ΔNp63 by liposomal siRNA’s in p53-
deficient thymic lymphomas mediates tumor regression. Representative 
western blot analysis of p53-deficient thymic lymphomas treated with indicated 
siRNA’s (a). Magnetic resonance imaging (MRI) of p53-deficient thymic lymphoma 
treated with siNT (b-f) or siΔNp63 (g-k). Tumor volumes (mm3) included in each 
panel. Yellow dashed line marks region of the tumor. UN-D refers to undetectable. 
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Tumor volume measurements for siNT treated (l) and siΔNp63 treated (j). Kaplan 
Meier (KM) plots indicating thymic lymphoma free survival, n=3 mice per group, 
p<0.0005.  
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collected 1 week after dose administration to determine the expression of ΔNp63. 
Interestingly, even 1 week after administering siΔNp63 into the p53-deficient thymic 
lymphoma, a significant downregulation of ΔNp63 expression and upregulation of 
TAp63 expression was observed (Figure 34a). Based on this analysis, a single dose 
of siΔNp63 was administered into the p53-deficeint thymic lymphoma at 10 weeks of 
age for period of 3 weeks. A significant reduction the tumor volume (Figure 34b-k) 
and increase in the life-span (Figure 34k) as observed in the p53-deficient mice 
upon treatment with siΔNp63 compared to the mice treated with non-targeting (NT) 
siRNA’s. This highlights an important therapeutic approach to treat p53-deficient 
tumors. 
Discussion 
 Current therapeutic approaches to treat p53-deficient human cancers are 
aimed towards reactivating wild-type p53 by inhibiting MDM2, negative regulator of 
p53(128). Although this approach is currently entering clinical trials some challenges 
remain in reactivating wild-type p53 across multiple cancers. However, by utilizing 
the function of p53-family members, I have demonstrated a novel approach to treat 
p53-deficient cancers in vivo. ΔNp63 and ΔNp73 are expressed in all epithelial 
cancers and not mutated making them unique targets for therapeutic intervention. I 
have demonstrated that by therapeutically targeting ΔNp63 using liposomal-coated 
siRNA’s in p53-deficient model of thymic lymphoma results in tumor regression and 
increased survival. Currently, I am expanding my analysis to target ΔNp73 and other 
downstream targets of ΔNp63/ΔNp73 that might promote tumor formation.  
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Chapter 8. Investigating the roles of p63 and p73 regulated lncRNAs in the 
context of p53-deficient cancers 
8.1. Introduction and Rationale 
 Long non-coding RNAs (lncRNAs) are similar to mRNAs but do not code for 
protein(95, 97). RNA molecules that are generally >200nt in length and those that do 
not code for protein are classified as lncRNAs. In general, lncRNAs are not 
evolutionary conserved, but have been implicated in disease and development. 
Particularly, lncRNAs are involved in multiple diseases from neurodegeneration to 
cancer. In cancer, lncRNAs could function as oncogenes or tumor suppressors 
depending on the cancer type and tissue context. Particularly, lncRNAs could 
mediate its function by either regulating the activity of certain mRNA genes which 
could be tumor suppressors or oncogenes. p53 functions to regulate the expression 
of multiple downstream targets and prevent tumor suppression(100-102). 
Interestingly, p53 could also regulate lncRNA function as in the case of linc-p21, 
PANDA or H19. Alternatively, expression of p53 could be regulated by lncRNAs as 
well as in the case of MALAT1, MEG3(99). The functions of these lncRNAs are 
executed by recruiting other cofactors to mediate tumor suppression or suppressing 
the effect of a mRNA like a tumor suppressor and acting as “sponge” through 
competitive endogenous mRNA (ceRNA). Since, lncRNA can also function as a 
predictor of disease status in human cancers, I was interested in determining the 
regulation of these lncRNA by the p53-family members, p63 and p73. Understanding 
the lncRNAs regulated by p63 and p73 would enable us to predict disease outcome 
and also unravel new pathways of regulation in p53-altered cancers.  
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To determine regulation of lncRNAs by p63 and p73, we performed RNA-
sequencing using two different cellular systems in a p53-deficient condition. In the 
first analysis, since p63 and p73 respond to DNA damage, I was interested in 
identifying lncRNA that could respond to genotoxic stress. In the second approach, 
to identify lncRNA that could play critical roles in the progression of p53-deficient 
lymphomas, analysis was performed using the ΔNp63Δ/Δ;p53-/- and 
ΔNp73Δ/Δ;p53-/- thymic lymphoma samples. By identifying and characterizing the 
function of these lncRNAs by the p53-family members, p63 and p73, I aim to 
delineate novel regulatory pathways that might help design better therapies to treat 
p53-altered cancers.  
 
8.2. Results 
8.2.1. p63 and p73 regulated lncRNAs that are responsive to genotoxic stress 
 p63 and p73 function as transcription factors and similar to p53 and respond 
to genotoxic stress and protect the genome by recruiting DNA repair genes. Unlike 
p53, which is often mutated in human cancers, p63 and p73 are less frequently 
mutated making them unique targets, which could possibly perform DNA repair even 
under diseased states. To determine the non-coding regulatory network of p63 and 
p73 upon genotoxic stress, mouse embryonic fibroblasts (MEFs) of the indicated 
genotypes were treated with or without doxorubicin to induce DNA damage. RNA-
sequencing was performed using the MEFs treated with or without DOX. A total of 
2094 lncRNAs were mapped using the mouse mm9 database. Since, I was  
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Figure 35: Pie chart representing the differentially expressed lncRNAs either 
dependent or independent of genotoxic stress. lncRNAs that are DOX 
dependent (n=7) and lncRNAs that are DOX independent (n=19). Red represents 
upregulated and green represents downregulated lncRNAS 
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Table 5: List of differentially expressed lncRNAs that are either dependent or 
independent of genotoxic stress 
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interested in identifying lncRNA that are regulated by p63 and p73, we overlapped 
the RNA-sequencing data with a ChIP-sequencing to mark all the lncRNAs that 
encode a p53-consensus binding site. Since, p53, p63 and p73 share a consensus 
binding site on the target genes, categorizing the lncRNAs based on the consensus 
increases stringency and provides more confidence.  
 By bioinformatic analysis, p63 and p73 lncRNAs were classified under two 
groups, lncRNAs that are doxorubicin dependent and lncRNAs that are doxorubicin 
independent. Upon, doxorubicin treatment a total of n=7 lncRNA were differentially 
expressed in which n=5 had a p53-consensus binding site. Interestingly, I observed 
n=4 lncRNAs to be downregulated and n=2 were upregulated. Similarly, upon 
analyzing the lncRNAs that are doxorubicin independent a total of n=19 were 
identified of which n=7 had a p53-consensus binding site. I observed, n=7 to be 
downregulated and n=2 to be upregulated. Currently, I am planning to perform 
further stringency analysis based on the expression pattern and develop assays to 
test and characterize the function of these novel lncRNAs. 
 
8.2.2. Identification of differentially expressed lncRNAs upon ablation of 
ΔNp63 and ΔNp73 in p53-deficient mouse tumors 
 ΔNp63 and ΔNp73 deletion in p53-deficient cancers results in tumor 
regression in vivo. I have identified a novel metabolic reprogramming mechanism 
through the recruitment of IAPP, which mediates this tumor regression. However, 
IAPP is activated by the tumor suppressor isoforms, TAp63 and TAp73, highlighting  
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Figure 36: Differentially expressed lncRNAs upon ablation of ΔNp63 and 
ΔNp73 in p53-deficient thymic lymphomas. Piechart representing number of 
differentially expressed lncRNAs (a). Pie chart representing lncRNA up and 
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downregulated in the thymic lymphoma samples (b). Graph representing the FKPM 
fold change values for the selected lncRNAs in the thymic lymphoma samples (c). 
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Table 6. List of differentially expressed lncRNA with ensemble ID and 
chromosomal location 
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the global role played by these genes in tumor suppression. Additionally, loss of ΔN 
isoforms of p63 and p73 could have restored the tumor suppressive role of non-
coding genes or suppressed the activity of certain oncogenes. Hence, to further 
expand our understanding on the p53-deficient tumor regression phenotype and 
identify biomarkers for disease prediction we utilized the RNA-sequencing data 
obtained by comparing the ΔNp63Δ/Δ;p53-/- and ΔNp73Δ/Δ;p53-/- versus the 
ΔNfl/fl;p53-/- tumors (Appendix 1).  
 Using bioinformatic analysis, a total of n=32 lncRNAs were identified to be 
differentially expressed between the ΔNp63Δ/Δ;p53-/-, ΔNp73Δ/Δ;p53-/- and 
ΔNfl/fl;p53-/- thymic lymphoma samples. Since, loss of both ΔNp63 and ΔNp73 
accelerates tumor regression in p53-deficient tumors, I focused on the n=8 lncRNAs 
that are differentially expressed. Of the n=8 lncRNAs, one lincRNA was 
downregulated and the remaining lncRNAs were all upregulated. Currently, I am 
performing experiments to determine a phenotypic characterization of these 
lncRNAs. 
Discussion 
 lncRNAs do not code for proteins, however, are implicated in diseases like 
cancer. Multiple lncRNAs are significantly expressed in cancer potentiating their 
roles as oncogenes. However, some lncRNAs that are regulated by tumor 
suppressors like p53 function to prevent cell proliferation and induce cell death. The 
gene regulation of lncRNAs is complex and sufficient in vivo models have not been 
developed. In an attempt to understand the regulation of p53-family members, p63 
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and p73, we mined the database for lncRNA using two distinct approaches. In the 
first approach, I aim to identify lncRNA that respond to genotoxic stress which may 
help in recruiting DNA repair genes and also induce cell-cycle arrest in a diseased 
state. In the second approach, I aim to identify lncRNAs that may play critical roles in 
p53-deficient tumor regression upon loss of ΔNp63 and ΔNp73.  
 Since, lncRNAs do not code for proteins, determining the function of the 
lncRNAs is challenging. Normally, from the bioinformatic analysis of the RNA-
sequencing data, a cluster of differentially expressed lncRNAs is obtained. To 
specifically determine the function of a select few lncRNA, I plan to apply the Guilt by 
association method (GBA) in which the function of the lncRNA is predicted 
depending upon the function and the direction of the mRNA genes. This assessment 
will help design assays depending on the predicted function to characterize the 
function of lncRNA. Additionally, a few criteria’s like determining the chromatin 
marks for activation or repression or the common consensus binding motifs on the 
lncRNA promoter will provide leads on determining the function of these lncRNA.  
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Chapter 9: Discussion, Conclusions and Future Directions 
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9. Discussion 
9.1. p53 mediated tumor suppression in human cancers 
 TP53 gene’s tumor suppressive properties are well documented in multiple 
cancer types. At physiological conditions, p53 expression is under tight regulation. 
Upon genotoxic stress, p53 expression levels increase to perform its cellular 
functions, thereby protecting the genome(133). p53 executes its cellular functions 
through the recruitment of multiple downstream targets which induce apoptosis or 
cell-cycle arrest(133). p53 expression is regulated by its own target, MDM2, an E3 
ubiquitin ligase that functions as an negative regulator of p53. When p53 is 
expressed at higher levels, MDM2 inhibits p53 transcriptional activity through its 
negative feedback mechanism(134). In normal cells, p53 functions to maintain 
cellular homeostasis. p53 functions to protect the genome from cellular insults and 
DNA damage. Upon, DNA damage or any form of stress, p53 levels are 
tremendously increase and direct the damaged cells to undergo cell death or cell 
cycle arrest. The downstream function if p53 is performed by the recruitment of 
known p53-targets like PUMA, Noxa or BAX for induction of apoptosis(2, 13)and 
p21, p16 and PML for the induction of cell cycle arrest or cellular senescence(17, 
135). More recently, the roles of p53 in multiple cellular pathways like 
metabolism(79), pluripotency(136), aging(137) etc. are being delineated and this 
represents the identification unique and novel targets regulated by p53. These 
functions of the TP53, highlight the importance of this gene in maintaining cellular 
homeostasis and tumor suppression.  
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 Unfortunately, in a majority of human cancers TP53 function is altered. TP53 
gene undergoes a mutation or deletion in most human cancers(118). This results in 
either gain of function or loss of function of p53. p53 loss corresponds to no activity 
of the p53 gene resulting in tumor progression upon cellular insults, as p53 is not 
functional and cannot execute its function of protecting the genome. However, 
approximately, 50% of human cancers harbor mutations in the p53 gene that are 
commonly referred to as “Hot Spot” mutations, which commonly occur in the DNA 
binding domain of p53 gene. As a result of these mutations, p53 exhibits gain of 
function properties promoting tumor growth(8, 23, 138). Mutant p53, because of the 
mutations in the DNA binding domain cannot be regulated by its negative regulator 
MDM2, as a result is constantly active. Further, mutant p53 promotes tumor growth 
by forming heterodimers with known tumor suppressors and preventing their function 
or by activating oncogenes(26). 
 In the context of cancer, the status of p53 is critical because one mechanism 
by which chemotherapy functions is to induce DNA damage which illicits a p53 
response which targets the cells to die. Since, p53 expression is altered in most 
cancers, this raises a concern in therapeutically treating p53-altered human cancers. 
Hence, the current therapeutic strategy to treat p53-altered cancers has been to 
reactivate wild-type p53 in p53-deficient human cancers, as this approach has 
shown promise in p53-deficient mouse models(32). In the case of p53-mutated 
human cancers, the aim has to been downregulate the expression of mutant p53 
through the activation of E3 ubiquitin ligases or other small molecule inhibitors(139). 
All these approaches have shown great promise but have been a challenge to 
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therapeutically execute them. This raises an unmet need to develop and identify 
alternate approaches to treat p53-deficient human cancers.  
p53 family members: p63 and p73 
 In a need to develop alternate approaches to treat p53-deficient human 
cancers, we have focused on understanding the role of the p53-family members, 
p63 and p73 in tumorigenesis. p63 and p73 are structurally similar to p53(45). 
However, unlike p53, both p63 and p73 are less frequently mutated making them 
unique targets for therapeutic intervention. p63 and p73 were initially identified as 
developmental regulators and their roles in tumorigenesis were controversial. This is 
because studies based on in vivo mouse models targeting p63 and p73, had a broad 
tumor spectrum highlighting the indispensable roles of these genes in tumor 
suppression(46) while some human cancers, expressed higher levels of p63 and 
p73, suggesting that they could be oncogenic in nature(49, 60, 140). These 
differences are primarily due to the multiple splice isoforms of p63 and p73. The 
splice variants of p63 and p73, are broadly classified into N-terminal isoforms and C-
terminal isoforms. The major N-terminal isoforms are classified as ones which have 
an acidic transactivation domain (TA) isoforms or the ones without a transactivation 
domain (ΔN) isoforms(45). The ΔN isoforms of p63 and p73, function as dominant 
negatively against p53, TAp63 and TAp73. Previous studies have demonstrated that 
the TA isoforms function as bonafide tumor suppressors(65, 120) while the role of 
the ΔNp63 and ΔNp73 in tumorigenesis is still unclear. Hence, in this thesis I aimed 
to determine the role of the ΔNp63 and ΔNp73 in tumorigenesis.  
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ΔNp63 and ΔNp73 conditional knockout mice 
 To determine the roles of the ΔNp63 and ΔNp73in tumorigenesis, we 
generated ΔNp63 and ΔNp73 conditional knockout mice were generated. These 
mice were crossed to a Zp3-CRE mouse to generate a ΔNp63+/- and ΔNp73-/- 
mice. In order to determine the role of the ΔN isoforms of p63 and p73, in the 
context of p53-deficiency and also to accelerate tumorigenesis, I generated a cohort 
of ΔNp63+/-;p53-/- and ΔNp73-/-;p53-/- mice, henceforth referred to as double 
mutant mice.  
ΔNp63/p53 and ΔNp73/p53 double deficient mice had reduced thymic 
lymphomagenesis 
 ΔNp63/p53 and ΔNp73/p53 double mutant mice had a significant reduction in 
the thymic lymphoma incidence and increased survival compared to the p53-
deficient mice, which develop thymic lymphoma at a 90% incidence rate. This 
suggests that loss of ΔNp63/ΔNp73 in the p53-deficient thymic lymphomas reduces 
tumor incidence. Upon analysis on the thymic lymphoma tissues of the double 
mutant mice, I observed a significant increase in the expression in the TAp63 and 
TAp73, the tumor suppressive isoforms of p63 and p73. This correlated with the 
induction of apoptosis targets and increase in cell death and also, induction of cell-
cycle targets and increase in cell-cycle arrest in the double mutant thymic 
lymphomas. This suggests that loss of ΔN isoforms of p63 and p73, results in the 
upregulation of tumor suppressive TAp63 and TAp73 isoforms mediating cell death 
and apoptosis. Since, TAp63 and TAp73 respond to genotoxic stress, 4 week old 
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double mutant mice were subjected to gamma radiation. I observed a significant 
increase in the expression of the TA isoforms of p63 and p73 that correlated with the 
induction of apoptosis and cell cycle targets. This further resulted in the induction of 
apoptosis and reduction in proliferation in the double mutant thymus tissues. This 
suggests that loss of ΔNp63/ΔNp73 in the p53-deficient thymic lymphomas restores 
the tumor suppressive functions of TAp63 and TAp73 thereby suppressing 
lymphomagenesis.  
Acute deletion of ΔNp63/ΔNp73 in p53-deficient mice reveals a novel 
metabolic gene signature that suppresses lymphomagenesis 
 Total loss of ΔNp63/ΔNp73 in the p53-deficient mice suppresses thymic 
lymphomagenesis. To test whether this is the case and also determine the molecular 
determinants that mediate this tumor suppression, ΔNp63 and ΔNp73 were acutely 
deleted from the p53-deficient thymic lymphoma. The ΔNp63/p53 and ΔNp73/p53 
deficient tumors had a significant reduction in the tumor volume and increased 
survival. This correlated with the increased expression of TAp63 and TAp73 and 
also induction of cell death and cellular senescence through the activation of targets. 
I reported that ΔN isoforms of p63 and p73, bind to the promoters of TAp63 and 
TAp73 preventing its transcriptional function. Further, TAp63 and TAp73 are 
required for the activation of the apoptosis and cell-cycle targets to mediate tumor 
regression in the p53-deficient mice.  
 Since, apoptosis or cellular senescence are downstream functions, I was 
interested in determining the global role of TAp63 and TAp73 in suppressing 
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tumorigenesis. RNA-Sequencing analysis of ΔNp63/p53 and ΔNp73/p53 tumors 
revealed that novel gene signature enriched with metabolic genes compared to the 
p53-deficient tumors. Ingenuity pathway analysis revealed a cluster of gene involved 
in glycolysis pathway, which includes known metabolic regulators like TIGAR(123) 
and GLS2(82) and novel target called IAPP. IAPP expression was significantly 
upregulated in the ΔNp63/p53 and ΔNp73/p53 deficient tumors suggesting that both 
TAp63 and TAp73 could activate IAPP. Indeed, I reported that TAp63 and TAp73 
bind and transcriptionally activate IAPP, which functions as its downstream target 
(Figure 35). Although, TIGAR and GLS2 were differentially regulated, I found that 
GLS2 was expressed at higher levels in the ΔNp63/p53 tumors suggesting that 
GLS2 could function as a TAp63 target. Similarly, TIGAR was significantly 
expressed at higher levels in the ΔNp73/p53 tumors suggesting that TAp73 could 
regulate TIGAR. For the purpose of this study, I focused on the combined tumor 
suppressive roles of TAp63 and TAp73. However, exploring the individual tumor 
suppressive functions of TAp63 and TAp73 could provide more mechanistic 
evidence of the interplay among the family in tumorigenesis.  
IAPP functions as bonafide tumor suppressor in p53-deficient tumors  
 IAPP encodes amylin, a 37 amino acid peptide secreted from the beta cells in 
the pancreas(83). IAPP has been demonstrated to play functional roles in glucose 
metabolism and apoptosis(84, 124). Interestingly, I reported that IAPP functions as a 
critical metabolic regulator in p53-deficient mouse embryonic fibroblasts (MEFs) 
upon ΔNp63/ΔNp73 loss or expressing IAPP. Since, IAPP is expressed at higher  
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Figure 37: TAp63 and TAp73 compensate for p53-loss by IAPP driven 
metabolic reprogramming. Model depicting loss of ΔNp63 & ΔNp73 in p53-
deficient cancers results in the upregulation of TAp63 and TAp73. TAp63 and TAp73 
recruit IAPP to mediate tumor regression in p53-deficient tumors  
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levels in the ΔNp63/p53 and ΔNp73/p53 double deficient tumors, I suspect the role 
of IAPP in suppressing thymic lymphomagenesis. However, the role of IAPP in 
tumor suppression is relatively less characterized. To determine the role of IAPP in 
tumorigenesis, IAPP was expressed in vivo in the p53-deficient thymic lymphomas. 
This resulted in significant tumor regression and increase in life span. Conversely, 
when IAPP was downregulated in the ΔNp63/p53 and ΔNp73/p53- deficient thymic 
the tumors continued to grow very similar to p53-deficient mice. This correlated with 
the decreased lactate production and also increased accumulation of intracellular 
ROS and cell death. These findings confirm that IAPP functions as a bonafide tumor 
suppressor in p53-deficient thymic lymphomas. 
Ablation of ΔNp63 and ΔNp73 induces IAPP mediated metabolic 
reprogramming in p53-deficient human cancer cells 
 Loss of ΔNp63/ΔNp73 in a p53-deficient mouse model of thymic lymphoma 
induces IAPP mediated metabolic reprogramming that results in suppression of 
thymic lymphomagenesis. To extend my analysis, to human cancers, ΔNp63/ΔNp73 
was knocked down or IAPP was expressed in p53-deficient human cancer cells. I 
observed a significant reduction in the glycolytic capacity that correlated with the 
accumulation of ROS and cell death upon ΔNp63/ΔNp73 deletion or IAPP 
expression. Previous studies have reported that IAPP at physiological levels, 
functions to inhibit the glycolysis pathway by indirectly inhibiting hexokinase through 
increasing the levels of glucose-6-phosphate. I observed a similar accumulation of 
glucose-6-phosphate upon ablation of ΔNp63/ΔNp73 or expression of IAPP in the 
p53-defiicent cells. Indeed, expression of hexokinase II in these p53-deficient cells, 
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completely restored glycolysis and reduced ROS levels and rescued cell death in the 
p53-deficient cells. This suggests that IAPP mediates its tumor suppressive function 
by inhibiting hexokinase the rate-limiting enzyme in the glycolysis pathway (Figure 
36).  
IAPP requires the activity of the Calcitonin and RAMP3 receptors to perform 
its tumor suppressive functions 
 IAPP is a secreted protein from the pancreas. Previous studies have reported 
that IAPP functions through the activity of the calcitonin and RAMP family of 
receptors(127) to perform its physiological functions. Since, IAPP functions as a 
metabolic regulator mediating tumor suppression in p53-deficient mouse tumors and 
p53-deficient human cancer cells, I wanted to determine whether IAPP requires the 
activity of the receptors. Interestingly, I demonstrated that IAPP, requires the activity 
of both the calcitonin and RAMP3 receptors to perform glycolytic inhibition, induction 
of ROS and cell death in the p53-deficient human cancer cells and also p53-deficient 
mouse tumors (Figure 36). Importantly, loss of function of any one of the receptor 
activity renders IAPP function ineffective. To test whether the expression of IAPP 
and its receptors correlate with patient survival, we performed a TCGA analysis of 
patient survival data. In a select group of patients harboring p53-mutations, we 
observed increased survival when IAPP, RAMP3 and calcitonin receptors are 
expressed at higher levels (Figure 37). This analysis proved true across a panel of 
human breast (Figure 37a), colorectal (Figure 37b) and lung squamous (Figure 37c) 
cell cancers. This data provides important information about selecting a patient 
group who might serve as better responders for pramlintide, synthetic analog of  
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Figure 38: IAPP mediated mechanism of glycolytic inhibition in p53-altered 
cancers. IAPP functions through the calcitonin and RAMP3 receptors to inhibit 
glycolysis by suppressing hexokinase activity. IAPP mediated glycolytic inhibition 
results in ROS accumulation and apoptosis.   
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IAPP, for treatment. Importantly, the patient populations, could be classified based 
on the receptor status which could serve as a biomarker. I would suspect that 
patients with less alterations in the calcitonin and RAMP3 receptor status would 
respond better to pramlintide based therapies.   
Pramlintide based therapy to treat p53-altered cancers 
 IAPP functions as a bonafide tumor suppressor in p53-deficient cancers. This 
raises the possibility of using pramlintide as a therapeutic approach to treat p53-
altered cancers. Pramlintide is a synthetic analog of IAPP, used in the treatment of 
Type 1 and Type 2 diabetes. Majority of the human cancers are hard to treat due to 
alterations in TP53, which makes them less responsive to chemotherapy. In such 
cases, pramlintide based approach may provide an alternative since IAPP functions 
by inhibiting glycolysis and does not depend on any alterations or mutations in the 
genes. Indeed, p53-deficient mice treated with pramlintide intratumorally and 
systemically had a significant thymic lymphoma regression compared to the placebo 
treated mice. Further pramlintide treatment in the p53-deficient human cancer cells, 
resulted in inhibition of glycolysis that correlated with increases in ROS and cell 
death. This suggests that pramlintide functions similar to IAPP in p53-defcient 
human cancer cells. Since, pramlintide also functions by inhibition of glycolysis and 
metabolic reprogramming, I suspect that pramlintide could be used to treat p53-
mutant cancer, which are generally hard to target. Indeed, a panel of mutant p53- 
human cancer cells harboring different p53-hotspot mutations where subjected to 
pramlintide therapy and I observed an inhibition of glycolysis and significant 
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Figure 39: Kaplan Meier Survival plots for expression of IAPP-CALCR-RAMP3 
in p53-mutated human cancer patients.   
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accumulation of ROS and cell death. Interestingly, pramlintide mediated tumor 
suppression was ineffective when the activity of the receptors was blocked. 
Currently, I am expanding the possibility of using pramlintide-based therapy to treat 
squamous cell cancers as a single agent. 
 Thus far it has become evident that pramlintide treatment mediates tumor 
suppression in p53-altered human and mouse tumors by inhibiting glycolysis. Since, 
pramlintide is already used as a diabetic drug, pramlintide use is associated with 
reduced cellular toxicity. Hence, I was interested in determining whether long term 
and early dosing of pramlintide could be used to prevent tumor formation. To test 
whether this is case, a cohort of p53-deficient mice was administered with increasing 
doses of pramlintide (30µg/kg, 45µg/kg and 60µg/kg body weight) at 4 weeks of age. 
The mice were administered a biweekly dose of pramlintide for a period of 6 weeks 
by intravenous (IV) delivery method and tumor progression were monitored by MR 
imaging. Additionally, blood glucose levels and body weight of the mice were 
measured every week to monitor the health of the mice upon pramlintide treatment. 
Interestingly, after 6 weeks of pramlintide treatment, I observed the thymic 
lymphoma in the p53-deficient mice were smaller in comparison to the placebo 
treated mice (Appendix 3). Interestingly, some of these treated mice had an 
extended survival compared to the placebo treated mice. From this initial pilot study, 
we were able to demonstrate that pramlintide could be used to p53-deficient mice 
and prevent tumor formation. Our current work is to understand how pramlintide 
prevents thymic lymphoma progression in these p53-deficient mice and expand our 
analysis to a larger cohort.  
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Therapeutically targeting ΔNp63 and ΔNp73 in human cancers 
 ΔNp63 and ΔNp73 function as oncogenes in p53-deficient cancers. 
Importantly, I have demonstrated that targeting the ΔN isoforms of p63 and p73 
restores the tumor suppressive function of TAp63 and TAp73. Importantly, TAp63 
and TAp73 compensate for p53 loss by activating downstream apoptosis and cell-
cycle targets thereby suppressing tumorigenesis. Additionally, targeting ΔNp63 and 
ΔNp73 also suppresses the expression of oncomiRs that promote tumor formation. 
Hence, this raises a novel therapeutic opportunity to target ΔNp63 and ΔNp73 to 
treat p53-deficient cancers. One approach that I have adopted is to deliver small 
interfering RNAs (siRNA’s) through DOPC liposomal nanoparticle based approach. 
In this case, siRNA’s targeting ΔN isoforms of p63 and p73, will be coated with 
neutral liposomal particles and can be delivered to the site of the tumor either 
intratumorally or systemically. Upon, delivering siRNA’s targeting ΔNp63, I observed 
a significant reduction in tumor volume of the p53-deficient mice that correlated with 
the increase in cell death and cell-cycle arrest. This approach of delivering siRNA’s 
targeting ΔNp63 and ΔNp73 can be applied to multiple cancer types and presents a 
unique opportunity to therapeutically treat p53-deficient cancers. 
 
9.2. Conclusions 
 TP53 is a highly mutated tumor suppressor gene rendering cancer therapies 
ineffective. Reactivation of the p53-pathway has been challenging to execute in 
human cancers. By utilizing the functions of the p53-family members, p63 and p73, I 
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have identified a novel approach to treat p53-altered cancers. p63 and p73, although 
structurally similar to p53, exhibit different functions depending on there splice 
variants. I have demonstrated that the shorter ΔN isoforms of p63 and p73 function 
in a dominant negative manner against p53, TAp63 and TAp73. Infact, the ΔN 
isoforms of p63 and p73, function as repressors of transcriptional function of TAp63 
and TAp73, preventing their tumor suppressive properties. Therefore, I have 
demonstrated that ablation of ΔN isoforms of p63 and p73 mediates tumor 
regression in p53-deficient mice through activation of tumor suppressive isoforms 
namely, TAp63 and TAp73. Importantly, TAp63 and TAp73 compensate for p53-loss 
by recruiting IAPP, which induces metabolic reprogramming induced regression of 
p53-deficient tumors. Additionally, TAp63 and TAp73 can also activate downstream 
apoptosis and cell-cycle targets mediating tumor suppression.  
 IAPP, 37-amino acid peptide secreted from the beta cells of pancreas 
functions as a critical regulator of glucose metabolism. IAPP inhibits glucose uptake 
and glycolysis by inhibiting hexokinase, the rate-limiting enzyme in the glycolytic 
pathway. This IAPP mediated glycolytic inhibition results in accumulation of 
intracellular ROS and cell death resulting in p53-deficient tumor suppression. 
Interestingly, Pramlintide a synthetic analog of IAPP, is used in the treatment of 
Type I and II diabetes also functions to inhibit glycolysis and result in ROS induced 
cell death in the p53-deficient cancer cells. This raises the possibility of utilizing 
Pramlintide based therapy to treat p53-deficient cancers. Upon administering 
pramlintide, p53-deficient mice showed significant reduction in thymic 
lymphomagenesis. Importantly, I have also identified that IAPP/Pramlintide mediates 
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its tumor suppressive function through the activity of the calcitonin and RAMP3 
receptors which could be used as biomarkers to classify patients for pramlintide 
based therapy.  
 Further, to expand my understanding of treating p53-mutant cancers, I have 
demonstrated that mutant p53 binds and inhibits TAp63/TAp73 mediated tumor 
suppression upon ablating ΔNp63/ΔNp73 in p53-mutant human cancer cells. Hence, 
two approaches to treat p53-mutant cancers, is to overcome the effect of mutant 
p53, by ablating the oncogenic isoforms of p63 and p73 and treating the cells with 
DNA damaging agent like doxorubicin. This results in increased accumulation of 
TAp63 and TAp73, which could possibly overcome mutant p53 effect. Second 
approach is to target the downstream glycolysis pathway using pramlintide based 
therapies. Treatment of mutant p53 human cancer cells with pramlintide has resulted 
in inhibition of glycolysis and ROS-induced cell death through the activity of the 
calcitonin and RAMP3 receptors. Since cancer cells are in general highly glycolytic 
supporting Warburg’s hypothesis, pramlintide based therapy would work as novel 
approach to treat these cancer types. Further, the only other available glycolytic 
inhibitor is 2-deoxy glucose (2-DG), which has potent effect in inhibiting glycolysis, 
however, 2-DG is highly toxic and cannot be used for therapeutic intervention. On 
the contrary, Pramlintide functions similar to 2-DG and is less toxic and is already 
used in the treatment of diabetes. Thus the use of pramlintide highlights a novel 
approach to treat p53-mutant cancers.  
 Finally, since I have demonstrated that ΔNp63 and ΔNp73 function as 
oncogenes in p53-deficient cancers, targeting these oncogenic isoforms has raised 
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a novel therapeutic opportunity to treat p53-deficient cancers. To therapeutically 
target ΔNp63/ΔNp73 in p53-deficient cancers, I delivered liposomal nanoparticle 
coated siRNA’s targeting ΔNp63 in vivo in to a p53-deficient thymic lymphoma. This 
resulted in a significant reduction in the thymic lymphomagenesis highlighting the 
therapeutic applications of targeting the oncogenic isoforms of p63 and p73 to treat 
p53-deficient cancers.  
 Thus far, my work has presented a novel and unique approach to treat p53-
deficient and mutant cancers. Importantly, understanding the interplay among the 
p53-family members has enabled us to delineate the intricate and individual 
functions of each of the isoforms in tumorigenesis.  Further, by characterizing the 
tumor suppressive role of IAPP, I have proposed the possibility of repurposing an 
existing diabetic drug with less toxicity towards cancer treatment.  
9.3. Future Directions 
 My thesis thus far has identified the intricate regulations among the p53-
family members, p63 and p73 and their role in tumor suppression. Importantly, I 
have identified novel therapeutic approaches to treat p53-deficient cancers by 
multiple approaches, one of which is through metabolic reprogramming induced by 
IAPP which mediates tumor regression and second approach by using DOPC-
labeled siRNA’s to target the oncogenic isoforms of p63 and p73.  
 Hence, from this study it is evident that both ΔNp63 and ΔNp73 function as 
oncogenes in a p53-deficient model of thymic lymphoma. Indeed this has been the 
trend in human cancers, were expression of ΔNp63 and ΔNp73 is significantly 
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upregulated. However, in some instances, ΔN isoforms could also function as tumor 
suppressors (unpublished data). Nevertheless, it is important to further understand 
and elucidate the larger roles played by ΔNp63 and ΔNp73 in tumorigenesis. ΔNp63 
and ΔNp73 function as repressors of gene function. As a result, it is important to test 
whether ΔNp63 and ΔNp73 could repress other transcription factors or even 
miRNAs which could function as tumor suppressors. ΔNp63 and ΔNp73 may 
perform these functions individually or by recruiting other co-repressors. Hence, by 
performing a ChIP-sequencing analysis we can determine the binding partners of 
ΔNp63 and ΔNp73. 
 Additionally, since ΔNp63 and ΔNp73 function as transcription factors, it is 
possible that these isoforms could transactivate certain oncogenes by activating 
oncogenic pathways to promote tumor formation. Hence, it is important to identify 
the transcription related functions of ΔNp63 and ΔNp73 as well. Further to suppress 
tumorigenesis, we could direct miRNAs that could function as “sponges” to control 
and limit the function of ΔNp63 and ΔNp73 in tumor formation.  
 Further, previous work and current work as again attested that TAp63 and 
TAp73 function as potent tumor suppressors. I have demonstrated that TAp63 and 
TAp73 jointly induce metabolic reprogramming by activating IAPP, a metabolic 
regulator. However, it is possible that TAp63 and TAp73 do have their individual 
targets to mediate tumor suppression. Given the possible role of the TA isoforms in 
regulating lncRNAs, TAp63 and TAp73 could play critical roles in activating lncRNAs 
to mediate tumor suppression. Also, TAp63 and TAp73 could have distinct tumor 
suppressive functions depending upon the tissue context. For example, p53 
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restoration in the thymic lymphomas induces apoptosis, while in the osteosarcomas, 
induces cellular senescence. Hence, similar to p53, TAp63 and TAp73 could have 
diverse functions depending on the tissue context and origin. Hence, it would be 
interesting to clearly delineate the diverse cellular process regulated by TA isoforms 
of p63 and p73 in tumor suppression.  
 Finally, metabolic reprogramming is becoming a well-debated topic and even 
emerged as one of the hallmarks of cancer. This is due to the fact that cancer cells 
are metabolically active promoting tumor cell proliferation and require large influx of 
energy to continue this process. Hence, therapeutically inhibiting this pathway 
seems more feasible and does not depend on the functional status of different 
genes. However, the metabolic circuitry is far more complex and constantly evolving. 
I have identified the role of a metabolic regulator called IAPP which functions to 
mediate tumor suppression by inhibiting glycolysis. Importantly, synthetic analog of 
IAPP called Pramlintide, a diabetic drug has shown tremendous potential towards 
the treatment of p53-deficient cancers. Currently, I have tested the use of 
pramlintide in multiple cancer types and I aim to test the efficacy of the drug using 
preclinical patient derived xenografts models. Results from this study will enable us 
to use the drug as a single agent or as a combinatorial drug with other standard of 
care therapy drugs.  
 Previously, as per Warburg’s hypothesis, mitochondrial oxidation does not 
contribute to tumor cell proliferation. However, recent evidence has demonstrated 
the mutations in the mitochondrial oxidation pathway have lead to tumor cell 
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proliferation. Hence as a therapeutic strategy, we could utilize both pramlintide and a 
mitochondrial inhibitor to suppress tumor cell proliferation.   
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Appendix 1: Mouse thymic lymphoma mRNA heat map. 
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Appendix 2: List of genes differentially expressed in ΔNfl/f;p53-/- vs ΔNp63Δ 
/Δ;p53-/- and ΔNp73Δ/Δ;p53-/- thymic lymphoma samples 
Gene Name ΔNfl/fl; 
p53-/- 
ΔNp63Δ/Δ;p53-/- 
ΔNp73Δ/Δ;p53-/- 
t-value p-value 
Lce6a 0.50623477 0.8510781 3.2239006 0.014574393 
Upp1 0.7964159 0.6226899 3.1032262 0.026755208 
Ssr4 0.58017164 0.30428436 5.612081 0.004953332 
Dph5 0.8363405 0.6458249 2.8655672 0.035176527 
Kcnj10 0.6928598 0.8021817 2.8215833 0.025714781 
Rplp1 0.89320916 0.40704307 3.2561753 0.047268085 
Chst15 0.34172666 0.39977396 7.654346 1.21E-04 
AI118078 0.70577794 0.823888 2.684871 0.0313175 
1700029J07Rik 0.80049235 0.41755116 3.6963458 0.020902188 
NR_033629 0.7805456 0.61027247 3.2125351 0.02366173 
Gpr55 0.8152403 0.50371623 3.3865895 0.027616808 
Apobec2 0.39166403 0.55679625 5.6879067 7.45E-04 
Tnpo2 0.46795464 0.5575977 5.1519804 0.001321112 
C1qtnf1 0.31462026 0.490858 6.9381404 2.24E-04 
Sncb 0.68061334 0.62077165 3.6268063 0.011007131 
Hemk1 0.7203515 0.7550949 2.9178421 0.026706224 
Rps2 0.7302686 0.7622172 2.852749 0.029076638 
Mapre2 0.8589156 0.5447324 3.0736532 0.037160475 
Fbxw2 0.7842838 0.76749945 2.6384406 0.038620915 
Clptm1 0.6981217 0.48885804 4.043158 0.015563355 
Cdkn2b 0.759716 0.8135128 2.5456023 0.04374917 
Tcstv3 0.27684957 0.5970781 6.0870256 4.97E-04 
Lrp4 0.7297057 0.64692396 3.3024392 0.021417892 
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Gene Name ΔNfl/fl; 
p53-/- 
ΔNp63Δ/Δ;p53-/- 
ΔNp73Δ/Δ;p53-/- 
t-value p-value 
Snph 0.5002801 0.97959596 2.5421705 0.038541656 
Atat1 0.53324264 0.97110534 2.5028503 0.040821623 
Ankrd60 0.2085665 0.828321 4.2540317 0.008060685 
Fzd3 0.7992467 0.53205603 3.378766 0.027817171 
Slc39a10 0.7468975 0.6011655 3.3935597 0.019386165 
Pogk 0.79479855 0.80082333 2.4766378 0.04802364 
Ssr4 0.67074746 0.58611465 3.8162637 0.012420383 
Arf1 0.60844433 0.71573335 3.5322573 0.009568775 
Rpl10 0.47247326 0.7212307 4.092963 0.004613714 
Glod4 0.58177453 0.9311328 2.5762439 0.036672536 
Tmem229b 0.7877702 0.7324492 2.755291 0.033059366 
Pcdh12 0.71684206 0.77184725 2.8627381 0.028698595 
Cpt1a 0.50031483 0.98236585 2.5269172 0.039410077 
Jub 0.8114347 0.75536054 2.5871568 0.04136963 
Marveld3 0.6655221 0.9202029 2.384675 0.048547305 
Mael 0.09720916 0.6674868 6.0559745 0.001770923 
Smoc2 0.6986251 0.6333105 3.4929614 0.012936638 
Usp46 0.7022045 0.66434157 3.3539565 0.015343993 
Atp5g1 0.741628 0.8482092 2.4646173 0.04317217 
Trpc6 0.52749956 0.8119151 3.3625886 0.012041636 
NR_040684 0.14194141 0.77539027 4.846768 0.004687081 
Acpp 0.6721452 0.8147476 2.839229 0.02507229 
Fut4 0.75040406 0.7059895 2.9948723 0.024167644 
Abcc1 0.7909167 0.738919 2.7202146 0.034632906 
Rragc 0.79355305 0.8044168 2.467177 0.048643574 
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Gene Name ΔNfl/fl; 
p53-/- 
ΔNp63Δ/Δ;p53-/- 
ΔNp73Δ/Δ;p53-/- 
t-value p-value 
Rab25 0.60436094 0.87930626 2.7644632 0.027915865 
Ror1 0.39281154 1.0071157 2.6372552 0.038682207 
Calu 0.61523455 0.9443378 2.4152248 0.046416476 
Marveld1 0.47468898 0.7533694 3.8917649 0.00596181 
Slc25a21 0.8176421 0.7046145 2.7429042 0.040651474 
Fam46c 0.54810005 0.5812634 4.5079803 0.004069225 
Gal3st4 0.6925565 0.81971294 2.7475557 0.02860464 
Rpl10a 0.69966877 0.8878008 2.4280963 0.045547623 
Gm5077 0.79221207 0.74436057 2.6956744 0.035781357 
Tpbg 0.8670789 0.57156676 2.9640145 0.041389212 
Smarca2 0.5522846 0.91535926 2.7418885 0.028839475 
Lrrc56 0.51858276 0.49713963 5.170814 0.002072778 
Mrgpra1 0.03466722 0.717363 5.57638 0.002555353 
Fam20b 0.59198934 0.89849436 2.7087545 0.030253453 
Rtn4 0.585884 0.93577594 2.541162 0.03859846 
Pth2r 0.06894411 0.7952146 4.771537 0.005007988 
Foxe1 0.06402541 0.7921452 4.804346 0.004864986 
Stt3a 0.68839693 0.6226994 3.5824049 0.011609451 
Gdpd4 0.05965448 0.775595 4.963919 0.004233855 
Prom2 0.29395136 1.0304649 2.683304 0.036375646 
Rffl 0.3702356 0.7321335 4.4629426 0.002925672 
Asb13 0.51346165 0.8901825 2.9896507 0.02023635 
NR_038165 0.06112718 0.7859784 4.864335 0.004615638 
10-Mar 0.04384523 0.78105056 4.9238796 0.004382753 
Akr1cl 0.586931 0.8700178 2.8650258 0.024163263 
	   166	  
Gene Name ΔNfl/fl; 
p53-/- 
ΔNp63Δ/Δ;p53-/- 
ΔNp73Δ/Δ;p53-/- 
t-value p-value 
Rpn2 0.8236423 0.74626064 2.5763524 0.041974813 
Iscu 0.3857484 0.7311601 4.404584 0.003139355 
Tacr3 0.40059546 0.88987154 3.322399 0.012723062 
Large 0.42922392 0.9303198 3.0033495 0.019847875 
Pak6 0.58600616 0.6490751 3.9564848 0.005486284 
Tuba4a 0.6070302 0.8479222 2.9073396 0.022746634 
Krtcap2 0.54625815 0.8307415 3.1979437 0.015108911 
NR_045888 0.03359216 0.76225203 5.1121187 0.003731821 
Bmp6 0.52605855 0.8455745 3.1881936 0.015315074 
Slc36a3 0.72738564 0.880149 2.3753183 0.04921976 
Apoc4 0.4426753 0.7864958 3.817456 0.006563929 
Rhox4b 0.49544 0.8362016 3.3415244 0.012393758 
Treml4 0.64355266 0.9215 2.4434934 0.04453018 
Spic 0.48758885 0.97271717 2.6121955 0.034802 
Galnt9 0.47929856 0.8997125 3.0390067 0.018873326 
1810046K07Rik 0.4811074 0.8500687 3.3114579 0.01291566 
Zkscan3 0.5762213 0.76946473 3.4009442 0.011427785 
Sbf2 0.5884245 0.8156363 3.1275332 0.01666711 
Ufsp2 0.3882136 0.93116844 3.1038597 0.017228816 
Tex2 0.6097382 0.6423541 3.872926 0.008237901 
NR_015497 0.046098124 0.7693352 5.0349994 0.003983822 
Bcap31 0.74081314 0.71593606 2.9943774 0.024183095 
Sync 0.41539133 0.7837205 3.9364207 0.00562912 
1520402A15Rik 0.4395788 0.66299117 4.6181703 0.00243139 
Fastkd2 0.6023917 0.85377264 2.8944259 0.023169441 
	   167	  
Gene Name ΔNfl/fl; 
p53-/- 
ΔNp63Δ/Δ;p53-/- 
ΔNp73Δ/Δ;p53-/- 
t-value p-value 
Muc15 0.48963168 1.0017498 2.4464188 0.044339523 
Tanc1 0.3942968 0.69174206 4.6445045 0.002357065 
Efhb 0.64946467 0.826088 2.8665035 0.024112253 
Nqo2 0.70100087 0.70463 3.1969662 0.018671393 
Ptgs2 0.6398621 0.92783684 2.4242017 0.04580874 
Egfr 0.47836643 0.8383031 3.3869758 0.01164735 
NR_015516 1.09E-05 0.78030497 4.9450326 0.007788752 
Mrpl32 0.7962867 0.80487895 2.4562397 0.04937077 
Klrc2 0.6295951 0.68254524 3.5947902 0.01143785 
Nfyc 0.42785197 0.8803824 3.3011353 0.013100242 
Ocln 0.53484064 0.67174685 4.088315 0.004640799 
Sec61g 0.5311733 0.91416025 2.8096251 0.026160005 
Manba 0.47241944 0.90458584 3.031675 0.019069478 
Pik3c2g 0.5235649 0.77561355 3.572338 0.00906853 
Tgfbr2 0.6057456 0.9590669 2.3689172 0.049685277 
Med11 0.5247877 0.68585765 4.058766 0.004817104 
Mrps6 0.5970628 0.87763494 2.795532 0.026695142 
NR_030738 0.5055372 1.0090405 2.3675964 0.049781892 
Abcb1b 0.5881341 0.9499241 2.463673 0.04323195 
Pla2g4c 0.6487061 0.7689414 3.1268964 0.016681964 
Iapp 0.37614614 0.7640406 4.2150292 0.003960948 
Zmpste24 0.7017584 0.88372415 2.4395854 0.044786185 
Praf2 0.516418 0.7758566 3.5985727 0.00875646 
Traf3ip2 0.5621396 0.7359082 3.6270857 0.00843042 
Naip7 0.66979957 0.90549463 2.4397695 0.044774093 
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Gene Name ΔNfl/fl; 
p53-/- 
ΔNp63Δ/Δ;p53-/- 
ΔNp73Δ/Δ;p53-/- 
t-value p-value 
Adamts14 0.64072967 0.8861263 2.6184433 0.034487177 
Clta 0.27749223 0.64808947 5.579663 8.34E-04 
Gnas 0.86566114 0.6538075 2.7268248 0.041436642 
1300017J02Rik 0.40781325 0.95330995 2.9224846 0.022261126 
Ly9 0.60790765 0.957329 2.371578 0.04949123 
NR_033567 0.6981446 0.8721835 2.5015848 0.040897276 
Galnt6 0.558411 0.7451528 3.5949407 0.008798962 
Cab39l 0.67603004 0.76048815 3.0611315 0.018294284 
6330409D20Rik 0.2894976 0.87401193 3.7218037 0.009831389 
Dhx29 0.6045901 0.9455439 2.43939 0.044799034 
Cd151 0.4969481 0.91345584 2.9121544 0.022591082 
Pgam2 0.43017796 0.9631706 2.8098369 0.026152052 
Rpl38 0.55708057 0.8995604 2.8088906 0.026187617 
Cd82 0.5228897 0.7125258 3.919965 0.005749298 
Tspan32 0.48725036 0.85251766 3.277781 0.013528376 
Extl2 0.671924 0.8576328 2.6498168 0.032950453 
Psma5 0.5289441 0.841474 3.2003438 0.015058617 
NR_033495 0.45328638 0.8283428 3.5287938 0.009613382 
C2cd2 0.60580796 0.82422304 3.0252416 0.019243384 
0610010O12Rik 0.5705635 0.9569846 2.4763649 0.042435452 
Slc25a12 0.7201853 0.86228335 2.4744027 0.042557597 
Ap4m1 0.5918478 0.8213844 3.0874119 0.017630924 
Gstp1 0.4371063 0.95067763 2.8648202 0.024170365 
Mrpl47 0.5924998 0.95079786 2.447101 0.044295173 
Rps24 0.5697426 0.9511336 2.5086052 0.04047941 
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Gene Name ΔNfl/fl; 
p53-/- 
ΔNp63Δ/Δ;p53-/- 
ΔNp73Δ/Δ;p53-/- 
t-value p-value 
Ncald 0.5127015 0.94034237 2.7223492 0.02966473 
Cacna1f 0.47335693 1.0060757 2.4611814 0.043390118 
BC048546 0.33758682 0.7778202 4.260159 0.003745855 
Fbxo10 0.49252775 0.9984751 2.4575386 0.04362243 
Cryaa 0.5712679 0.94908345 2.5148673 0.0401104 
Clnk 0.49137715 0.86753416 3.181155 0.015465769 
Fam19a1 0.6111891 0.9431995 2.4322996 0.045267522 
Ugt1a1 0.44555384 0.9623292 2.7765749 0.027433163 
1810006K21Rik 0.21862034 1.0390533 2.7403898 0.04077316 
Eps8l1 0.43315858 1.0194954 2.4765108 0.042426385 
Arhgef17 0.61637163 0.84924567 2.8701138 0.023988103 
Med22 0.36853078 0.9276793 3.1742754 0.019214507 
NR_029468 0.35080907 0.9451299 3.107887 0.020905085 
Scgb3a2 0.2620157 0.8053907 4.2967877 0.005110728 
Scml4 0.65128565 0.9152222 2.4501765 0.04409585 
Asah2 0.46289924 0.8275435 3.5008683 0.009981358 
Fam98a 0.62171805 0.9417445 2.4094806 0.04680969 
Taz 0.13061292 0.9723755 3.2965355 0.021557627 
Fau 0.48894367 0.9964673 2.4774058 0.0423708 
NR_045290 0.6946559 0.8758147 2.4966183 0.041195575 
Syvn1 0.47107065 0.77000326 3.8079958 0.006645221 
Pdlim1 0.6388014 0.91971564 2.4659784 0.04308614 
NR_003965 0.6674969 0.89619136 2.4893866 0.041633945 
Mup8 0.28921473 1.0305451 2.6907148 0.036018368 
Afg3l2 0.47320518 0.9837088 2.587048 0.03609968 
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Gene Name ΔNfl/fl; 
p53-/- 
ΔNp63Δ/Δ;p53-/- 
ΔNp73Δ/Δ;p53-/- 
t-value p-value 
4931408A02Rik 0.5731959 0.94342273 2.5383627 0.038756575 
Ssu72 0.20708062 1.0556824 2.6451163 0.045694012 
Pigu 0.47711998 0.94269335 2.805804 0.026303977 
9930012K11Rik 0.7243802 0.88134074 2.3795633 0.0489135 
Clrn1 2.46E-05 0.87987256 4.069787 0.00963597 
Gm3258 0.33341172 1.0345705 2.588222 0.041310463 
Tspan8 0.77924377 0.7922718 2.562129 0.04278586 
Nmur2 0.32798997 0.99668837 2.8342068 0.029792687 
Lman1 0.26106992 0.92545706 3.4305842 0.013961174 
NR_033474 0.34091642 0.8583539 3.6919248 0.010185443 
B230217C12Rik 0.41473922 0.88270944 3.325502 0.012669002 
Sv2b 0.51376563 0.9290682 2.7799869 0.027298767 
Ptp4a2 0.27657467 0.9073741 3.5217657 0.012491772 
Ankrd6 0.46388268 0.80018413 3.6573663 0.008098511 
Fau 0.46296304 1.0127833 2.4475908 0.04426337 
Folh1 0.5174267 0.9502935 2.656049 0.03265377 
Arid5a 0.51709694 0.9645196 2.5805302 0.03644415 
Mup2 0.47848442 0.9453433 2.7874343 0.027007809 
Klra4 0.37658283 0.9900398 2.7747087 0.03222138 
Slc40a1 0.1771824 1.0311472 2.8428626 0.036124878 
Glrx3 0.5580255 0.8876175 2.8671272 0.024090758 
Tbc1d5 0.4829335 0.90015644 3.0259233 0.019224878 
NR_045514 4.46E-06 0.9485071 3.5368476 0.0166182 
2310008H09Rik 0.010931266 0.9003462 3.9053736 0.011347706 
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Gene Name ΔNfl/fl; 
p53-/- 
ΔNp63Δ/Δ;p53-/- 
ΔNp73Δ/Δ;p53-/- 
t-value p-value 
Tnfrsf19 0.1674707 0.93556035 3.5172882 0.016968133 
Cfhr2 0.23195125 1.0613495 2.5768409 0.0496218 
Llgl1 0.0021698 0.892555 3.9677355 0.010660225 
D630023F18Rik 0.37240082 0.8146346 3.8862486 0.006004374 
Rpl19 0.079263635 0.9787726 3.2910182 0.021689147 
Nsun4 0.4416605 0.91613525 3.0523489 0.018521847 
Cnih4 0.39498183 0.95586914 2.938306 0.021765612 
Nadk 0.42643613 1.03985 2.372246 0.04944263 
Ankrd34a 0.19225873 0.7893165 4.612589 0.00577403 
Dhrs1 0.39609712 0.9833172 2.7718215 0.027621552 
Hopx 0.5611796 0.9375947 2.601936 0.035325464 
Ltb4r2 0.32045794 1.0218899 2.6908607 0.03601137 
G630090E17Rik 0.5017128 0.8816087 3.0717993 0.018021865 
Ermap 0.100690484 1.0353256 2.881328 0.034534495 
Ubac2 0.4101417 0.93958837 2.9980452 0.01999735 
Pcdhgb1 0.28273576 0.98378414 3.0019758 0.023947064 
Rgs22 0.44141433 1.0208169 2.4505277 0.04407315 
Paqr7 0.6668556 0.76181465 3.089987 0.017567312 
Klrb1a 0.22580683 1.0472682 2.6770046 0.04397767 
Tmsb10 0.17267758 1.0051781 3.023695 0.029292101 
Sdr9c7 0.1983991 1.0443401 2.7305067 0.041255385 
Dnm2 0.29322225 0.99542636 2.9078968 0.02705447 
Cops7a 0.40569085 0.9745358 2.8019078 0.026451634 
Ccl19 0.22727525 0.9722433 3.1730046 0.02473142 
Ttll11 0.21911533 0.9631975 3.247384 0.02276186 
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Gene Name ΔNfl/fl; 
p53-/- 
ΔNp63Δ/Δ;p53-/- 
ΔNp73Δ/Δ;p53-/- 
t-value p-value 
Pold4 0.2391084 0.92063814 3.506603 0.01716284 
Gm1987 0.2326995 1.0171548 2.865371 0.035184603 
Syn1 0.010146572 0.9074213 3.8498783 0.012002615 
Atrnl1 0.42843425 1.0190974 2.4892452 0.04164256 
Klk1b8 0.39827925 0.9093671 3.2101076 0.014855861 
Tmem87a 0.52063036 0.97502416 2.5148137 0.04011355 
5830411N06Rik 0.5213376 0.865152 3.0992453 0.01734063 
Eif4a2 0.09404888 1.0454574 2.8158395 0.037290826 
Lpcat1 0.16151527 1.0282186 2.8792467 0.03461853 
Sec24c 0.34898728 0.91431296 3.3065064 0.016275393 
Prl2c5 0.16585448 0.88248074 3.9134727 0.011255602 
NR_045551 0.27606234 0.8820939 3.6977692 0.010115091 
Slc25a13 0.3427428 0.97040373 2.968056 0.025020428 
Spryd4 0.4059689 1.0225371 2.517598 0.045434296 
Col6a4 0.42790028 0.99260974 2.6444578 0.033207808 
Mrps10 0.19412164 1.0520066 2.6845717 0.043580882 
Wwtr1 0.5607859 0.9568985 2.503545 0.040780153 
Eml1 0.31955248 1.0166045 2.7256072 0.034385867 
Kank3 0.33374676 0.98271513 2.910037 0.026979113 
4930579G22Rik 0.24159038 1.0129989 2.8796208 0.03460341 
Ptpn3 0.18376632 1.009624 2.9804668 0.030783365 
BC068157 0.44300586 1.0300736 2.3934824 0.047922913 
Kcnj16 0.1452977 0.9886137 3.1676726 0.02487983 
Cubn 0.4371116 0.9212942 3.0348473 0.018984344 
C030006K11Rik 0.3596322 1.0092193 2.69375 0.035873126 
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Gene Name ΔNfl/fl; 
p53-/- 
ΔNp63Δ/Δ;p53-/- 
ΔNp73Δ/Δ;p53-/- 
t-value p-value 
Wscd1 0.3796186 1.0385841 2.475681 0.048085954 
Filip1 0.3174312 1.0554887 2.4859033 0.04742458 
Epb4.1l5 0.27832347 1.0483567 2.5945826 0.040959068 
Pou2f1 2.04E-04 1.0830048 2.5851943 0.049121927 
Hn1l 0.33259466 1.0364295 2.5781753 0.04187205 
Naaa 0.3033944 1.0623595 2.4658666 0.048730098 
Lrp11 0.4181843 1.0247229 2.4786282 0.04229501 
Zp3 0.33273584 1.0134135 2.7208018 0.034605913 
BC020535 0.13597594 1.0502218 2.75375 0.040131155 
NR_003559 0.31307563 1.0081371 2.7907507 0.031546272 
Ap4s1 0.47268093 0.97784877 2.621144 0.034352 
Spink8 0.17779204 1.0021979 3.038038 0.02881531 
Grhl2 0.33539027 0.9735747 2.9638171 0.025158186 
Trim65 0.29378456 1.0665808 2.4543815 0.04949545 
1110067D22Rik 0.33296582 1.027188 2.6348464 0.038807075 
Kap 0.18033898 0.9351312 3.5023742 0.0172406 
Bnip1 0.1973908 1.0033227 3.006044 0.029891029 
Higd1b 0.30218932 1.0357987 2.6355996 0.038767986 
Lce1a2 0.12076877 0.96750176 3.3405473 0.020540189 
Lyplal1 0.30945802 1.0592098 2.4758434 0.04807537 
Tmprss2 0.25288934 1.0497423 2.6236742 0.046889488 
Hbb-bh1 0.096041106 0.94791174 3.5035288 0.017219327 
Gsc 0.15691313 0.9495058 3.4307046 0.018621366 
Scube1 0.2076112 1.048915 2.689168 0.043341804 
AW551984 1.30E-04 1.0293053 2.9558487 0.031670462 
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Gene Name ΔNfl/fl; 
p53-/- 
ΔNp63Δ/Δ;p53-/- 
ΔNp73Δ/Δ;p53-/- 
t-value p-value 
Dab1 0.0501478 0.9338845 3.635904 0.014967592 
Kcnk16 0.106278725 0.9433708 3.5284772 0.016766937 
Pou5f1 0.21591836 1.0218856 2.857435 0.035512984 
NR_040725 0.050579414 1.0547882 2.771202 0.039309315 
Serpine3 0.071880594 1.0747625 2.6265485 0.046727255 
Triobp 0.001302765 0.95452374 3.4921272 0.01743069 
Cpb2 0.17187624 1.0402282 2.7875478 0.03855644 
Wdsub1 3.49E-04 1.0074637 3.1093168 0.026571333 
Pla2g10 0.08787624 0.9853477 3.238725 0.022981795 
Sall3 0.16996822 1.001712 3.0504706 0.028409056 
Prss3 0.16676864 1.0712739 2.5847702 0.049147174 
B020004J07Rik 0.050596338 0.9881912 3.2372963 0.02301831 
Prkg1 0.016211495 1.0360569 2.9079576 0.033479154 
NR_045499 0.121789984 0.9866879 3.2035015 0.023901505 
Dcst1 0.023635086 0.9728535 3.355415 0.02020886 
Hist1h1t 0.12700328 1.0330417 2.8779435 0.034671262 
Nr2e3 0.06102681 0.9930714 3.1982481 0.024042198 
Ppp1r42 0.10658224 1.0088007 3.0608091 0.028076116 
Serpina1a 1.44E-05 1.0836018 2.5811038 0.049366016 
Nog 0.064044625 0.9909495 3.211993 0.023676045 
NR_045471 0.07664614 1.0190103 3.0081723 0.029818088 
Gpr123 0.009730205 0.98342794 3.2806072 0.021939807 
NR_045403 0.07147401 1.0313613 2.9248602 0.03282796 
Dync1i2 0.066882834 1.0650269 2.6951408 0.043033276 
Fam178b 6.77E-06 1.0829573 2.5855205 0.049102522 
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Gene Name ΔNfl/fl; 
p53-/- 
ΔNp63Δ/Δ;p53-/- 
ΔNp73Δ/Δ;p53-/- 
t-value p-value 
NR_045139 0.06735169 1.008584 3.085693 0.027292563 
Naaladl1 0.053612288 1.0680281 2.6793606 0.043853704 
Prkag3 0.06384879 1.0049062 3.1131773 0.026455523 
Slc22a20 0.03645663 0.9997913 3.159037 0.025122324 
Kcnq2 0.036764227 1.0096254 3.089353 0.027179392 
Caps2 0.015649516 0.9968863 3.1835794 0.024440022 
Gm5415 0.034550942 1.0045222 3.125965 0.026075933 
Hsd17b13 0.03275477 1.0138159 3.06079 0.028076725 
Plec 0.045199126 1.0173177 3.0328953 0.028985256 
Gpr45 0.012568595 0.99713814 3.182096 0.024480665 
Gpr151 0.034017283 1.0244093 2.9862201 0.030580075 
Mas1 0.021702003 1.0055172 3.1214514 0.026209213 
Ugt2b35 0.015060733 0.9937249 3.2062118 0.02382928 
Opn4 0.025556093 1.0219386 3.00519 0.029920353 
NR_045633 0.019177223 1.0061882 3.1170616 0.026339568 
Sez6l2 0.010578183 1.0408726 2.8749948 0.034790907 
Gm15085 0.014337389 1.0038928 3.133896 0.02584359 
Nkain2 0.012200879 1.0196103 3.0232098 0.029308382 
Dlg5 0.005792228 1.0646698 2.7109206 0.042229768 
Fkbp10 0.002660292 1.042329 2.8652275 0.03519051 
Kcnq2 0.001736278 1.0002984 3.1601448 0.02509107 
Sgce 6.18E-06 1.0689567 2.6815572 0.043738477 
Mum1l1 1.76E-06 1.0081193 3.1046782 0.026711244 
NR_040301 0.008865041 0 436.87704 5.24E-06 
NR_040302 0.06453177 0 59.975018 1.02E-05 
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Gene Name ΔNfl/fl; 
p53-/- 
ΔNp63Δ/Δ;p53-/- 
ΔNp73Δ/Δ;p53-/- 
t-value p-value 
Defb19 0.71080106 0 4.9688 0.015658686 
Myt1 0 0.001229972 3856.5217 0 
Myt1 0 0.012753357 371.91794 2.67E-12 
Myt1 0 0.06677306 70.94985 1.05E-08 
Ccdc34 0.7565142 0.7743096 2.7106729 0.035074696 
NR_038063 0.9059068 0.108112104 3.610451 0.03649204 
Hsd3b1 0.9762237 0.1183075 3.242564 0.047757953 
NR_045294 0.71784025 0.876197 2.4221497 0.04594694 
Rsrc2 0.7443213 0.27466303 4.3815093 0.022009687 
Bcl2l10 0 0.17948449 26.190445 1.52E-06 
Dnm2 0.7816765 0.7036265 2.8824856 0.027966736 
Ccdc73 0.7500891 0.80644923 2.606324 0.04031871 
Gast 0.899202 0.49879313 3.0194435 0.039184667 
Cnnm3 0.6512607 0.85505253 2.728589 0.029398533 
Ssb 0.89562666 0.46026605 3.1269035 0.035290547 
Ppfia1 0.17896304 0.4426226 9.011467 4.23E-05 
NR_015569 0.8817025 0.6314438 2.7326956 0.04114804 
Cspp1 0.9237553 0.30175745 3.3034446 0.04561552 
Nr1h2 0.80819005 0.7916678 2.465703 0.048740912 
Ccar1 0.7473373 0.33813232 4.2108502 0.024464315 
Cd97 0.7391347 0.7507099 2.8657172 0.028586878 
Rbm25 0.56713337 0.34691033 5.5523005 0.005149068 
Larp7 0.7287209 0.7800584 2.7866962 0.031715456 
NR_040337 0.9435602 0.2577174 3.270256 0.046767995 
Brd3 0.9159391 0.5309495 2.8696134 0.045486327 
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Gene Name ΔNfl/fl; 
p53-/- 
ΔNp63Δ/Δ;p53-/- 
ΔNp73Δ/Δ;p53-/- 
t-value p-value 
Tob2 0.8125718 0.69766694 2.785804 0.03863599 
NR_027656 0.4660744 0.40277642 6.213478 0.00157788 
Calm2 0.68383205 0.74108434 3.1140285 0.02074208 
Fam100b 0.8499497 0.54074174 3.1237369 0.035398606 
Celf2 0.8482771 0.6944917 2.662934 0.04472609 
Ap1m1 0.8313259 0.30461124 3.7822196 0.03239436 
Bod1l 0.8083337 0.27769783 3.9667544 0.028626364 
Cdk5r1 0.8614844 0.46018153 3.283664 0.030395865 
Brd9 0.88041836 0.30041733 3.5238216 0.038810708 
Zfp161 0.9409301 0.5197001 2.7949195 0.04906509 
Rnf6 0.44702148 0.908454 3.0818298 0.017769653 
Srek1 0.81591403 0.58965653 3.126639 0.026056103 
4930578N16Rik 0.59512186 0.44799608 4.8665276 0.004606811 
Itgb5 0.73957336 0.3174806 4.313101 0.022953564 
Crebzf 0.6561649 0.8002372 2.9595892 0.021117367 
Abcc5 0.51673055 0.36533624 5.938121 0.004032765 
Btbd6 0.7685415 0.50855094 3.6003833 0.022750376 
NR_045578 0.9126684 0.48834902 2.9865665 0.040475197 
Arpp21 0.8975752 0.33963913 3.3679037 0.043478187 
Asb13 0.51212585 0.8886454 3.0019608 0.019886896 
NR_037588 0.7172673 0.7719071 2.860952 0.028765805 
Mmadhc 0.75836766 0.47774488 3.7490823 0.01996297 
Rps11 0.35408777 0.9651544 2.9759834 0.024764983 
Dcaf17 0.5781421 0.69776237 3.7513547 0.007155442 
Rtf1 0.5206674 0.43033463 5.5381308 0.002633922 
	   178	  
Gene Name ΔNfl/fl; 
p53-/- 
ΔNp63Δ/Δ;p53-/- 
ΔNp73Δ/Δ;p53-/- 
t-value p-value 
Zrsr1 0.56968236 0.9738193 2.3920841 0.04802149 
Mfsd2b 0.93503726 0.53652716 2.7782524 0.049907636 
Ube2d2 0.8636002 0.6110902 2.8639185 0.03524445 
Ttbk1 0.8831647 0.62915653 2.7337832 0.041094817 
Zfp574 0.55221087 0.5197923 4.810299 0.002969328 
Dhx30 0.7612478 0.6757851 3.0636566 0.027985187 
Ahdc1 0.7171415 0.684632 3.2106376 0.01835228 
Pura 0.56960326 0.4479001 5.0545273 0.003918179 
Mgat1 0.7375186 0.8573658 2.4397557 0.044775 
Wscd2 0.8613684 0.5395813 3.0772598 0.037030213 
Csnk1g2 0.83794755 0.6719081 2.7754176 0.039113607 
Ssb 0.6503541 0.9072962 2.4900734 0.0415921 
Rock1 0.71568114 0.7212333 3.0715823 0.021897644 
Kin 0.89099675 0.48331088 3.092922 0.036470704 
Hmg20b 0.66140604 0.52969086 4.095439 0.009396655 
2-Mar 0.8640084 0.40957704 3.3909113 0.04274617 
Cklf 0.7687318 0.72835547 2.8410273 0.029527117 
Zc3h14 0.7551423 0.62978643 3.255054 0.022569034 
Taf3 0.38079923 0.9247394 3.1617765 0.0158889 
Arhgef10l 0.6336453 0.5946082 3.9706135 0.007361795 
N6amt1 0.7559443 0.85042006 2.4093246 0.04682041 
Rbm17 0.85908145 0.6336144 2.8141544 0.037364904 
NR_028577 0.6761663 0.7327598 3.1792881 0.019093057 
Fndc1 0.8455971 0.46573249 3.3447828 0.02870774 
Syk 0.5447683 0.9641938 2.5088084 0.040467385 
	   179	  
Gene Name ΔNfl/fl; 
p53-/- 
ΔNp63Δ/Δ;p53-/- 
ΔNp73Δ/Δ;p53-/- 
t-value p-value 
Hnrnpm 0.800717 0.46694723 3.561675 0.023550654 
NR_030673 0.835641 0.5774963 3.0792713 0.03695779 
Uimc1 0.7633097 0.48195842 3.7100184 0.020653702 
Shc1 0.44396058 0.68393433 4.4583945 0.002941736 
Ing3 0.7795554 0.72993296 2.7948492 0.031376243 
Phf14 0.82985073 0.5457115 3.198287 0.03295459 
Mex3b 0.6063178 0.43012962 4.864984 0.004613023 
Anxa2 0.8367505 0.67850846 2.7584453 0.039908197 
Reck 0.6805226 0.69872534 3.3054204 0.016297424 
Bptf 0.76309305 0.8378896 2.4369915 0.044956952 
Rnf39 0.40021583 1.0008725 2.6583276 0.032546 
Raf1 0.8120058 0.4597659 3.5246024 0.024348741 
Lrrcc1 0.7895861 0.44642094 3.6763673 0.021271734 
Thoc2 0.2576664 0.5756566 6.437475 3.54E-04 
4933430H15Rik 0.70253646 0.8906831 2.406515 0.047014035 
Pigv 0.794924 0.45385212 3.6278434 0.022202266 
NR_030779 0.90529424 0.57521474 2.7983265 0.048894897 
E030030I06Rik 0.6243755 0.5619415 4.165929 0.005905252 
Snap23 0.84929556 0.524234 3.1724238 0.033779275 
Mier2 0.8059555 0.78203076 2.5090163 0.04596432 
Cir1 0.7852969 0.5092136 3.5151021 0.024558416 
Bcl11b 0.6159637 0.46623135 4.6406145 0.005629563 
Cetn4 0.6991679 0.73771614 3.0688279 0.021975018 
Cyth2 0.75424033 0.7992667 2.6206896 0.039549675 
Palm 0.822884 0.7263186 2.6487508 0.04549472 
	   180	  
Gene Name ΔNfl/fl; 
p53-/- 
ΔNp63Δ/Δ;p53-/- 
ΔNp73Δ/Δ;p53-/- 
t-value p-value 
Vps4a 0.7282406 0.5738591 3.5787551 0.015895769 
Kif5a 0.62185764 0.48612505 4.515499 0.00630892 
Wrnip1 0.6356815 0.78147686 3.118717 0.01687398 
Tulp2 0.54497343 0.7128762 3.8204868 0.006538115 
Lmo4 0.66365415 0.8370295 2.7692146 0.027725447 
Ppp1r10 0.6500399 0.9239539 2.4127975 0.046582222 
Elavl4 0.15755658 0.63556826 6.255576 0.001530557 
Fbxl14 0.6255018 0.6577499 3.7264848 0.009777168 
Akap5 0.75391114 0.69257015 3.0312917 0.023059575 
Igfbp6 0.7547445 0.652518 3.1749818 0.024676641 
Csnk1g3 0.6171592 0.5976586 4.04312 0.006778718 
Klk5 0.6948286 0.6554953 3.4215493 0.014116849 
4930452B06Rik 0.83182234 0.5254681 3.2476401 0.031445812 
Csnk1e 0.7655034 0.600903 3.3106167 0.021226026 
Ube2n 0.6042501 0.6818456 3.7117028 0.007537909 
Ddhd1 0.5254294 0.62025064 4.422035 0.003073707 
Ints3 0.68637633 0.56756693 3.810743 0.012490577 
Dcaf8 0.6433541 0.9240245 2.4321096 0.045280144 
Syf2 0.75671476 0.73409146 2.8644576 0.028634055 
Rai1 0.7688361 0.58904004 3.336076 0.020641034 
Mlf2 0.55079055 0.5159931 4.8399463 0.002880945 
NR_015349 0.8180218 0.7322675 2.6456184 0.038251977 
Brd4 0.78793657 0.523612 3.4582684 0.02585857 
Axin1 0.6970009 0.743669 3.0525334 0.022438858 
Zfp295 0.8054627 0.76213 2.5836973 0.041562386 
	   181	  
Gene Name ΔNfl/fl; 
p53-/- 
ΔNp63Δ/Δ;p53-/- 
ΔNp73Δ/Δ;p53-/- 
t-value p-value 
Top1 0.6067318 0.6072432 4.0532465 0.006701471 
Arid4b 0.5123038 0.77038735 3.644609 0.008236586 
Rfesd 0.45654958 0.84788245 3.4036427 0.011385886 
BC005561 0.5326797 0.6388459 4.2796435 0.003656983 
NR_033442 0.6421799 0.7713979 3.1403644 0.01637085 
Dbndd1 0.8621894 0.64172083 2.7772841 0.039027292 
Adamtsl5 0.79542696 0.5411376 3.368849 0.028073633 
Wdr33 0.69219875 0.80477273 2.8128295 0.026039911 
Ndufs1 0.7671161 0.7572592 2.7382882 0.033812333 
Dact1 0.5049645 0.5545078 4.9262686 0.001701469 
Sorbs1 0.72754884 0.62102324 3.4090002 0.019064002 
Wdr53 0.56409645 0.978322 2.3835714 0.04862613 
Ubl7 0.421326 0.61160135 5.075129 0.001438832 
Alx3 0.5302911 0.9404301 2.6734247 0.031841222 
Aagab 0.6572083 0.63159823 3.6926894 0.010176208 
Zfp672 0.13123523 0.7517969 5.088889 0.003805714 
Tbxa2r 0.7575673 0.60550946 3.3301222 0.020776184 
Mknk2 0.44224867 1.0299667 2.3957646 0.047762465 
Fam177a 0.5899091 0.68773896 3.7481132 0.007185903 
NR_027957 0.5725367 0.61177254 4.212026 0.005610548 
Tcp11 0.79367644 0.70578396 2.8290186 0.036717057 
Gpc3 0.6709766 0.7733604 3.0243428 0.019267814 
Rad52 0.5025112 0.9872908 2.494428 0.041327845 
NR_027859 0.7378596 0.68268377 3.1330378 0.020246252 
Hectd2 0.51094145 0.9664823 2.5860868 0.036150273 
	   182	  
Gene Name ΔNfl/fl; 
p53-/- 
ΔNp63Δ/Δ;p53-/- 
ΔNp73Δ/Δ;p53-/- 
t-value p-value 
NR_027008 0.6537888 0.63087565 3.712074 0.009945159 
Dact3 0.6942757 0.8681166 2.5316873 0.03913635 
Mtap4 0.657026 0.7007251 3.3952367 0.014581224 
Prss53 0.68146247 0.7189174 3.2168279 0.018209754 
2310035K24Rik 0.8634628 0.6797194 2.6541584 0.045199968 
Dcaf4 0.45337337 0.56417084 5.2055607 0.001245379 
Upf3b 0.48036706 0.60581875 4.763459 0.002051215 
Fbxo46 0.40984645 0.89562535 3.2615662 0.013834438 
Rexo1 0.87334 0.63144875 2.7650402 0.03959734 
Srek1ip1 0.8395489 0.6457891 2.8530421 0.03569622 
Zkscan3 0.45221916 0.74121994 4.0579915 0.004821822 
Etl4 0.17413361 0.6203647 6.3700395 7.03E-04 
Dguok 0.7053372 0.89199996 2.392085 0.048021425 
Atxn2l 0.4271552 0.76592535 4.0048165 0.0051582 
Adarb2 0 0.7746691 4.9992986 0.004107182 
Phf21a 0.70575136 0.82782346 2.6682532 0.032080833 
1300018I17Rik 0.5401398 0.7832738 3.4681034 0.010432599 
Arnt 0.6687846 0.7261573 3.2368786 0.017756354 
Angptl1 0.8247388 0.6986858 2.7365696 0.040958814 
Cox7a2l 0.23154019 0.6239354 6.0568757 9.18E-04 
Cep97 0.5411474 0.93019515 2.696865 0.030778343 
NR_045268 0.5481574 0.74986714 3.6121795 0.008599197 
Rnase10 0 0.7747412 4.998601 0.004109637 
Myt1 0 0.7747441 4.998573 0.004109736 
Usp16 0.21065246 0.7395884 4.998531 0.002455932 
	   183	  
Gene Name ΔNfl/fl; 
p53-/- 
ΔNp63Δ/Δ;p53-/- 
ΔNp73Δ/Δ;p53-/- 
t-value p-value 
Anapc11 0.62159806 0.75412816 3.298472 0.013148325 
D330028D13Rik 0.81690884 0.6869514 2.8058786 0.03773109 
NR_037865 0.6036144 0.8308061 3.0011466 0.01990981 
Klc3 0.61332154 0.87530315 2.7555535 0.028276635 
CK137956 0 0.7751593 4.9945555 0.004123905 
Bcl2l1 0.83993524 0.65894616 2.8096044 0.03756574 
NR_045836 0.78177375 0.5636572 3.3609936 0.02008611 
Ubxn6 0.49219784 0.72642493 3.976024 0.005350981 
Npepps 0.6244869 0.7334903 3.382713 0.011715255 
Trp53i13 0.7999554 0.78777355 2.5082364 0.046012808 
Rhoa 0.6461705 0.76251376 3.1653295 0.015810406 
Shank2 0.89041245 0.5714423 2.8684409 0.045540113 
Zfp14 0.7922065 0.65131646 3.024311 0.02927144 
NR_037994 0 0.7783602 4.9636917 0.004234684 
Map2k7 0.6341646 0.90655434 2.5423002 0.03853436 
Cep164 0.87164605 0.66907 2.6570299 0.045044303 
Ythdc1 0.76479363 0.67449814 3.0539968 0.028295005 
Pi4kb 0.10819078 0.77908874 4.872118 0.004584393 
Dnajc5b 0 0.77953666 4.952396 0.004276094 
Pptc7 0.7900982 0.79142 2.528216 0.04478743 
Phf14 0.44339877 0.8663194 3.3374078 0.012463856 
Mta3 0.6046586 0.73495823 3.4565203 0.010597348 
4930404N11Rik 0.6045984 0.922098 2.5550313 0.03782484 
Celf1 0.510967 0.90942675 2.893551 0.023198381 
Wnt11 0.8077902 0.6352808 3.0144293 0.029604806 
	   184	  
Gene Name ΔNfl/fl; 
p53-/- 
ΔNp63Δ/Δ;p53-/- 
ΔNp73Δ/Δ;p53-/- 
t-value p-value 
Pik3ca 0.43003753 0.79575723 3.806954 0.006654241 
Dalrd3 0.4499849 0.63253427 4.7649264 0.002047728 
Abca6 0.78884876 0.78179115 2.568847 0.042400736 
Med10 0.68042433 0.9132144 2.3725033 0.04942393 
Rnase10 0 0.7790405 4.9571567 0.004258584 
Lrrc55 0.49998307 0.7044652 4.068538 0.004757999 
Os9 0.6712847 0.916248 2.3858652 0.048462443 
Armcx2 0.5472892 0.9352324 2.65326 0.032786198 
AI597468 0.15942389 0.98546755 3.1743722 0.024693517 
Nprl2 0.44184563 0.80489534 3.708528 0.007569478 
NR_037957 0.64764315 0.8573473 2.729844 0.029345294 
Prkg1 0.5095542 0.7167073 3.955685 0.005491902 
Dync1i2 0.2762159 0.85682684 3.8763223 0.008205559 
Safb2 0.7134781 0.8293146 2.63606 0.033615317 
Ppil2 0.07427365 0.9993173 3.1475754 0.0254483 
Foxp4 0.71792686 0.7712024 2.861434 0.028747648 
Senp8 0.6936455 0.75356686 3.0240614 0.02327509 
Galnt1 0.72600716 0.87310547 2.4097717 0.04678968 
Bcl7b 0.5419179 0.668453 4.0718465 0.00473817 
Cdkn1b 0.6115648 0.86368525 2.8168738 0.025889166 
Phf17 0.52273506 0.97663397 2.5007133 0.040949456 
Htatsf1 0.7188913 0.66379094 3.2844977 0.016728327 
Nms 0 0.7861389 4.88947 0.004515614 
Zranb2 0.6593553 0.8404091 2.7683823 0.027758704 
Wipf2 0.6554555 0.8603764 2.6906781 0.031055236 
	   185	  
Gene Name ΔNfl/fl; 
p53-/- 
ΔNp63Δ/Δ;p53-/- 
ΔNp73Δ/Δ;p53-/- 
t-value p-value 
NR_045199 0.7937492 0.7310667 2.738319 0.033810955 
Dgcr6 0.59782135 0.74148375 3.4529839 0.010648205 
Snx15 0.55247813 0.9107759 2.764956 0.027896052 
Rps9 0.5673595 0.9254546 2.6464233 0.033113178 
Zfp865 0.6092422 0.681453 3.690992 0.007746457 
Ubap2l 0.49465027 0.90207225 2.98109 0.020483203 
Prpf38b 0.14805315 0.8123992 4.508817 0.006347803 
Sema3c 0.6181054 0.9336318 2.4593935 0.04350398 
Egfl8 0.5520453 0.9853867 2.3781722 0.049013652 
Mex3d 0.771046 0.70845985 2.9057271 0.02713109 
Fam76b 0.6104966 0.9041898 2.6249244 0.034163717 
Tfap2b 0.6116507 0.7360093 3.4230442 0.011089454 
2010109K11Rik 0.542541 0.8724677 2.9934573 0.0201276 
Hmg20b 0.3917597 0.67028075 4.811871 0.001939541 
Cnot3 0.59446603 0.79876924 3.188295 0.015312916 
Map3k1 0.5970785 0.9522292 2.4271564 0.0456105 
NR_028296 0.6637605 0.87100047 2.6157708 0.034621477 
Abtb1 0.50172323 0.87733525 3.0950723 0.017442416 
Abcf3 0.5553815 0.8647535 2.9924054 0.02015759 
Sdccag8 0.5323854 0.81639963 3.3214037 0.012740452 
Hoxa7 0.5585729 0.8714137 2.9481747 0.021462454 
Apcdd1 0.5051843 0.7833241 3.6003404 0.008735855 
Zfp653 0.49923918 0.8417716 3.2979968 0.013156923 
Stau1 0.4474471 0.94864327 2.8500662 0.0246861 
Mylpf 0.50479585 0.81522506 3.425224 0.011056672 
	   186	  
Gene Name ΔNfl/fl; 
p53-/- 
ΔNp63Δ/Δ;p53-/- 
ΔNp73Δ/Δ;p53-/- 
t-value p-value 
Fsd1 0 0.7863221 4.887735 0.004522437 
Il11ra2 0.61620104 0.76958287 3.2469985 0.014115741 
Safb 0.37423646 0.7603252 4.2480645 0.003802212 
Ppm1h 0.6729283 0.8142038 2.8389108 0.025083728 
Lrrc58 0.5103216 0.8714947 3.1000147 0.017321933 
Jkamp 0.41460916 0.75396657 4.1315413 0.004395489 
Psmd8 0.5353771 0.89093375 2.919222 0.02236478 
Sirt2 0.14304742 0.78501093 4.7576427 0.005070019 
Zxdb 0.47418293 1.0151492 2.4081335 0.046902396 
Hnrnpd 0.5728875 0.81935 3.1637008 0.015846336 
Ankrd11 0.43313587 0.8988593 3.1767614 0.015560637 
Zfand2b 0.39990926 0.94115597 3.0143824 0.019540753 
Otud1 0.56800467 0.8183331 3.1859396 0.015363161 
Sema4d 0.5153147 0.85833365 3.1551049 0.016037423 
Ubqln2 0.4239337 0.83499956 3.586618 0.0088972 
Casp7 0.50147617 0.8450988 3.2722661 0.013631649 
Pfn1 0.6683331 0.90442926 2.449092 0.04416604 
Zfp575 0.53988343 0.9070609 2.821359 0.02572306 
Fnbp1 0.68849593 0.8814452 2.4909873 0.0415365 
Polr3gl 0.4477471 0.90510195 3.099109 0.017343946 
Gm1965 0.42112926 0.9808967 2.7284148 0.029405933 
Pias1 0.4457344 0.8892454 3.1966069 0.015137001 
Fbxw2 0.15463954 0.81758016 4.4528923 0.006684369 
Kif5b 0.43570784 1.0276177 2.4237242 0.045840863 
Tnrc6c 0.66337115 0.87159204 2.6143215 0.034694538 
	   187	  
Gene Name ΔNfl/fl; 
p53-/- 
ΔNp63Δ/Δ;p53-/- 
ΔNp73Δ/Δ;p53-/- 
t-value p-value 
Gltp 0.38288268 0.82021946 3.8148606 0.006586124 
Zcchc9 0.5295479 0.8421459 3.1947608 0.015175884 
Zfp746 0.55000275 0.986537 2.3774047 0.049068995 
Luc7l2 0.4103945 0.7733772 4.0217533 0.005048355 
Mbd6 0.6565342 0.8940796 2.5326927 0.039078906 
Vps52 0.7230967 0.74511886 2.9476469 0.025691297 
Madd 0.19218214 0.8782817 3.9008439 0.011399596 
Tmem87a 0.22999342 0.8496132 4.040552 0.006798464 
Zfx 0.41627964 0.8609656 3.4525816 0.010654006 
Brpf3 0.29247937 0.9484173 3.213643 0.01828293 
Jrkl 0.5435012 0.9413882 2.6317518 0.033826392 
Rbm39 0.48131838 0.9155187 2.9452748 0.02155107 
Golga4 0.30404538 1.030618 2.6651375 0.037267577 
Tfap2a 0.60686105 0.881113 2.7478771 0.028591381 
Ccnd3 0.56583333 0.838158 3.0933197 0.017485354 
Spata2 0.6961633 0.8437004 2.6320195 0.033813234 
4931406P16Rik 0.68034136 0.9147077 2.3659296 0.04990409 
Slc9a3r1 0.4199101 0.8802602 3.3251781 0.012674631 
Fam160a2 0.44770044 0.80820495 3.667785 0.00798761 
Lemd3 0.28939173 0.92756474 3.3578362 0.015270467 
Traf2 0.58860505 0.88668454 2.7774503 0.027398612 
Tnrc6a 0.511472 0.9447334 2.7020664 0.030547556 
NR_029456 0.65506744 0.9291513 2.373567 0.04934667 
Dlg4 0.5196946 0.8870266 2.9876306 0.020294316 
Gmfg 0.42317215 0.7901299 3.867104 0.006154682 
	   188	  
Gene Name ΔNfl/fl; 
p53-/- 
ΔNp63Δ/Δ;p53-/- 
ΔNp73Δ/Δ;p53-/- 
t-value p-value 
Upf3a 0.6123128 0.8699901 2.7842424 0.02713211 
Pnn 0.41805092 0.96476513 2.8300912 0.025402868 
Smarca4 0.6719411 0.90782696 2.4226136 0.045915656 
Awat2 0.5209645 0.9677513 2.5530062 0.03793679 
Rnf40 0.3068969 1.0508443 2.5327797 0.044512395 
Rbbp6 0.5850337 0.80909884 3.1716893 0.015670931 
Brf1 0.4712073 1.0162349 2.4089258 0.046847846 
Rltpr 0.34825724 1.0382304 2.5381734 0.044189647 
Zfp944 0.6489769 0.89386845 2.5568717 0.037723396 
Acbd3 0.40046698 1.0362217 2.447836 0.04993729 
Ppt2 0.37942636 0.96377856 2.9272077 0.026382707 
Otud5 0.49579063 1.0041763 2.4180584 0.046223752 
Klraq1 0.533447 0.82808465 3.255893 0.013943267 
Kctd18 0.5246526 0.93503547 2.7176883 0.02986521 
Nosip 0.5893446 0.9329006 2.5456784 0.038344756 
Zbtb6 0.47570738 1.0147368 2.4068995 0.04698749 
Son 0.47068703 0.9096398 3.0082474 0.019710906 
NR_033144 0.33773857 0.901285 3.4182365 0.014174408 
NR_033533 0 0.8434303 4.37366 0.007197289 
Rara 0.47495085 0.93557715 2.851272 0.024643514 
Arfgap1 0.4605324 0.958281 2.7617369 0.028025743 
Morf4l1 0.16247232 1.0578351 2.678828 0.043881696 
NR_040364 0.33407247 1.0161631 2.7011828 0.03552007 
Ctxn1 0.4020231 0.97524655 2.806226 0.026288034 
Rpl7 0.1919353 1.0504241 2.6975646 0.04290877 
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Gene Name ΔNfl/fl; 
p53-/- 
ΔNp63Δ/Δ;p53-/- 
ΔNp73Δ/Δ;p53-/- 
t-value p-value 
Hnrnpm 0.2584016 0.882235 3.7372499 0.009653731 
Ip6k2 0.29890493 0.9385806 3.2647974 0.017145496 
Csrnp2 0.38077858 1.01384 2.6223764 0.039460406 
Taok2 0.1777848 1.0426848 2.7648022 0.039608512 
Gm15308 0.4768259 0.99174565 2.5332248 0.039048538 
Padi4 0.36532962 0.90153503 3.3457909 0.012321553 
Mad2l1bp 0.12638676 1.020686 2.9631574 0.031404153 
Tnip1 0.22696185 1.059517 2.59527 0.048526328 
Fbxw5 0.15047543 1.0633327 2.65292 0.04526728 
Hnrnpa2b1 0.17599827 0.96665406 3.2853882 0.021824293 
Dnajc5b 0 1.0000035 3.1622527 0.02503172 
Htr1a 0 1.0000107 3.1622012 0.025033167 
Trpc5 0 1.0000254 3.1620963 0.025036117 
NR_046179 0 1.0000457 3.161953 0.025040148 
NR_040623 0 1.0000765 3.1617327 0.025046345 
Hs3st2 0 1.0001408 3.1612759 0.025059203 
Abcc6 0 1.0001798 3.160998 0.025067024 
Hoxc13 0 1.0001892 3.1609318 0.025068892 
4921517D21Rik 0 1.0001997 3.1608567 0.025071006 
NR_045048 0 1.0002116 3.1607728 0.025073372 
Serpinb9f 0 1.0002161 3.1607397 0.025074305 
6030405A18Rik 0 1.0003294 3.1599348 0.025096994 
Sstr5 0 1.0003574 3.1597345 0.025102643 
NR_003959 0 1.0012333 3.1535068 0.025279019 
Dnajc5b 0 1.0015857 3.1510015 0.025350364 
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Gene Name ΔNfl/fl; 
p53-/- 
ΔNp63Δ/Δ;p53-/- 
ΔNp73Δ/Δ;p53-/- 
t-value p-value 
NR_033632 0 1.0018922 3.1488233 0.02541258 
Tas2r129 0 1.0064082 3.1167903 0.02634765 
NR_024257 0 1.0238483 2.9939997 0.03030757 
Tecrl 0 1.0314263 2.941053 0.03221734 
NR_024326 0 1.0000061 3.1622343 0.03411084 
NR_045451 0 1.0006084 3.157949 0.03425143 
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Appendix 3: Pramlintide treatment as a preventive approach to suppress 
thymic lymphomagenesis in p53-deficient mice 
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